Nouveau regard sur la signalisation AMPK : multiples fonctions de nouveaux interacteurs by Zorman, Sarah
A fresh look at AMPK signaling: multiple functions of
novel interacting proteins
Sarah Zorman
To cite this version:
Sarah Zorman. A fresh look at AMPK signaling: multiple functions of novel interacting pro-
teins. Biomolecules [q-bio.BM]. Universite´ de Grenoble, 2013. English. <tel-00877237>
HAL Id: tel-00877237
https://tel.archives-ouvertes.fr/tel-00877237
Submitted on 28 Oct 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 Université Joseph Fourier / Université Pierre Mendès France /  
Université Stendhal / Université de Savoie / Grenoble INP  
THÈSE 
Pour obtenir le grade de 
DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE 
Spécialité : Biologie Moléculaire & Cellulaire  
Arrêté ministériel : 7 août 2006 
 
 
 
Présentée par 
Sarah ZORMAN 
 
 
Thèse dirigée par Uwe SCHALTTNER 
 
 
Préparée au sein du Laboratoire de Bioénergétique Fondamentale 
et Appliquée, dans l'École Doctorale de Chimie et Sciences du 
Vivant  
 
Nouveau regard sur la 
signalisation AMPK : multiples 
fonctions de nouveaux 
interacteurs 
 
 
Thèse soutenue publiquement le 8 novembre 2013, 
Devant le jury composé de :  
Theo WALLIMANN 
Professeur émérite de l’Université ETH Zurich, Rapporteur 
Philippe ROUET 
Directeur de recherche INSERM, Rapporteur 
Jérôme GARIN  
Directeur de recherche INSERM, Examinateur 
Marc BILLAUD 
Directeur de recherche CNRS, Examinateur 
Michel SEVE 
Professeur de l’Université Joseph Fourier, Président 
Uwe SCHLATTNER 
Professeur de l’Université Joseph Fourier, Directeur de Thèse
  
  
1 
 
Remerciements 
Avant d’aborder le travail scientifique qui fait l’objet de mon doctorat, je voudrais remercier 
ceux qui ont participé à différents niveaux à sa maturation. Je tiens à remercier Uwe 
Schlattner pour son accompagnement tout au long de ces trois ans, sa confiance, son écoute 
et la pertinence de ses conseils scientifiques.  
Je remercie les membres du jury, Theo Walliman, Philippe Rouet, Jérôme Garin, Marc Billaud 
ainsi que Michel Sève pour avoir donné de leur temps et de leur compétence afin de juger ce 
travail.  
Merci aux membres du laboratoire, en particulier Evangelia Mourmoura et Marie Le Guen 
pour leur soutien et leur amitié tout au long de ces trois années, mais aussi à Clovis Chabert, 
Fecal Ounnas et Martin Pelosse qui m’auront beaucoup fait rire. Cette thèse s’est déroulée 
au LBFA, où j’ai bénéficié de l’excellente qualité du service technique. Pour cela merci Sarah 
Hamant et Gérard Larmurier toujours disponibles et sérieux vous avez facilité ma vie au 
quotidien. Merci également à Stéphane Attia pour son assistance ainsi qu’à Hervé 
Dubouchaud pour sa gentillesse et son aide avec mon indispensable collègue, l’ordinateur. 
Finalement je voudrais remercier Christine Demeilliers qui m’a introduit au sein de ce 
laboratoire.  
J’ai eu la chance de collaborer avec Pascual Sanz (IBV, Valencia, Espagne) qui m’a accueillie 
au sein de son laboratoire pendant trois mois. Merci à lui et toute son équipe très 
chaleureuse, auprès de qui j’ai beaucoup appris. 
Je tiens à associer à ces remerciements le ministère de la recherche pour le financement de 
mon doctorat. 
Pour terminer, mes pensées vont à ceux qui sont la clé de qui je suis aujourd’hui : Mick et 
Michel. Merci de m’avoir tout donné et même un peu plus. Cyril, Laurent, Sylvain mais aussi 
Virginie, ces 27 ans à grandir à vos côté m’ont énormément apporté. Un grand merci à 
chacun des petit zormans pour leurs rires qui rendent la vie plus douce. 
Je ne pourrais finir sans remercier Alex pour son amour et son humour qui m’accompagnent 
chaque jour. 
  
  
3 
 
Abstract. AMP-activated protein kinase (AMPK) is a central energy sensor and regulator of cellular 
energy state, but the AMPK signaling network is still incompletely understood. Two earlier non-
biased screens for AMPK interaction partners and substrates performed in the laboratory identified 
several candidate proteins, but functional and physiological roles remained unclear. Here we 
characterized the functional relationship of AMPK with four different protein interaction partners: 
gluthatione S-transferases (GSTP1 and GSTM1), fumarate hydratase (FH), an E3 ubiquitin-ligase 
(NRDP1), and vesicle-associated membrane proteins (VAMP2 and VAMP3). Each of these interaction 
partners seems to have a different function in AMPK signaling, either acting up- or down-stream of 
AMPK. GSTP1 and GSTM1 can contribute to AMPK activation by facilitating S-glutathionylation of 
AMPK under mildly oxidative conditions. This non-canonical regulation suggests AMPK as a sensor of 
cellular redox state. Mitochondrial FH was identified as the only clear AMPK downstream substrate, 
but surprisingly the phosphorylation site is present in the mitochondrial targeting prepeptide, 
possibly affecting mitochondrial import. NRDP1, whose expression as a full-length soluble protein 
was achieved here for the first time, is phosphorylated by AMPK only at low levels. The interaction 
does neither serve for AMPK ubiquitinylation, but rather affects NRDP1 turnover. Finally, interaction 
of VAMP2/3 with AMPK does not involve phosphorylation or activation events of one of the partners. 
Instead, we propose VAMP2/3 as scaffolding proteins that recruit AMPK to exocytotic vesicles which 
could favor phosphorylation of vesicular AMPK substrates for exocytosis. Collectively, our results add 
some new elements to the AMPK signaling network, suggesting that it is much more complex than 
anticipated. In addition to upstream kinases and downstream substrates, regulation of AMPK 
signaling occurs by secondary protein modifications other than phosphorylation, by effects on 
protein turnover, and probably also by specific subcellular recruitment of AMPK. 
 
Résumé. La protéine kinase activée par AMP (AMPK) est un senseur et régulateur central de l’état 
énergétique cellulaire, mais ces voies de signalisation ne sont pour le moment que partiellement 
comprises. Deux criblages non-biaisés pour la recherche de partenaires d’interaction et de substrats 
d’AMPK ont précédemment été réalisés dans le laboratoire. Ces derniers ont permis l’identification 
de plusieurs candidats (protéines), mais leur rôle fonctionnel et physiologique n’était pas encore 
établi. Ici nous avons caractérisé la fonction de la relation entre AMPK et quatre partenaires 
d’interaction : gluthation S-transferases (GSTP1 and GSTM1), fumarate hydratase (FH), l’E3 
ubiquitine-ligase (NRDP1), et les protéines associées à la membrane (VAMP2 and VAMP3). Chacune 
de ces interactions parait avoir un rôle différent dans la signalisation AMPK, agissant en amont ou en 
aval de la protéine AMPK. GSTP1 et GSTM1 contribueraient  à l’activation d’AMPK en facilitant la S-
glutathionylation d’AMPK en conditions oxydatives moyennes. Cette régulation non-canonique 
suggère que l’AMPK peut être un senseur de l’état redox cellulaire. FH mitochondrial est l’unique 
substrat AMPK clairement identifié. Etonnamment le site de phosphorylation se trouve dans le 
peptide signal mitochondrial, ce qui pourrait affecter l’import mitochondrial. NRDP1, protéine pour 
laquelle nous avons pour la première fois développé un protocole de production de la protéine 
soluble, est faiblement phosphorylée par l’AMPK. L’interaction ne sert pas à l’ubiquitination d’AMPK, 
mais affecte le renouvellement de NRDP1. Finalement, l’interaction de VAMP2/3 avec AMPK 
n’implique pas d’évènement de phosphorylation ou d’activation d’un des partenaires. Nous 
proposons un mécanisme de recrutement d’AMPK par VAMP2/3 (« scaffold ») au niveau des 
vésicules en exocytose. Ce recrutement favoriserait la phosphorylation de substrats de l’AMPK à la 
surface des vésicules en exocytoses. Une fois mis en commun, nos résultats enrichissent les 
connaissances sur les voies de signalisation AMPK, et suggèrent une grande complexité de ces 
dernières. Plus que les kinases en amont et des substrats en aval, la régulation de la signalisation 
d’AMPK se fait via des modifications secondaires autres que la phosphorylation, via des effets sur le 
renouvellement de protéines, et probablement via un recrutement spécifique de l’AMPK dans 
certains compartiments cellulaires.  
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An introduction to 
AMP-activated 
protein kinase 
(AMPK) 
Abstract. AMP-activated protein kinase (AMPK) is a 
heterotrimeric serine/threonine kinase. It is the most 
relevant kinase in the context of metabolic stability 
and energy homeostasis, playing a central role in 
sensing and regulating energy homeostasis at the 
cellular, organ and whole-body level. Activation 
involves covalent phosphorylation and allosteric 
binding of AMP or ADP that cooperate in a complex 
manner. Once activated, AMPK phosphorylates a 
broad range of downstream targets, resulting in the 
inhibition of anabolism and activation of catabolism, 
to maintain high levels of cellular ATP. Disturbance of 
energy homeostasis underlie a number of disease 
such as cardiovascular pathologies, 
neurodegenerative disease, cancer and type 2 
diabetes. Since few years AMPK has emerged as a 
potential therapeutic target for some of these 
pathologies. 
 
Résumé. La protéine kinase activée par l’AMP 
(AMPK) est une serine/thréonine kinase 
hétérotrimérique. Cette kinase est la plus 
importante dans le cadre de la stabilité métabolique, 
jouant un rôle central de senseur et régulateur de 
l’homéostasie énergétique au niveau de la cellule, de 
l’organe et de l’individu. Son activation requiert une 
phosphorylation covalente et une régulation 
allostérique par l’AMP ou l’ADP. Une fois activée, 
l’AMPK phosphoryle un grand nombre de cibles en 
aval, provoquant une inhibition de l’anabolisme et 
une activation du catabolisme, permettant le 
maintien d’un haut niveau d’ATP. Un grand nombre 
de pathologies sont sous-jacentes à des 
perturbations de l’homéostasie énergétique, telles 
les maladies cardiovasculaires, les maladies 
neurodégénératives, les cancers et le diabète de 
type 2. Depuis maintenant quelques années l’AMPK 
est considérée comme une cible thérapeutique 
potentielle. 
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Homeostasis of cell metabolism 
Metabolism 
Without external input of energy, entropy of a system will tend to a maximum; for living 
organisms, this disorder corresponds to death. Living organisms are highly organized, thus 
they need to constantly struggle against disorder. Oxidation of macromolecules generates a 
free energy reservoir in form of “high energy” compounds such as nucleotide triphosphates, 
which serves as fuel to maintain biological order. The overall metabolism process consists in 
coupling exergonic to endergonic reactions to maintain life, in other words metabolism utilizes 
the free energy to carry out vital functions such as biosynthesis of complex molecules, active 
transport, or mechanical work. (Atkins, 1984; Voet, 2011) 
 
Figure 1. General scheme of cellular metabolism. Catabolic reactions generating ATP (top), through coupling to 
anabolic reactions (biosynthesis, bottom) using ATP, maintain cell structural organization as an expression of the 
decrease of internal entropy (ΔSin < 0) and are also the source of energy for cellular work (Wc). Abbreviations: 
ΔSex, excess entropy; ΔSin, input entropy; ΔSt, total entropy; ΔGex, excess Gibbs free energy. For further details 
see text. Reproduced from (Saks, 2007). 
 
The chemical reactions of metabolism are organized into metabolic pathways, in which a 
macromolecule is transformed into another one by a series of consecutive enzymatic 
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reactions. (Alberts, 2002; Atkins, 1984; Voet, 2011). Their reactants, intermediates, and 
product are referred to as metabolites. There are two subfamilies of enzymatic reactions 
composing the metabolic pathway (Figure 1). 
(1) Catabolism, which  breaks down complex molecules (nutrients and cell constituents) 
into more simple ones to generate building blocks and conserve free energy in form of 
a small number of compounds. The latter occurs mainly through the synthesis of ATP 
from ADP and phosphate and the reduction of the coenzyme NADP+ to NADPH. 
Proteins, lipids and polysaccharides are broken down by enzymatic digestion into 
smaller molecules, such as amino acids, sugar, fatty acids and glycerol, respectively. 
Such small units can be taken up into the cell and oxidized. 
(2) Anabolism, which uses the free energy sources and building blocks provided by 
catabolic processes to synthesize again more complex molecules needed to sustain a 
living cell. Anabolic processes are powered by the hydrolysis of ATP. Processes such as 
gluconeogenesis, glycogenesis, lipogenesis and protein synthesis are all anabolic 
processes which tend towards “building up” organs and tissues. 
 
Metabolic reactions are accelerated by enzymes which are among the more effective catalysts 
known, capable of accelerating reactions up to a factor of 1014. They thereby allow reactions 
that would otherwise not proceed rapidly at cell temperatures. More than 4500 enzymatic 
reaction are listed to date. (Alberts, 2002; Fruton, 1999; Kornberg, 1991)  
 
Post-translational modification of proteins  
Post-translational modifications (PTMs) are all chemical protein modifications that occur after 
translation. Mostly, these are covalent modifications of amino acid residues. Reversible PTMs 
can occur rapidly and have regulatory roles in different physiological responses. Multiple PTMs 
on a single protein create a large combinatorial pattern or “mod-forms”. Distinct mod-forms 
can elicit distinct downstream responses and thus knowledge of PTMs is the most informative 
measure of a protein’s state (Khoury et al., 2011).  
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Over 200 types of PTM have been identified (Jensen, 2006), which can be divided in two kinds 
of processes. A first type of PTMs are polypeptide modifications such as covalent binding of 
ubiquitin (ubiquitinylation) and ubiquitin-like moieties (e.g. sumoylation, neddylation) 
(Schwartz and Hochstrasser, 2003). Addition of these polypeptide molecules requires an 
entire group of specific enzymes. A second type of PTMs is based on a group of smaller 
molecules (e.g. acetyl, ADP-ribosyl, phosphoryl) which are provided by metabolic donors (e.g. 
acetyl-CoA, NAD, ATP) that are derived from basic cell metabolism. The final covalent binding 
is processed by single enzymes (Prabakaran et al., 2012).  
 
Figure 2. Top experimentally observed post-translational modifications. Occurrence of experimentally detected 
PTMs, as curated from SwissProt. Figure from (Khoury et al., 2011). 
 
Phosphorylation events dominate by large the number of experimentally observed PTMs 
(Figure 2). However, these numbers probably do not reflect the physiological proportion of 
these PTMs, but rather the preponderance of phosphorylation studies in literature. 
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Phosphorylation plays a key role in cell signaling for a wide range of cellular processes by 
providing a simple “on”/“off” switch for enzymes or receptors. This PTM is catalyzed by 
protein kinases and reversed by protein phosphatases. AMPK is an important effector of 
cellular protein phosphorylation.  
 
AMPK, structure and localization 
Role of AMPK in metabolism 
Adenosine monophosphate-activated protein kinase (AMPK) is the most relevant kinase in the 
context of metabolic stability and energy homeostasis. AMPK is phylogenetically one of the 
most ancient eukaryotic protein kinases, conserved  in all eukaryotic genomes that have been 
sequence to date, from protozoa and yeast to plants and human (Hardie, 2003). AMPK 
participates in sensing and controlling cellular and whole-body energy balance by its sensitivity 
to AMP and ADP. AMPK is allosterically activated by increasing AMP:ATP and ADP:ATP ratios 
(Hardie et al., 2012a), and its covalent phosphorylation by upstream kinases. It operates as a 
“metabolic master switch” at cellular, organ and whole-body levels (Hardie and Carling, 1997; 
Winder and Hardie, 1999). Activation of AMPK generally aims at compensating ATP loss via 
acceleration of catabolism and inhibition of anabolism.  
 
AMPK structure 
AMPK is part of a structurally related family of serine/threonine protein kinases (the AMPK-
related-kinases [ARKs]) comprising around 14 members (Lizcano et al., 2004). It is a 
heterotrimeric complex consisting of a catalytic α-subunit and regulatory β- and γ-subunits 
(Figure 3). Further complexity is added by the existence of multiple subunit genes encoding 
each different isoforms of each subunit. In mammals, there are two genes encoding the AMPK 
α catalytic subunit (α1 and α2), two β genes (β1 and β2) and three γ subunit genes (γ1,γ2 and 
γ3) with γ2 and γ3 existing as splice variants (Hardie, 2007). Each of these subunit takes on a 
specific role in both the stability and activity of AMPK (Stapleton et al., 1996). 
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Figure 3. Schematic representation of AMPK subunits. Cartoon of the three AMPK subunits, highlighting key 
amino acid residues and regions implicated in the regulation of AMPK activity. The major upstream kinases 
phosphorylating Thr172 are LKB1 and CaMKKβ. AMP is shown bind to each of the three nucleotide-binding sites 
in the γ subunit. CBM, carbohydrate binding module; CBS, cystathionine β-synthetase.  Figure from (Carling et 
al., 2012).  
 
The α-subunit contains the catalytic domain and an inhibitory activation loop involved in its 
regulation (Crute et al., 1998; Pang et al., 2007). The key site for AMPK activation is found on 
the activation loop as threonine 172 (Thr172) which is phosphorylated by upstream kinases. 
The C-terminal α-domain is interacting with both the β-subunit and loop(s) contacting the γ-
subunit (Pang et al., 2007) 
The β-subunit tethers both α- and the γ-subunits (Iseli et al., 2005) as a scaffold protein with 
it C-terminal domain (aa 187 to 272) and also bears a carbohydrate binding module (CBM) 
(Hudson et al., 2003; Polekhina et al., 2003), that is found in a number of enzymes that 
metabolize polysaccharides, such as glycogen or starch (Hudson et al., 2003; Polekhina et al., 
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2003). Consistent with the presence of a CBM, AMPK can bind to glycogen in vitro (Hudson et 
al., 2003; Polekhina et al., 2003). Functions in subcellular targeting to glycogen granules and 
regulation of glycogen metabolism have been proposed (McBride et al., 2009).  
The γ-subunits Conserved in all γ-subunit are the four cystathionine β-synthetase (CBS) 
domains forming pairs called Bateman domains (Kemp, 2004) assembled in a head to head 
manner. The two Bateman domain bear four cavities to bind ligands, but since one site is non-
functional, there are only three binding sites for nucleotide (AMP, ADP and ATP). These three 
functional sites have different affinity for nucleotides and play different roles in allosteric 
activation of AMPK (Hardie et al., 2011; Xiao et al., 2007).  
 
AMPK subcellular localization 
There is some evidence that AMPK isoforms determine intracellular distribution, protein 
recognition or tissue-specific functions, and especially provide selectivity for specific subsets 
of substrates within the ever increasing list of AMPK substrates (Carling et al., 2012; Hardie et 
al., 2012a, 2012b). AMPK is generally observed as a soluble complex with diffuse cytosolic 
localization. Functional differences are reported for the two catalytic α subunits, particularly 
for their responsiveness to AMP and upstream kinases, as well as their nuclear localization 
(Hedbacker and Carlson, 2008). In fact, α2-containning complexes, when activated, can 
translocate into the nucleus to phosphorylate important substrates (transcription factors, 
histones, and histone deacetylases) as seen after exercise in skeletal muscle (McGee et al., 
2003; Suzuki et al., 2007). Also, α1 subunit has been shown to localize to the nucleus under 
some conditions (diurnal regulation) (Lamia et al., 2009). The β-subunit is post-translationally 
modified by myristoylation and phosphorylation, which has been shown to be required for 
proper activation of AMPK or its localization to membranes (Oakhill et al., 2010) which might 
favor membrane bound complex. AMPK may also be recruited into specific complexes via 
interaction with its upstream kinases, downstream substrates, or more general scaffolding 
proteins. Scaffolding proteins can provide specificity in cell signaling by isolating activated 
kinases from bulk signaling and directing the information flow into specific pathways.  
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Upstream regulation of AMPK 
The requirement of biological systems to maintain high cellular ATP:ADP ratios and 
concomitantly ATP:AMP ratios at all times, even under conditions of high metabolic workload, 
is reflected by the dynamic and stringent control of AMPK activity. Regulation of AMPK activity 
is an elaborate process involving at least two upstream kinases and one protein phosphatase, 
as well as allosteric mechanisms (Hardie and Sakamoto, 2006; Hardie et al., 2006). 
 
Allosteric regulation 
AMPK is a highly conserved sensor of intracellular adenosine nucleotide levels that is activated 
when even modest decreases in ATP production results in relative increases in AMP or ADP 
(Carling et al., 1989; Hardie et al., 1998). Under these conditions, AMP or ADP bind to the two 
tandem Bateman domains (Kemp, 2004; Oakhill et al., 2011; Xiao et al., 2011) on the  
regulatory  γ-subunit, leading to a conformational change that allosterically activates the 
kinase and protects the activating phosphorylation of AMPK at Thr172 (Bland and Birnbaum, 
2011; Hardie et al., 2011; Oakhill et al., 2011; Xiao et al., 2011) against dephosphorylation by 
protein phosphatases (Davies et al., 1995; Suter et al., 2006). It was originally reported that 
AMP also promoted phosphorylation of AMPK by an upstream kinase (Hawley et al., 1995), 
later identified as LKB1 (Hawley et al., 2003; Woods et al., 2003).  
 
Regulation by upstream kinases 
Full activation of AMPK requires phosphorylation of the Thr172 residue in the α-subunit by 
different upstream kinases (Hawley et al., 1996; Stein et al., 2000). So far, two protein kinases 
are certain to phosphorylate this residue in vivo, namely liver kinase B1 (LKB1) (Hawley et al., 
1995; Shaw et al., 2004a; Woods et al., 2003) and Ca²+/Calmodulin-dependent kinase, 
especially the β isoform (CaMKKβ) (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 
2005).  
LKB1 is a serine/threonine kinase which plays vital roles maintaining cell polarity thereby 
inhibiting inappropriate expansion of tumor cells. Germinal mutations in the LKB1 gene have 
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been associated with Peutz-Jeghers cancer syndrome (PJS), characterized by the development 
of polyps in the gastrointestinal tract (Hemminki et al., 1997; Scott et al., 2008). More recent 
studies show a large number of somatic mutations of the LKB1 gene present in lung, cervical, 
breast, intestinal, testicular, pancreatic and skin cancer (Forbes et al., 2010; Sanchez-
Cespedes, 2007). LKB1 is an important upstream kinase of AMPK, thus suggesting an 
unexpected connection between AMPK and cancer (Luo et al., 2005; Motoshima et al., 2006; 
Shackelford and Shaw, 2009). LKB1 suppresses growth and proliferation by activating a group 
of 14 protein kinases, comprising AMPK and AMPK-related kinases (Ark) (Jaleel et al., 2005; 
Lizcano et al., 2004). Available evidence suggests that the tumor suppressor function of LKB1 
is related to AMPK activation, in particular the ability of the latter to inhibit mTor signaling 
that triggers cell growth and proliferation (Alessi et al., 2006; Inoki et al., 2003; Shaw et al., 
2004b).  
CaMKKβ is also capable of phosphorylating and activating AMPK, thereby linking cytoplasmic 
Ca²+ levels to AMPK activity (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005).  
Modest elevation of intracellular Ca2+ provoked by K+-depolarization in neural tissue leads to 
a threefold activation of AMPK (Hawley et al., 2005). The tissue distribution of CaMKKs, with 
the highest levels in brain, suggests that they may play important roles in the nervous system. 
For example, brain AMPK may contribute to the survival of neurons under stress condition 
(Culmsee et al., 2001). Thus preservation of ATP levels by signaling from CaMKK to AMPK may 
represent a neuronal survival pathway. 
In addition some other kinases seem to phosphorylate AMPK. The mammalian transforming 
growth factor β-activated kinase (TAK1), in complex with its accessory protein TAB1, was 
identified as a third possible upstream kinase capable of phosphorylating AMPK at Thr172 for 
activation (Herrero-Martín et al., 2009; Momcilovic et al., 2006; Xie et al., 2006). Also 
phosphorylation of AMPK at other sites has been reported, such as Ser485 (in α1) or Ser491 
(in α2) by Akt/PKB (Horman et al., 2006; Kovacic et al., 2003), α-Ser173 by PKA (Hurley et al., 
2006) or even by autophosphorylation reactions which reduce the accessibility of Thr172 to 
upstream kinases (Horman et al., 2006; Hurley et al., 2006). 
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Inactivation by protein phosphatases 
Less known but not less important for the α-Thr172 phosphorylation state is regulation by 
protein phosphatases. Different phosphatases can dephosphorylate AMPK at Thr172 in vitro 
like protein phosphatase 2Cα (PP2Cα), protein phosphatase 2A (PP2A), and protein 
phosphatase 1 (PP1) (Davies et al., 1995; Marley et al., 1996). In heart and endothelial cells, 
the expression level of PP2A and PP2Cα are correlated with AMPK activation (Wang and 
Unger, 2005; Wu et al., 2007).  
 
AMPK consensus recognition motif 
AMPK phosphorylation sites have been described so far in more than 50 substrate proteins, 
especially during recent years. Many more sites may exist in substrate candidates resulting 
from large-scale screenings that are not yet characterized. Generally, to ascertain specificity 
in cell signaling, protein kinases recognize a specific motif on the surface of the substrate that 
is primarily defined by a particular amino acid sequence. In case of AMPK, a stringent motif 
has been proposed with the first substrates over 20 years ago: Φ(β,X)XXS/TXXXΦ, where  is 
a hydrophobic residue (predominantly M, V, L, I or F),  is a basic residue (R, K or H) and the 
parentheses indicate that the order of residues at the P-4 and P-3 positions is not critical (Dale 
et al., 1995). 
Detailed analysis of available data on AMPK phosphorylation sites reveals the presence of this 
stringent motif in about half of the described sites (Figure 4). However, another half of the 
identified sites corresponds only partially to this motif, either lacking one of the hydrophobic 
residues at P-5 and P+4, or the basic residue at P-3 or P-4 (Figure 5). With two sites, the motif 
is so N- or C-terminal in the sequence that part of the motif is missing. Also an AMPK phospho-
motif screen using a library of synthetic peptides indicated lower conservation of the original 
AMPK motif, in particular for the positions from -1 to +4 (Gwinn et al., 2008). These data 
indicate that substrate recognition by AMPK may be less stringent than thought earlier.  
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UniProt Name Ref. Abbr., P-site  5 4 3   0    4   
     Ф β   P    Ф   
Q9BZL4 Protein phosphatase 1 regulatory subunit 12C (Banko et al., 2011) hPP12c-Ser452 G L Q R S A S S S W L E G 
Q07866 Kinesin light chain 1 (McDonald et al., 2010) hKLC1-Ser521 N M E K R R S R E S L N V 
Q16875 6-phosphofructo-2-kinase (Marsin et al., 2002) hF262-Ser461 P L M R R N S V T P L A S 
P49815 Tuberin (Inoki et al., 2003) hTSC2-Ser1387 P L S K S S S S P E L Q T 
P49815 Tuberin (Inoki et al., 2003) hTSC2-Thr1271 P L P R S N T V A S F S S 
Q53ET0 CREB-regulated transcription coactivator 2 (Koo et al., 2005; 
Screaton et al., 2004) 
hCRTC2-Ser171 A L N R T S S D S A L H T 
Q06210 Glucosamine-fructose-6-phosphate aminotransferase 1 (Li et al., 2007) hGFPT1-Ser261 N L S R V D S T T C L F P 
P41235 Hepatocyte nuclear factor 4-alpha (Hong et al., 2003) hHNF4A-Ser313 K I K R L R S Q V Q V S L 
O70405 Serine/threonine-protein kinase ULK1 (Egan et al., 2011; 
Shang et al., 2011) 
hULK1-Ser638 D F P K T P S S Q N L L A 
P04049 RAF proto-oncogene serine/threonine-protein kinase 
(Sprenkle et al., 
1997) hRAF1-Ser621 K I N R S A S E P S L H R 
P13834 Glycogen synthase, muscle (Carling et al., 1989) rbGYS1-Ser8 P L S R T L S V S S L P G 
A2RRU1 Glycogen synthase, muscle (Jørgensen et al., 
2004) 
rGYS1-Ser8 P L S R S L S V S S L P G 
Q95XA8 Protein CRTC-1 (Mair et al., 2011) ceCRTC1-Ser179 Q I N R A R S D P A I H N 
P51639 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Clarke and Hardie, 1990) rHMDH-Ser871 H M V H N R S K I N L Q D 
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Ching et al., 1996) hHMDH-Ser871 H M I H N R S K I N L Q D 
Q09472 Histone acetyltransferase p300 (Yang et al., 2001) hEP300-Ser89 E L L R S G S S P N L N M 
P50552 Vasodilator-stimulated phosphoprotein (Blume et al., 2007) hVASP-Ser322 T L P R M K S S S S V T T 
Q62600 Nitric oxide synthase, endothelial (Chen et al., 1999) hNOS3-Thr495 G I T R K K T F K E V A N 
Q9UQL6 Histone deacetylase 5 (McGee et al., 2008)  hHDAC5-Ser259 P L R K T A S E P N L K V 
O70405 Serine/threonine-protein kinase ULK1 (Egan et al., 2011) hULK1-Ser467 A I R R S G S T S P L G F 
Q05469 Hormone-sensitive lipase (Garton and Tonks, 
1994) 
rLIPS-Ser565 S M R R S V S E A A L A Q 
Q16526 Cryptochrome-1 (Lamia et al., 2009) hcry1-Ser71 N L R K L N S R L F V I R 
P13569 Cystic fibrosis transmembrane conductance regulator (King et al., 2009) hCFTR-Ser768 Q A R R R Q S V L N L M T 
Q8N122 Regulatory-associated protein of mTOR (Gwinn et al., 2008) hRPTOR-Ser792 K M R R A S S Y S S L N S 
Q92538 Golgi-specific GTP/GDP exchange factor 1 
(Miyamoto et al., 
2008) hGBF1-Thr1337 K I H R S A T D A D V V N 
Q8VIP2 Carbohydrate-responsive element-binding protein (Kawaguchi et al., 2002) rChREBP-Ser568 L L R P P E S P D A V P E 
O00763 Acetyl-CoA carboxylase 2 (Merrill et al., 1997) hACC2-Ser222 T M R P S M S G L H L V K 
P35570 Insulin receptor substrate 1 
(Jakobsen et al., 
2001) rIRSI-Ser794 H L R L S S S S G R L R Y 
P11497 Acetyl-CoA carboxylase 1 (Munday et al., 1988) rACC1-Ser79 H M R S S M S G L H L V K 
Q8N122 Regulatory-associated protein of mTOR (Gwinn et al., 2008) hRPTOR-Ser722 R L R S V S S Y G N I R A 
 
 
Figure 4. AMPK substrates with the stringent AMPK 
consensus recognition motif. Phospho-sites of published 
AMPK substrates were analyzed for their compliance with 
the consensus sequence of AMPK substrate recognition (Dale 
et al., 1995; Scott et al., 2002) which is Φ(β,X)XXS/TXXXΦ (Φ 
being a hydrophobic residue and β any basic residue). Top: 
Sequences including six amino acids N- and C-terminal of the 
Ser or Thr phosphoacceptor (P) were aligned (UniProt 
identifiers, protein name and phosphosites are given; amino 
acids corresponding to the consensus sequence are color 
coded – orange: A,F,I,L,M,V,W; blue: K,R,H: green: S,T).  
Right: The frequency of individual amino acids at a specific 
position was calculated using the sequence logo algorithm 
(Crooks et al., 2004; Schneider and Stephens, 1990). 
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UniProt Name Ref. Abbr., P-site  5 4 3   0    4   
     Ф β   P    Ф   
Q9UQB8 Brain-specific angiogenesis inhibitor 1-assoc. protein 2 (Banko et al., 2011) hBAIP2-Ser366 T L P R S S S M A A G L E 
O70405 Serine/threonine-protein kinase ULK1 (Egan et al., 2011) hULK1-Thr575 K L P K P P T D P L G A V 
Q9UQL6 Histone deacetylase 5 (McGee et al., 2008) hHDAC5_Ser498 P L S R T Q S S P L P Q S 
P30260 Cell division cycle protein 27 homolog (Banko et al., 2011) hCDC27-Ser379 A L P R R S S R L F T S D 
O43524 Forkhead box protein O3 (Greer et al., 2007) hFOXO3-Ser413 L M Q R S S S F P Y T T K 
P52292 Importin subunit alpha-2 (Wang et al., 2004) hIMA2-Ser105 A A R K L L S R E K Q P P 
P46527 Cyclin-dependent kinase inhibitor 1B (Liang et al., 2007) hCDN1B-Thr198 G L R R R Q T - - - - - - 
O70405 Serine/threonine-protein kinase ULK1 (Egan et al., 2011) hULK1-Ser556 L G C R L H S A P N L S D 
Q16526 Cryptochrome-1 (Lamia et al., 2009) hCRY1-Ser280 K K V K K N S S P P L S L 
O60343 TBC1 domain family member 4 (Geraghty et al., 2007) hTBC1D4-Ser588 M R G R L G S V D S F E R 
O60343 TBC1 domain family member 4 (Geraghty et al., 2007) hTBC1D4-Thr642 F R R R A H T F S H P P S 
Q14654 ATP-sensitive inward rectifier potassium channel 11 (Chang et al., 2009) Hirk11-Ser385 K P K F S I S P D S L S - 
Q9UBS5 Gamma-aminobutyric acid type B receptor subunit 1 
(Terunuma et al., 
2010) hGABR1-Ser912 L R H Q L Q S R Q Q L R S 
Q9BU19 Zinc finger protein 692 (Inoue and Yamauchi, 2006) hZN692-Ser470 A H R S S K S H P A L L L 
Q9NYV6 Transcription initiation factor IA (Hoppe et al., 2009) hTIFIA-Ser635 T H F R S P S S S V G S P 
Q62600 Nitric oxide synthase, endothelial (Chen et al., 1999) hNOS3-Ser1177 S R I R T Q S F S L Q E R 
P42345 Serine/threonine-protein kinase mTOR (Cheng et al., 2004) hMTOR-Thr2446 K R S R T R T D S Y S A G 
P50552 Vasodilator-stimulated phosphoprotein (Blume et al., 2007) hVASP-Thr278 A R R R K A T Q V G E K T 
Q07866 Kinesin light chain 1 
(McDonald et al., 
2010) hKLC1-Ser524 K R R S R E S L N V D V V 
P04637 Cellular tumor antigen p53 (Jones et al., 2005) hP53-Ser15 S V E P P L S Q E T F S D 
O95278 Laforin (Romá-Mateo et al., 
2011) 
hEPM2A-Ser25 E L L V V G S R P E L G R 
P49674 Casein kinase I isoform epsilon (Um et al., 2007) hKC1E-Ser389 G A P A N V S S S D L T G 
P13405 Retinoblastoma-associated protein (Dasgupta and Milbrandt, 2009) hRB-Ser804 Y I S P L K S P Y K I S E 
O00418 Eukaryotic elongation factor 2 kinase (Browne et al., 2004) hEFK2-Ser398 S L P S S P S S A T P H S 
Q9UQK1 Protein phosphatase 1 regulatory subunit 3C (Vernia et al., 2009) hPPR36-Ser33 R L C L A H S P P V K S F 
O75899 Gamma-aminobutyric acid type B receptor subunit 2 (Terunuma et al., 2010) hGABR2-Ser783 T S V N Q A S T S R L E G 
Q13621 Kidney-specific Na-K-Cl symporter (Fraser et al., 2007) hNKCC2-Ser126 P K V N R P S L L E I H E 
Q95XA8 Protein CRTC-1 (Mair et al., 2011) ceCRTC1-Ser76 G H N L G G S L P N V H Q 
Q9UQK1 Protein phosphatase 1 regulatory subunit 3C (Vernia et al., 2009) hPPR36-Ser293 E S T I F D S P R L A S G 
Q13177 Serine/threonine-protein kinase PAK 2 (Banko et al., 2011) hPAK2-Ser20 A P P V R M S T I F S T G 
P26285 6-phosphofructo-2-kinase (Rider et al., 2004) bF262-Ser466 V R M R R N S V T P L A S 
P12277 B-type creatine kinase Ramirez unpubl. hBCK-Ser9  M P F S N S H N A L K L 
 
Figure 5. AMPK substrates with non-consensus recognition 
motifs. Phospho-sites of published AMPK substrates were 
analyzed for their compliance with the consensus sequence 
of AMPK substrate recognition (Dale et al., 1995; Scott et 
al., 2002) which is Φ(β,X)XXS/TXXXΦ (Φ being any 
hydrophobic residue and β any basic residue). Top: 
Sequences including six amino acids N- and C-terminal of 
the Ser or Thr phosphoacceptor (P) were aligned (UniProt 
identifiers, protein name and phosphosites are given; 
amino acids corresponding to the consensus sequence are 
color coded – orange: A,F,I,L,M,V,W; blue: K,R,H; green: 
S,T). Right: The frequency of individual amino acids at a 
specific position was calculated using the sequence logo 
algorithm (Crooks et al., 2004; Schneider and Stephens, 
1990). 
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AMPK signaling downstream 
Once activated, AMPK regulates a large number of downstream targets (Figure 6), shutting 
down anabolic pathways and stimulating catabolic pathways. Metabolic changes induced by 
AMPK are both acute changes due to direct phosphorylation of metabolic enzymes and 
chronic changes due to effect on gene expression by phosphorylation of transcription 
(co)factors and histone deacetylases (HDACs). Both result in the preservation  of ATP levels 
(Carling, 2005; Hardie and Sakamoto, 2006). AMPK also participates in the control of non-
metabolic processes such as cell proliferation and cell cycle (Beevers et al., 2006; Browne et 
al., 2004; Hay and Sonenberg, 2004).  
 
 
Figure 6. Metabolic changes known to be induced by AMPK in muscle. Question marks indicate that the direct 
target for AMPK responsible for the observed downstream is not known. (Hardie and Sakamoto, 2006). 
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AMPK regulates carbohydrate metabolism 
Glucose uptake across the plasma membrane is dependent on the glucose gradient as well as 
a family of transmembrane glucose transporters (GLUT). GLUTs are stored in cytosolic vesicles 
that translocate to the plasma membrane in response to triggers like muscle contraction, 
AMPK activation and insulin. Importantly, during exercise, glucose uptake increases 
independent of the insulin signaling pathway (Jørgensen et al., 2006) due to AMPK activation. 
Active AMPK increases GLUT4 translocation in muscle, cardiomyocytes and adipocytes (Kurth-
Kraczek et al., 1999; Webster et al., 2010; Yamaguchi et al., 2005) and also increases GLUT3 
translocation in neurons (Weisová et al., 2009). The signaling events, by which activation of 
AMPK leads to the translocation of these transporters remain unclear. Some studies revealed 
a critical role for the Rab GTPases Akt substrate of 160 kDa (AS160) (Cartee and Wojtaszewski, 
2007; Sakamoto and Holman, 2008; Zaid et al., 2008). AMPK was shown to directly 
phosphorylate AS160, an effect which directly enhances binding to 14-3-3 (Geraghty et al., 
2007), which in turn regulates vesicle translocation (Sakamoto and Holman, 2008; Treebak et 
al., 2006). Finally, AMPK increases the subsequent glycolytic flux via phosphorylation and 
activation of 6-phosphofructosekinase-2 (PFK2) (Marsin et al., 2000).  
AMPK affects carbohydrate metabolism also in the long-term via transcriptional regulation. 
Phosphorylation of both peroxisome proliferator-activated receptor gamma co-activator-1 
alpha (PGC-1α) (Horman et al., 2006) and histone deacetylase (HDAC) 5 (McGee et al., 2008) 
mediates transcriptional up-regulation of rate-limiting enzymes for the uptake of glucose, 
such as GLUT4 (Steinberg and Kemp, 2009) and hexokinase II (HKII) (Stoppani et al., 2002).  
Hepatic glucose production, is negatively regulated by AMPK activation. Active AMPK 
downregulates the transcription of the gluconeogenic enzymes, L-type pyruvate kinase (L-PK) 
(Leclerc et al., 1998; da Silva Xavier et al., 2000), phosphoenol pyruvate carboxykinase (PEPCK) 
(Lochhead et al., 2000), and glucose-6-phosphatase (G-6-Pase) (Woods et al., 2000) by 
phosphorylation of transcription factor HNF-4α and transcriptional activator CREB (Steinberg 
and Kemp, 2009).  
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AMPK regulates lipid metabolism 
Uptake of fatty acids (FA), similar as in case of glucose, depends on a transmembrane 
transporter (FAT/CD36) that is stored in cytosolic vesicles and translocated to the plasma 
membrane after AMPK activation (van Oort et al., 2009; Schwenk et al., 2010), thus increasing 
FA uptake (Shearer et al., 2004, 2005). It is unknown whether AMPK acts directly on CD36 or 
indirectly as is the case of regulation of glucose uptake. 
AMPK is a main regulator of Acetyl-coA carboxylase (ACC), able to phosphorylate a number of 
serine residues on both cytosolic and mitochondrial ACC isoforms, (ACC1 and ACC2, 
respectively). The function of ACC is to regulate the metabolism of fatty acids. ACC catalyzes 
the carboxylation of acetyl-CoA to malonyl-CoA, a building block for FA synthesis and an 
allosteric inhibitor of mitochondrial carnitine palmitoyltransferase 1 (CPT1), a rate limiting 
enzyme for FA import and β-oxydation in the mitochondria (Bianchi et al., 1990; Merrill et al., 
1997; Munday, 2002; Merrill et al., 1997). AMPK-mediated short term inhibition of ACC 
suppresses FA synthesis and increases FA β-oxydation by relieving the inhibitory effect of 
malonyl CoA on CPT1 (Munday, 2002). 
The regulation of triglyceride (TG) turnover is a balance between biosynthesis and hydrolysis 
of TG, and AMPK is suggested to inhibit both. AMPK regulates TG synthesis via reducing 
activity of glycerol-3-phosphate acyl transferase (GPAT), which regulate one of the first steps 
of TG synthesis (Muoio et al., 1999). AMPK also appears to negatively regulate hormone-
sensitive-kinase (HSL) activity and thus TG degradation (Watt et al., 2006). 
Finally, AMPK phosphorylates and inhibits the rate-limiting enzyme for isoprenoid and 
cholesterol synthesis, the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), thus 
preventing energy consuming cholesterol synthesis (Clarke and Hardie, 1990).  
 
AMPK regulates protein metabolism, cell polarity, growth and apoptosis 
Protein synthesis accounts for a large proportion of cellular ATP use. AMPK-mediated 
inhibition of protein synthesis is thus an important mechanism to maintain high ATP level. 
AMPK blocks the ribosomal elongation step by phosphorylation and activation of the 
eukaryote elongation factor 2 kinase (eEF2K) which in turn inhibits eEF2 (Browne et al., 2004).  
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AMPK also acts via cross-talk with other major cellular signaling hubs like the mammalian 
target of rapamycin complex (mTORC) which is inhibited by activated AMPK via two major 
distinct mechanism. The first involves the phosphorylation of the tuberous sclerosis complex 
protein-2 (TSC2) (Inoki et al., 2003) upstream of mTORC. The second mechanism involves 
direct phosphorylation of the mTORC subunit Raptor, causing mTORC inactivation (Gwinn et 
al., 2008). mTORC is a serine/threonine protein kinase which controls many aspects of 
metabolism, peptide translation, ribosome biogenesis, but also cell growth, cell proliferation, 
cell motility, and apoptosis, suggesting that AMPK-mediated modulation of mTORC is involved 
in regulation of these pathway (Beevers et al., 2006; Hay and Sonenberg, 2004).  
 
AMPK regulates whole body energy metabolism 
AMPK is established since long as a cellular energy sensor. The finding that hormones (e.g. 
leptin, adiponectin) activate AMPK in muscle and liver provides evidence for AMPK regulation 
of whole body energy status (Orci et al., 2004; Wang et al., 2007, 2005). Hypothalamic AMPK 
regulates food intake (Minokoshi et al., 2004) by the anorexigenic hormone leptin which leads 
to a reduction in food intake and the orexigenic hormone ghrelin as well as pharmacological 
activation of AMPK in hypothalamus which both leads to increased food intake (Andersson et 
al., 2004).  
 
AMPK in human disease and as a therapeutic target 
Cardiovascular pathologies 
Several mutations in Bateman domains of the AMPK γ-subunits have been mapped and lead 
to a glycogen storage disorder and a related hereditary heart disease (Wolff-Parkinson-White 
syndrome), involving cardiac hypertrophy, contractile dysfunction and arrhythmias (Blair et 
al., 2001; Davies et al., 2006; Gollob et al., 2001; Milan et al., 2000; Scott et al., 2004). These 
mutations have been found to impair both the binding of AMP to the isolated Bateman 
domains and the activation of the heterotrimeric complex by AMP (Burwinkel et al., 2005; 
Scott et al., 2004). These mutations affect not only AMP binding, but also reduce ATP binding, 
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an inhibitory nucleotide (Burwinkel et al., 2005; Scott et al., 2004), resulting in increased basal 
activity of the mutated AMPK complexes (Arad et al., 2002; Burwinkel et al., 2005; Hamilton 
et al., 2001). The higher basal activity appears to cause excessive storage of glycogen in cardiac 
myocytes, possibly through increased basal glucose uptake (Arad et al., 2002; Burwinkel et al., 
2005). In cardiac myocytes, this excessive glycogen storage is harmful and leads to improper 
development and function of the heart muscle. Interestingly, a similar mutation (R200Q) 
affecting a conserved basic residue in the first CBS motif of the γ3 isoform (which is expressed 
at the highest levels in skeletal muscle) leads to abnormal deposition of glycogen in skeletal 
muscle of pigs (Milan et al., 2000).  
 
AMPK related neurodegenerative diseases 
Brain is the most energy-consuming organ in our body, but specific functions of AMPK in this 
organ have only recently been studied. The kinase is widely expressed in the brain, and AMPK 
activity is tightly coupled to the energy status of both neuronal and whole-body levels. Recent 
studies revealed an important role of AMPK in neurodegenerative disease.  
AMPK is particularly implicated in Alzheimer disease (AD) (Salminen et al., 2011)), which is 
characterized by accumulation of pathological protein aggregates like extracellular amyloid β 
(Aβ) plaques and intracellular neurofibrillary tangles, as well as by neuronal loss (Bettens et 
al., 2010; Bürklen et al., 2006; Jellinger, 2006). Aβ is the key molecule in AD, and it has been 
shown to be down-regulated by AMPK in primary cortical neurons and N2a neuroblastoma 
cells (Chen et al., 2009; Marambaud et al., 2005; Won et al., 2010). AMPK also has an inhibitory 
effect on Aβ production (Vingtdeux et al., 2010) and regulates Aβ degradation and removal 
from neurons (Vingtdeux et al., 2011).  
Although studies on the involvement of the AMPK signaling cascade in other 
neurodegenerative disorders are still scarce, the role of AMPK does not seem to be limited to 
AD. In Hutington disease (HD), the AMPKα1 subunit was selectively activated and enriched in 
the nucleus of striatal neurons. AMPK over-activation enhanced neuronal death and 
formation of Huntington aggregates. In contrast, suppression of AMPK activity showed a 
neuroprotective effect (Ju et al., 2011). Similar effects of AMPK activation has been observed 
in Parkinson disease (PD), (Choi et al., 2010). 
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AMPK is related to cancer  
Cancer is a broad group of pathologies involving unregulated cell growth. Cancer cells have a 
huge demand for energy to allow rapid growth and division. A large number of evidence 
suggests that basal AMPK activity, as well as its activation under energy-limiting conditions, 
antagonize cancer cell growth. First, activation of AMPK causes a reduction in anabolic 
pathways, ultimately leading to reduced cell growth (reviewed in (Shackelford and Shaw, 
2009)). Second, the AMPK signaling cascade contains a number of tumor suppressors including 
its upstream kinase LKB1 and its downstream targets p53, TSC1/2 and mTOR. AMPK activation 
affects these targets to decrease cell growth, thus acting as a tumor suppressor. Another 
pathway by which AMPK can affect tumors growth is via its impact on lipid synthesis. Cancer 
cells exhibit high rates of de novo fatty acid synthesis (Alò et al., 1999; Milgraum et al., 1997; 
Swinnen et al., 2000) and a number of studies have shown that inhibition of FA synthesis result 
in significant anti-tumor activity, by inhibiting growth and increasing apoptosis (Kuhajda, 
2000; Pizer et al., 2000). In the liver, FA synthase (FAS) gene expression is downregulated by 
AMPK (Foretz et al., 1998; Woods et al., 2000). As mentioned above, AMPK phosphorylates 
and inhibits also acetyl-CoA carboxylase (ACC), an important step in FA synthesis (Chajès et 
al., 2006; Hardie and Carling, 1997).  
All of these mechanisms imply that AMPK acts as a tumor suppressor and that activation of 
AMPK would be advantageous in treating cancer. However, more recent studies have 
emerged that lead to the opposite conclusion. In certain cancer cells (e.g. prostate), increased 
AMPK activity provides the cells with an advantage by increasing the rate of glucose uptake 
and glycolysis (Banko et al., 2011; Massie et al., 2011), increasing mitosis (Banko et al., 2011), 
and increasing cell migration (Frigo et al., 2011). Cells lacking AMPK can be resistant to 
oncogenic transformation (Laderoute et al., 2006). The levels of AMPK subunits α, β, and γ are 
elevate in 2% to 25% of human cancers (cancergenome.nih.gov) and cancer cell lines. There is 
now solid proof for AMPK supporting tumor proliferation (Liang and Mills, 2013).  
To date, it is difficult to reconcile these apparently opposing effects of AMPK on cell growth. 
Possibly, AMPK acts as a tumor suppressor only during the early events of oncogenic 
transformation, while in more developed, in particular solid tumors, its anti-stress effect 
facilitates tumor growth. More research is required to determine the precise role of AMPK in 
cancer. 
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AMPK a potential target for treatment of type 2 diabetes 
Type 2 diabetes is a metabolic disorder characterized by hyperglycemia and altered lipid 
metabolism, caused by the islet β cells being unable to secrete adequate amounts of insulin. 
Regular exercise is an effective method of treating insulin resistance and type 2 diabetes 
(Saltiel and Kahn, 2001), and this beneficial effect is at least partly mediated by AMPK 
activation (Fujii et al., 2008). Metformin, the most widely prescribed Type 2 diabetes drug, has 
been shown to activate AMPK (Zhou et al., 2001) and to do so in an LKB1 dependent manner 
(Shaw et al., 2005). In intact cells, metformin increases AMPK activity, resulting in increased 
fatty acid oxidation, downregulation of lipogenic genes, decreased hepatic glucose production 
and stimulation of glucose uptake (Zhou et al., 2001). Nonetheless, metformin, AICAR 
(AICAriboside, an indirect AMPK activator) (Halseth et al., 2002), and A769662 (a direct AMPK 
activator (Cool et al., 2006), as well as genetic expression of constitutively active AMPK in liver 
(Foretz et al., 2005) all lower blood glucose levels, suggesting AMPK activation as a primary 
target for diabetes prevention and therapy (Zhang et al., 2009).  
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Rationale of the project 
Intracellular sensors of cellular energy and nutrient status are emerging as key players in the 
regulation of cell metabolism in health and disease. AMP-activated protein kinase (AMPK) has 
a central role in the regulation of cellular and whole body energy metabolism, and an ever 
increasing number of studies imply AMPK in major pathologies affecting modern societies 
such as cancer, cardiovascular and neurodegenerative diseases, diabetes and metabolic 
syndrome (Carling et al., 2012; Chuang et al., 2013; Zaha and Young, 2012). AMPK seems to 
become a promising drug target for these diseases, and particular efforts have been invested 
so far in the development of AMPK activators as anti-diabetic drugs (Zhang et al., 2009; Zhou 
et al., 2001). However, while the pleiotropic physiological actions of AMPK have favored its 
role as a putative therapeutic target, they also suggest that AMPK activators or inhibitors 
should be envisaged with caution for clinical therapy. This has been recognized for example 
for the use of AMPK activation in anti-cancer therapy (Chuang et al., 2013). Thus, targeting 
AMPK to cure diseases requires more fundamental research to understand the essential and 
pleiotropic roles of AMPK in cell metabolism.    
Protein-protein interactions are essential for the majority of complex biological functions. 
Protein interactions include not only high affinity interactions leading to formation of stable 
protein complexes, but also lower affinity transient interactions, more frequent in signal 
transduction (e.g. ligand-receptor). In the latter case, interacting proteins can just provide a 
scaffold for another protein to recruit it to specific localizations, or they use the interaction to 
modify the interacting partner (e.g. via secondary modifications like phosphorylation). Indeed, 
proteins always have to interact to carry out their biological function.  
Identification of AMPK interactors is essential to understand its upstream regulation and 
downstream function. Emergence of high throughput screening methods has largely 
facilitated such approaches. So far, few large-scale screens yielded information on AMPK 
interaction partners and substrates: in vitro phosphoscreens (e.g. Thali et al., 2010; Tuerk et 
al., 2007), chemical genetic screens (Banko et al., 2011) and peptide library/bioinformatics 
approaches (Gwinn et al., 2008) for AMPK substrates, as well as yeast-two-hybrid (Y2H) 
screens (Moreno et al., 2009) and large scale anti-bait co-immunoprecipitation (IP) follow by 
LC-ESI-MS/MS (e.g. Ewing et al., 2007) for interaction partners. However, only few of the 
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identified putative AMPK substrates and interactors were confirmed by a second method 
and/or in vivo.  In particular co-IP studies do not allow confirming a direct interaction, so many 
of the identified proteins may interact only indirectly with AMPK.  
 
Aim of the project 
Different non-biased screening approaches for AMPK substrates (surface-plasmon-resonance 
(SPR) screening combined with LC-MS/MS and in vitro phosphorylation) and for AMPK 
interaction partners (Y2H screens), performed by our group, had yielded a number of 
candidate proteins. These screening procedures as well as some initial confirmation and 
characterization experiments for selected candidates, were carried out within the PhD thesis 
of Anna Brückner and the postdoctoral work of Cécile Polge and Alexandre Berthier. However, 
many molecular details (like e.g. interaction domains) and most importantly the physiological 
function of these interactions remained unclear. Other candidates were not yet characterized 
beyond the initial screening data. 
Table 1. Confirmed AMPK interactors.  
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AMPK 
phosphorylation 
consensus-site1 
Glutathione-S-transferase 
(GST) 
 Detoxification 
 Antioxidant 1 
X X X X 
Fumarate hydratase (FH)  Mitochondrial: Krebs cycle 
 Cytosolic: tumor suppressor  
3 X  X X 
E3 ubiquitin-protein ligase 
NRDP1 (NRDP1) 
 Protein degradation 1 X X   
Vesicle associate membran 
protein (VAMP2/3) 
 Endo & exocytose 
 Glucose and fatty acid uptake - 
X X X X 
Interactions found by targeted analysis (green), SPR interaction/phosphorylation assays (red) and Y2H techniques (blue) were 
confirmed by at least two other, independent interaction methods. 1 Consensus sites were determined by sequence analysis 
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The goal of this thesis was therefore to further investigate some of the AMPK interactors and 
to understand the biological function of the interaction. From the list of putative AMPK 
interactors and substrates, four proteins have been selected based on their potential 
importance in metabolic pathways known to be regulated by AMPK (Table 1). The resulting 
sub-projects are presented in four separate chapters, followed by a general discussion:  
 
 Glutathione S-transferase (GST). Multiple evidence (Y2H, SPR and co-IP) demonstrated 
AMPK/GST interaction, and initial data suggested that this served to phosphorylate AMPK. 
However, subsequent mass spectrometry analysis indicated that the main 
phosphorylation occurred in the Strep-tag of the recombinant protein. Thus other putative 
functions AMPK/GST interaction had to be explored like GST-facilitated glutathionylation 
(Zmijewski et al., 2010) and glutathionylation-induced AMPK activation (Manevich et al., 
2004; Ralat et al., 2006; Townsend et al., 2009), which were both, albeit separately, 
described in literature. The aim of this sub-project was thus to set-up glutathionylation 
assays and to look into GST-dependent glutathionylation of AMPK. The results have been 
published in the meantime (Klaus et al., 2013).  
 
 Fumarate hydratase (FH). Initial Y2H and in vitro phosphorylation experiments had shown 
that FH interacts with and is phosphorylated by AMPK. The interaction was confirmed by 
SPR and another Y2H method. The aim of this sub-project was to further validate the 
interaction by co-IP, examine its consequences on FH activity in vitro and in vivo and 
identify the involved AMPK phospho-residue(s). Part of these results has been published 
(Klaus et al., 2012) 
 
 E3-ubiquitin-ligase (NRDP1). NRDP1 was the only entirely soluble candidate interactor 
found in the initial Y2H screen. In addition, other E3-ubiquitin-ligases have been shown to 
be regulated by AMPK like MuRF1 and Atrogin-1 (Baskin and Taegtmeyer, 2011), or to 
regulate AMPK like malin in complex with laforin (Moreno et al., 2010). The aim of this 
sub-project was to produce for the first time the full-length NRDP1 protein and examine 
both putative regulations: of NRDP1 by AMPK, and of AMPK by NRDP1.  
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 Vesicle-associated membrane proteins (VAMP2 and VAMP3). VAMP proteins seemed the 
most attractive candidate interactors in the initial Y2H screen, since they are key elements 
of energy-dependent exocytotic processes, but on the other hand they also improve 
energy state by cell surface expression of nutrient transporters. However, VAMPs turned 
out not to be phosphorylated by AMPK. The aim of the sub-project was thus to further 
characterize the VAMP/AMPK interaction and to study its function by developing a 
strategy for its disruption in vitro and in vivo. 
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Glutathione S-
transferase 
interacts with AMP-
activated protein 
kinase: evidence for  
S-glutathionylation 
and activation in 
vitro 
Abstract. AMP-activated protein kinase (AMPK) is 
a cellular and whole body energy sensor with 
manifold functions in regulating energy 
homeostasis, cell morphology and proliferation in 
health and disease. Here we apply multiple, 
complementary in vitro and in vivo interaction 
assays to identify several isoforms of glutathione 
S-transferase (GST) as direct AMPK binding 
partners: Pi-family member rat GSTP1 and Mu-
family members rat GSTM1, as well as 
schistosoma japonicum GST. GST/AMPK 
interaction is direct and involves the N-terminal 
domain of the AMPK β-subunit. Complex 
formation of the mammalian GST-P1 and -M1 
with AMPK leads to their enzymatic activation 
and in turn facilitates glutathionylation and 
activation of AMPK in vitro. GST-facilitated S-
glutathionylation of AMPK may be involved in 
rapid, full activation of the kinase under mildly 
oxidative physiological conditions. 
 
Résumé. La protéine kinase activée par l’AMP 
(AMPK) est  un senseur métabolique de la cellule 
et de l’organisme avec diverses fonctions dans la 
régulation de l’homéostasie énergétique, ainsi 
que dans la morphologie et la prolifération 
cellulaires, que ce soit en conditions 
physiologiques ou pathologiques. Dans cette 
étude nous avons appliqué divers tests 
d’interaction in vitro et in vivo pour 
l’identification d’isoformes de la glutathion S-
transferase (GST) interagissant directement avec 
l’AMPK: GSTP1 et GSTM1 (de rat) respectivement 
membre de la sous-famille Pi- et  Mu-GST, et la 
GST de schistosoma japonicum. L’interaction 
GST/AMPK est directe et implique le domaine N-
terminal de la sous-unité β de l’AMPK. La 
formation d’un complexe entre GSTP1 ou GSTM1 
avec l’AMPK conduit à leur activation 
enzymatique, facilitant la glutathionylation et 
l’activation de l’AMPK in vitro. La S-
glutathionylation de l’AMPK par GST peut être 
impliquée dans l’activation rapide et totale de la 
kinase en conditions physiologiques légèrement 
oxydatives. 
This part has been published in PLoS One [Klaus, A., Zorman, S., Berthier, A., Polge, C., Ramirez, S., 
Michelland, S., Sève, M., Vertommen, D., Rider, M., Lentze, N., et al. (2013). Glutathione S-Transferases 
Interact with AMP-Activated Protein Kinase: Evidence for S-Glutathionylation and Activation In Vitro. PloS 
One 8, e62497.]. I am co-first author of this publication, I did the functional study that concerns AMPK 
gluthathionylation and activation by GST 
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Introduction 
AMP-activated protein kinase (AMPK) is an evolutionary conserved heterotrimeric 
serine/threonine kinase that plays a central role in sensing and regulating energy homeostasis 
at the cellular, organ and whole-body level (recently reviewed in (Carling et al., 2012; Hardie, 
2011; Hardie et al., 2012; Neumann et al., 2003a; Steinberg and Kemp, 2009; Viollet et al., 
2009; Zhang et al., 2009)). It exerts pleiotropic control of metabolic pathways and other 
physiological functions like cell growth, proliferation, motility or appetite control by affecting 
enzyme activities and transcription. This has made the kinase a prime pharmacological target 
for treating metabolic disorders or cancer (Fogarty and Hardie, 2010; Neumann et al., 2003b; 
Zhang et al., 2009). Activation of AMPK is triggered by a diverse array of external (e.g. 
hormones, cytokines, nutrients) and internal signals (e.g. AMP, ADP) linked to limited energy 
availability in physiological and pathological situations. Activation involves covalent 
phosphorylation of the α-subunit and allosteric binding of AMP or ADP to the γ-subunit. 
Covalent activation is complex, since it involves stimulated phosphorylation by upstream 
kinases (LKB1, CamKKβ) and inhibited dephosphorylation by phosphatases, both favored by 
binding of AMP and also ADP to different sites in the γ-subunit (Oakhill et al., 2011; Xiao et al., 
2011) and myristoylation at the β-subunit (Oakhill et al., 2010). 
Increasing evidence suggests that AMPK is also activated by reactive oxygen or nitrogen 
species (ROS, RNS), although the involved mechanisms are not entirely clear. The known 
inhibitory effect on mitochondrial ATP generation may simply increase cytosolic ADP/ATP and 
AMP/ATP ratios (Hawley et al., 2010), but also other, non-canonical activation mechanisms 
are conceivable. We and others have reported for example that ROS/RNS, in particular 
peroxynitrite, may interfere with AMPK upstream signaling (Xie et al., 2006, 2008; Zou et al., 
2004). Vice versa, AMPK activation is involved in downstream redox regulation that can 
prolong cell survival (Jeon et al., 2012) and induces expression of anti-oxidative proteins like 
superoxide dismutase (SOD), catalase or thioredoxin (Colombo and Moncada, 2009; Kukidome 
et al., 2006; Wang et al., 2010). 
More recently, S-glutathionylation of Cys299 and Cys304 in the AMPK α-subunit via exposure 
to the strong oxidant H2O2 was reported to activate AMPK (Zmijewski et al., 2010). This 
reversible posttranslational protein modification can act as a functional switch like the well-
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known protein phosphorylation and also protect thiol groups against further oxidation 
(reviewed in (Pastore and Piemonte, 2012; Pimentel et al., 2012; Xiong et al., 2011)). In case 
of AMPK, it probably causes activating conformational changes similar to those provoked by 
AMP-binding (Chen et al., 2012; Riek et al., 2008). Protein S-glutathionylation is often induced 
non-enzymatically upon expose to strong oxidants, in particular in vitro in combination with 
high glutathione levels (Pastore and Piemonte, 2012; Pimentel et al., 2012; Xiong et al., 2011), 
as shown for AMPK in presence of 200 mM H2O2 (Zmijewski et al., 2010). Intracellular levels 
of H2O2, e.g. in human fibroblasts, may at best reach the low nanomolar range (Arbault et al., 
1997), thus spontaneous S-glutathionylation in vivo would occur rather slowly and at low 
levels (Xiong et al., 2011). It may be more important in pathological, highly oxidative situations 
which change the cellular thiol redox state (ratio of reduced to oxidized glutathione, 
GSH/GSSG) and generate radical intermediates or oxidized cysteins. In vivo, protein 
glutathionylation is rather facilitated by specific enzymes that may constitute a dynamically 
regulated S-glutathionylation cycle (Anathy et al., 2012; Pimentel et al., 2012; Xiong et al., 
2011). Sulfiredoxins (SRx) and glutaredoxins (Grx) can act in protein deglutathionylation, and 
the latter enzyme also catalyzes the inverse reaction. More recently, isoforms of glutathione 
S-transferase (GST (Townsend et al., 2009)), mainly GSTP1, were identified as catalysts of 
protein S-glutathionylation (de Luca et al., 2011; Manevich et al., 2004; Ralat et al., 2006; 
Townsend et al., 2009; Wetzelberger et al., 2010) confirming earlier models proposed by 
Townsend, Tew and colleagues (for recent reviews see (Tew and Townsend, 2011, 2012; Tew 
et al., 2011)). 
GSTs occur as a large superfamily of mitochondrial and cytosolic proteins. In mammals, there 
are seven classes of cytosolic GSTs, including the Alpha-, Mu-, and Pi-families (Hayes et al., 
2005), and lower eukaryotes express orthologs of these. A GST of the unicellular parasite 
Schistosoma japonicum belonging to the Mu-family is well known as the GST-tag used in fusion 
proteins to favor solubility and purification of proteins (Smith, 2000). Historically, GSTs were 
characterized as class II detoxification enzymes that react glutathione with electrophilic 
compounds like by-products of oxidative stress and xenobiotics, thus facilitating their 
elimination from the cell (reviewed in (Frova, 2006; Hayes et al., 2005; Lo and Ali-Osman, 
2007)). However, some GSTs are now also emerging as ligands or modulators of signaling 
kinases like JNK, ASK1, PKC, PKA or EGFR, where either the interacting kinase or the GST is 
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modified, functionally altered or relocated within the cell (Adler et al., 1999; Cho et al., 2001; 
Gilot et al., 2002; Lo et al., 2004; Yin et al., 2000). 
In particular GSTP1 was proposed to initiate a coordinated redox regulation of stress kinases 
to reduce cell death (Adler et al., 1999; Cho et al., 2001; Gilot et al., 2002; Lo et al., 2004; Yin 
et al., 2000). While this kind of redox regulation relies exclusively on GST protein interactions, 
the catalytic activity of GST is required for its role in protein glutathionylation. By hydrogen 
bonding of glutathione to their active site tyrosine, GST-Alpha, -Mu and -Pi enzymes decrease 
the pKa of the glutathione thiol group (R-SH) and thus favor thiol deprotonation to form the 
highly nucleophilic thiolate anion (R-S2) (Graminski et al., 1989; Nieslanik and Atkins, 2000; 
Pimentel et al., 2012). Such activated glutathione is used in various detoxification reactions, 
but also allows for S-glutathionylation of sulfenic acids (-SOH) on proteins with low pKa 
cysteines (Manevich et al., 2004; Townsend et al., 2009; Wetzelberger et al., 2010). Inversely, 
it has been speculated that low GST peroxidatic activity in presence of peroxides could 
generate glutathione sulfenic acid intermediates that would react with protein cysteine 
thiolates (Pimentel et al., 2012). The exact biochemical determinants of GST-catalyzed S-
glutathionylation remain to be fully established. In particular, most studies so far were 
dedicated to the role of GSTP1 following expose to high concentrations of ROS or RNS, while 
few is known on its role under more physiological conditions and other GST isoforms (Xiong 
et al., 2011).  
Here we describe an in vitro glutathionylation and activation of AMPK that is catalyzed by two 
mammalian GST isoforms, GSTM1 and -P1, and relies on close and direct interaction of these 
GSTs with the AMPK β-subunit as evidenced by multiple assays. Such AMPK/GST complexes 
may amplify kinase activation under mildly oxidative, physiological conditions. 
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Materials & Methods  
Cloning and protein production 
Cloning, expression and purification of GSTM1, GSTP1, GSTSj, CamKKβ, AMPK α2β2γ1 
(221WT) and AMPK α2T172Dβ2γ1 mutant (221TD) is described in (Neumann et al., 2003b; 
Riek et al., 2009) and Methods S1. For phosphorylation assays, the N-terminal Strep-tag in 
GSTM1 and P1 was removed, since mass spectrometry identified a serine being 
phosphorylated by AMPK within this tag (peptide ASWpSHPQFEK, see Methods S1, Figure S1). 
 
Yeast two-hybrid assays 
Cytosolic yeast two-hybrid (Y2H) systems, Cyto-Y2H (Möckli et al., 2007) and Split-Trp-Y2H 
(Tafelmeyer et al., 2004), both as variants developed by Dualsystems Biotech (Schlieren, 
Switzerland), are described in Methods S1 and (Möckli et al., 2007). In short, GST and AMPK 
subunits were expressed as fusion proteins, in Cyto-Y2H with a membrane anchor and the C-
terminal end of ubiquitin conjugated to a transcription factor (bait) or with the N-terminal end 
of ubiquitin (prey), and in Split-Trp-Y2H with the C-terminal (bait) or the N-terminal (prey) 
portion of Trp1p. Selective media to control the presence of bait and prey plasmid lacked 
tryptophan and leucine (SD-WL, Cyto-Y2H) or uracil and leucine (SD-UL, Split-Trp-Y2H), and 
additionally adenine and histidine (SD-AHWL, Cyto-Y2H) or tryptophan (SDUWL, Split-Trp-
Y2H) for protein interaction analysis. Spotted plates were incubated 72 h at 30°C (Cyto-Y2H) 
or up to 9 days at 27°C (Split-Trp-Y2H). 
 
Rat liver extracts, protein 
Rat liver was obtained from animals anesthetized with sodium pentobarbital (40 mg/kg, i.p.) 
according to the protocol approved by the Grenoble Ethics Committee for Animal 
Experimentation (no. 36_LBFA-LK-01). Liver tissue was immediately extracted in 10 mM HEPES 
pH 7.4 (containing 220 mM mannitol, 70 mM sucrose, 0,1% bovine serum albumin (BSA), 0.2 
mM EDTA) and centrifuged twice (1000 g and 12 000 g for 10 min each) to obtain soluble 
proteins in the supernatant for pull-down and immunoprecipitation. Protein concentrations 
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were determined according to Bradford (Bradford, 1976) with the Biorad microassay (Biorad, 
Reinach, Switzerland) and BSA as standard. 
 
GST pull-down, immunoprecipitation and immunoblotting 
For pull-down assays, either 30 mg of purified recombinant protein (GST-Sj, rat GSTM1 and -
P1, or GST-tagged acetyl-CoA carboxylase, GST-ACC (Scott et al., 2002)) or 1 mg proteins from 
liver extract were incubated with 30 mg recombinant AMPK (α2β2γ1 wild type, 221WT; or 
T172Dα2β2γ1 mutant, 221TD) for 1 h in PD-buffer (20 mM HEPES pH 7.4, 50 mM NaCl, 2,5 
mM MgCl2, 10% glycerol, 6 g/L BSA, 0,5% Tween 20, 0,02% NaN3) before addition of 
Glutathione Sepharose beads and incubation for an additional hour at 4°C. Where indicated, 
1 mM glutathione was included. Sepharose beads were washed eight times and resuspended 
in SDS sample buffer. For immunoprecipitation, 1 mg protein from liver extracts were reacted 
with anti-GSTM (ab53942, Abcam) or GSTP1 (ab53943, Abcam) antibody (1:240) in PD-buffer 
overnight at 4°C. Protein A Sepharose was added, incubated for another hour at 4°C, and 
washed 8 times before being resuspended in SDS-PAGE sample buffer. Solubilized, denatured 
proteins were subjected to SDS-PAGE and immunoblotting using anti-AMPKα primary 
antibody (dilution 1: 1000, 2532, Cell Signaling Technology, Danvers, MA, USA) and anti-rabbit 
secondary antibody (1: 5000, NA934, GE Healthcare) for detection with a chemiluminescence 
kit (ECL plus, GE Healthcare) and a CCD camera (ImagerQuant LAS 4000, GE Healthcare). Bands 
were quantified densitometrically by Image J (imagej.nih.gov/ij) and normalized. Statistical 
analysis was done by students T-test. Where indicated, proteins stained in PAGE gels with 
colloidal Coomassie Blue were identified by MALDI-TOF/TOF mass spectrometry. 
 
Surface Plasmon Resonance (SPR) and mass spectrometry (MS) 
For SPR with BIAcore (GE Healthcare), GSTs were covalently immobilized by standard amine 
coupling (GE Healthcare) on the carboxylic functions of two different chips. Gold chips 
functionalized by mixed self-assembled monolayers as described (Boireau et al., 2009) were 
kindly provided by Wilfrid Boireau (FEMTO-ST, CNRS Besançon, France). They used 97% 11-
mercapto-1-undecanol to reduce non-specific adsorption of proteins to the surface, and 3% 
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16-mercaptohexadecanoic acid for protein immobilization to obtain well controlled, low 
ligand densities as convenient for initial experiments with GST-Sj. CM5 chips (GE Healthcare) 
allowing higher ligand surface densities were used for sequential analyte injection during 
detailed kinetic analysis. GST (30 mg/ml) in 10 mM acetate buffer pH 6 (GST-Sj), pH 5 (GSTM1) 
or pH 4 (GSTP1) were injected at 5 ml/min to immobilize <2.5 ng GST/ mm2. Interaction 
measurements were carried out in running buffer (10 mM HEPES pH 7.4, 100 mM NaCl, 50 
mM EDTA, 0.005% Surfactant P20) at a flow rate of 20 ml/min. AMPK diluted to different 
concentrations just prior to measurements was injected onto the GST surfaces for 180 to 300 
s at 20 or 30 ml/min which excludes mass transfer limitations (not shown). Experimental 
curves were corrected for bulk refractive index changes. Fitting of association and dissociation 
curves for kinetic analysis was done with BIAevaluation software. GSTs were identified by 
MALDITOF/TOF and peptide mass fingerprinting, potential phosphosites by LC-MS/MS as 
described in Methods S1. 
 
AMPK glutathionylation 
AMPK 221WT (1 mM, stocks preserved at -80°C) in 0.1 M phosphate buffer pH 6.5 was 
incubated with or without 10 mM glutathione alone or together with GSTM1 or -P1 (0.5 mM) 
for 10 min at 30°C. Alternatively, AMPK (1 mM, reduced by overnight incubation with 1 mM 
ß-mercaptoethanol in phosphate buffer as above) was incubated with EDTA (1 mM) at 30°C 
alone or together with GSTM1 or -P1 (10 mM, added after 5 min). After 15 min, 0.1 mM 
glutathione was added for 2 or 4 min. The reaction was stopped by heating in SDS sample 
buffer and samples separated by non-reducing SDS-PAGE and immunoblotted using primary 
anti-glutathione antibody (1:1000, MAB5310, Millipore Corporation, Billerica, USA) and anti-
mouse secondary antibody (1: 4000, 31430, Pierce, Rockford, USA) for luminescent detection 
and quantification as described above. Blotted proteins were also visualized by Ponceau 
staining to reveal Mr shifts due to glutathionylation. 
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AMPK phosphorylation 
AMPK 221WT (25 nM) was incubated for 10 min at 30°C with or without glutathione (10 mM) 
and in presence or absence of GSTM1 or -P1 (125 nM) in kinase buffer containing 200 mM [γ-
32P]ATP (specific activity 400 mCi/mmol ATP), 50 mM AMP, 5 mM MgCl2, 1 mM DTT, and 10 
mM HEPES (pH 7.4). Recombinant CamKKβ (1.25 nM) was added and samples were incubated 
for 3 min at 30°C. The reaction was stopped by heating in SDS sample buffer and AMPK 
phosphorylation at Thr-172 as an indicator of AMPK activity was probed by SDS-PAGE and 
immunoblotting with anti-phospho-T172 AMPKα primary antibody (1: 1000, 2531, Cell 
Signaling Technology, Danvers, MA, USA) and anti-rabbit secondary antibody for luminescent 
detection and quantification as described above. 
 
AMPK substrate phosphorylation 
To analyze GST phosphorylation in vitro, AMPK 221WT (4 pmol) was activated by incubation 
with CamKKβ (1 pmol) for 20 min at 30°C in kinase buffer with cold ATP. Purified GSTs and ACC 
(Scott et al., 2002) (200 pmol each) were then incubated for 3–60 min at 37°C in the presence 
or absence of pre-activated AMPK 221WT (4 pmol) in kinase buffer. For negative controls, 
GSTs were incubated with 1 pmol CamKKβ alone without AMPK. To analyze effects of 
GST/AMPK complexes on in vitro phosphorylation of AMPK substrates, AMPK 221WT (4 pmol, 
reduced as above) was pre-activated with CamKKβ in kinase buffer with cold ATP and 
glutathionylated with 0;1 mM glutathione in presence or absence of GSTM1 or -P1, both as 
described above. Then, ACC (200 pmol) (Scott et al., 2002) and [γ-32P]ATP were added and the 
mixture incubated for 2 min at 37°C. Kinase reactions were stopped as above, separated on 
SDS-PAGE and analyzed by Typhoon phosphoimager (GE Healthcare). 
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Results 
GST-Mu and -Pi isoforms interact with AMPK in vitro 
In the course of our interactomic research on AMPK, we repeatedly pulled down recombinant 
heterotrimeric AMPK with recombinant proteins fused to a GST-tag that is derived from 
S.japonicum GST (GST-Sj). In fact, GST-Sj alone can pull down AMPK 221WT (Figure 1). We first 
examined whether such heterologous interaction of GST-Sj with rat AMPK reflects an 
interaction that evolved with homologous rat GSTM1 (closest homologue of GST-Sj, 44% 
sequence identity) and GSTP1 (30% sequence identity). Both enzymes were cloned from a rat 
cDNA library, bacterially expressed and purified. In an assay with fivefold molar excess of GST, 
both GSTM1 and -P1 were able to pull down AMPK 221WT even after extensive washing 
(Figure 1). These results suggest that the GST/AMPK interaction evolved in at least two 
different eukaryotic GST classes: the Mu and Pi families. 
 
 
Figure 1. GST isoforms and GST-tag interact with full-length AMPK in pull-down assays. Pull-down of 
recombinant AMPK 221WT with GST-Sj (S. japonicum), GSTM1 or GSTP1 (R. norvegicus). In all assays, AMPK 
(0.075 mg/ml) was incubated with or without (negative control) GST proteins (0.075 mg/ml). Pull-down with 
Glutathione Sepharose 4B was subjected to immunoblot analysis using anti-AMPKα antibody. Left: 
representative data; right: quantification (mean ± SD, n = 3; * p<0.01 and # p<0.05 versus no GST). 
 
GST-Mu and -Pi isoforms directly interact with AMPK β-subunits in Y2H assays 
A potential direct interaction of GSTs with AMPK in vivo was verified by two different last-
generation Y2H assays (Brückner et al., 2009). Here, bait/prey interaction leads to 
reconstitution of split proteins in the yeast cytosol, either of ubiquitin (Cyto-Y2H) or an enzyme 
in tryptophan biosynthesis (Split-Trp-Y2H). Readout is provided via transcription factor release 
by ubiquitin-specific proteases that triggers transcription of reporter genes (Cyto-Y2H), or 
more directly by allowing growth on Trp-deficient medium (Split-Trp-Y2H) (Tafelmeyer et al., 
2004). While the transcriptional amplification of the Cyto-Y2H read-out makes it very sensitive 
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to detect even weak or transient interactions, the direct readout of the Split-Trp-Y2H is more 
proportional to interaction strength.  
The three examined GSTs (GST-Sj, GSTM1, GSTP1) did not interact with AMPK α -subunits in 
the sensitive Cyto-Y2H assay (Figure 2A). However, all three showed interaction with AMPK β-
subunits: β1 and β2 in case of GST-Sj, and preferentially β2 in case of GSTM1 and -P1. The N-
terminal domain of the β-subunits (Δβ1 or Δβ2, amino acids 1–54) was sufficient for GST/ 
AMPK binding, suggesting that it is part of the interaction domain. Control experiments 
confirmed expected GST homodimerization and AMPK α/β-subunit interaction, while no 
binding to unrelated protein Large T (LT) was detected. The Split-Trp-Y2H assay confirmed 
these data (Figure 2B), although the readout was weaker in some cases, as e.g. in case of the 
AMPK α-/β-subunit interaction. In both assays, results were similar, irrespective whether GST-
Sj was used as bait or prey (not shown). 
 
 
Figure 2. Y2H analysis identifies GST isoforms as AMPK interaction partners and the AMPK interaction domain. 
Two different cytosolic Y2H systems were applied to analyze interaction of AMPK with Schistosoma japonicum 
GST (GST-Sj) and mammalian (rat) GSTM1 and GSTP1. (A) Cyto-Y2H: interacting proteins lead to reconstitution 
of ubiquitin and a transcriptional readout allowing growth on medium lacking adenine and histidine (SD-AHWL). 
Spots represent yeast grown for 72 h at 30°C. (B) Split-Trp-Y2H: interacting proteins lead to reconstitution of 
Trp1p, an enzyme in tryptophan biosynthesis, and allow growth on medium lacking tryptophan (SD-UWL). Yeast 
was grown for 8–9 days at 27°C. Δβ, N-terminal domain of AMPK β-subunit. Controls: LT, Large T Antigen of 
Simian Virus (amino acids 84–704; negative control); GST, GST-Sj (positive control). A representative data set out 
of three independent experiments is shown. For more details see Materials and Methods and Supporting 
Information. 
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GST/AMPK interaction occurs in rat liver 
To test whether also endogenous rat GST isoforms bind to AMPK, we used crude rat liver 
extracts for co-immunoprecipitation and GST pull-down assays. Liver contains mainly GST-
Alpha and -Mu isoforms and few GST-Pi. Endogenous rat AMPK indeed co-
immunoprecipitated with antibodies specific for GSTM1/2 and GSTP1 (Figure 3A) and pulled 
down together with three major endogenous GST isoforms, GSTA1, GSTA3 and GSTM1, as 
identified by MALDI mass spectrometry (Figure 3B). If glutathione is then added to the extract, 
the pull-down assay becomes more stringent. Mainly GSTM1 is now pulled down, while GSTA1 
and GSTA3 are strongly reduced, without affecting the quantity of associated AMPK. Finally, 
when liver extracts were spiked with additional recombinant AMPK 221WT or 221TD, even 
more AMPK was pulled down (Figure 3C). More inactive AMPK 221WT was recovered as 
compared to AMPK 221TD, a mutant mimicking active AMPK (Stein et al., 2000). 
 
 
Figure 3. AMPK interacts with endogenous GST isoforms in rat liver. GST immunoprecipitation (A) or pull-downs 
(B, C) were performed with rat liver extract. AMPK in immunoprecipitates or pull-down fractions was detected 
by immunoblot analysis with anti-αAMPK antibody. The main liver GST isoforms in pull-down fractions were 
detected by Ponceau staining and mass spectroscopy. (A) Immunoprecipitation of endogenous AMPK by anti-
GSTM1/2 or anti-GSTP1 antibodies. (B) GST pull-down of endogenous liver AMPK by liver GST isoforms in absence 
or presence of glutathione. Note: Addition of glutathione reduces pull-down of GSTA isoforms without affecting 
pull-down of AMPK. (C) GST pull-down of added AMPK 221WT or constitutively active 221TD. Left: representative 
data sets; right: quantification (mean ± SD, n = 3; * p<0.01 and # p<0.05 versus no GST (A), GSTM1 (B) or no 
extract (C)). Extr, liver extract. 
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GST/AMPK interaction is direct and rapid 
To obtain quantitative data on the GST/AMPK interaction in respect to kinetics and affinity, 
we performed a series of in vitro experiments with surface plasmon resonance spectroscopy 
(SPR). The GST interaction partner was chosen for covalent immobilization since it appeared 
more stable in this setup. We first used a sensor chip where the gold surface had been 
functionalized with a self-assembled monolayer that reduces non-specific adsorption to the 
surface and allows immobilization of low ligand densities for analyzing GST-Sj. Sensorgrams 
with AMPK 221WT, 221TD or BSA (negative control) injected onto this surface confirmed a 
direct GST/AMPK interaction (Figure 4A) that was not affected by glutathione (not shown). 
The equilibrium response was 203641.5 RU for AMPK 221WT, which was reduced to 121627 
RU for AMPK 221TD, as compared to 863.7 RU for BSA (Figure 4B). Conventional CM5 sensor 
chips were then used to confirm a specific interaction of rat GSTM1 or GSTP1 with rat AMPK 
(Figure 4C) and to extract affinity data for GSTM1 by injecting an AMPK concentration series 
(Figure 4D). The simple kinetics could be very well fitted to a Langmuir 1:1 model (Figure 4D) 
as seen by the very low residuals of the fit (<1 RU). The fast association (ka = 3.1.105 M21 s21) 
and the very slow dissociation (kd= 1.6.10-3 s-1) resulting in a KD of about 5 nM. 
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Figure 4. Surface plasmon resonance identifies high 
affinity interactions between GSTs and AMPK. 
Freshly diluted, recombinant full-length AMPK was 
injected onto immobilized GST. (A) GST-Sj binding of 
10 nM AMPK 221WT (black full line), constitutive 
active AMPK 221TD (grey full line) or BSA (grey 
dotted line) at a flow rate of 20 ml/min (surface: self-
assembled monolayer). (B) Equilibrium response 
from (A), mean ± SD, 12 (221TD), 6 (221WT) or 3 
(BSA) independent experiments (* p<0.01 versus 
control; 1 p<0.01 versus AMPK-TD). (C) Comparison 
of GSTM1 (black) or GSTP1 (grey) association and 
dissociation kinetics of 10 nM AMPK 221WT (full 
lines) or 100 nM of BSA (dotted lines) and a flow rate 
of 30 ml/min (surface: CM5). (D) GSTM1 association 
and dissociation kinetics of AMPK 221WT at 
different concentrations (dashed black lines) and a 
flow rate of 30 ml/min (surface: CM5), single 
exponential fit of experimental data (grey lines) and 
corresponding residuals (to assess the quality of the 
fit, lower panel). Representative sensorgrams of at 
least two repetitions are shown. Bars on the top of 
sensorgrams indicate protein injection (association, 
black) or injection of running buffer (white). 
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GST/AMPK complexes do not lead to relevant GST phosphorylation but increase GST activity 
To gain insight into the putative role(s) of GST/AMPK complexes, we first examined whether 
they lead to GST phosphorylation and/or affect GST activity. In vitro phosphorylation assays 
with CamKKβ-activated AMPK and a 50-fold excess of GSTs revealed no phosphorylation of 
GST-Sj and slow, very low level phosphorylation of GSTM1 and GSTP1 as compared to ACC 
(Figure 5), reaching less than 7% of the ACC phosphorylation level within 1 hour (Figure S2). 
Presence of glutathione did not further increase this phosphorylation (not shown) as it was 
reported for PKA and PKC (Lo et al., 2004), and no specific phosphosites could be identified by 
mass spectrometry (not shown). However, in an activity assay using the model substrate 1-
chloro-2,4-dinitrobenzene (CDNB), addition of AMPK 221WT to GSTM1 or GSTP1 led to a 
moderate increase of vmax by about 25% at almost unchanged apparent Km (Table 1, Figure 
S3). This increase occurred only after mixing GST with AMPK, not with BSA, and did not require 
addition of active AMPK 221TD (Table 1). Thus, GST activation is not due to unspecific 
stabilization by protein addition and unrelated to the faint and slow GST phosphorylation. 
Rather, specific GST/AMPK complex formation itself altered the catalytic properties of GST, 
since GST activation also depended on the amount of AMPK 221WT added (Figure S3). 
 
Figure 5. GST is a poor AMPK substrate. AMPK 221WT (4 pmol) pre-activated by CamKKβ (1 pmol) does not 
phosphorylate GST-Sj and phosphorylates GSTM1 and -P1 only at low levels as compared to ACC (all at 200 pmol). 
In vitro phosphorylation assays were run for 3 min (GST-ACC), 30 min (GSTP1, GSTM1) or 60 min (GST-Sj) and 
analyzed by SDS-PAGE and Typhoon phosphoimager. Note the autophosphorylation of the AMPK β-
subunit.Representative data with quantification are shown. Detailed phosphorylation kinetics is shown in Figure 
S2.   
 
Table 1. Enzyme kinetic parameters of GSTP1 in presence or absence of AMPK or BSA. 
  Vmax  kcat  Km(CDNB)  
  (U mg-1)  (s-1)  mM  
 GSTM1 21.6±0.8  16.9±0.5  0.037±0.005  
 GSTM1 + BSA 20.9±0.8  16.4±0.5  0.033±0.006  
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 GSTM1 + AMPK 221 25.5±0.7  20.0±0.5  0.045±0.005  
 GSTM1 + AMPK 221TD 25.9±0.9  20.3±0.6  0.043±0.006  
 GSTP1 20.4±2.9  16.0±2.3  1.9±0.4  
 GSTP1 + BSA 24.6±1.1  19.3±0.9  1.5±0.1   
 GSTP1 + AMPK221-P 1) 26.8±0.5  21.0±0.8  1.7±0.1  
        
GST enzyme activity was determined with variable concentrations of model substrate 1-chloro-2.4-
dinitrobenzene at a fixed glutathione concentration (10 mM for GSTM1, 2 mM for GSTP1) at 25°C. Vmax and 
Km values were obtained by direct fitting of values to Michaelis-Menten kinetics. Enzyme activity given in U 
is equivalent to mmol/min. Values are means ± SD, n = 3. 1) AMPK221 preactivated by phosphorylation with 
CamKKβ. 
 
GST/AMPK complexes lead to AMPK glutathionylation and activation 
It has previously been shown that GSTM1 and -P1 were able to modulate signal transduction 
through an interaction with JNK and/or other stress activated kinases ((Adler et al., 1999; Yin 
et al., 2000), reviewed in (Lo and Ali-Osman, 2007)). Hence, we hypothesized that GST could 
modulate AMPK activity by glutathionylation as it was shown recently (Zmijewski et al., 2010). 
At very high glutathione concentrations of 10 mM, spontaneous auto-glutathionylation 
occurred with AMPK 221WT already in absence of mammalian GSTs (Figure 6A). However, at 
more limiting conditions using 0.1 mM glutathione and AMPK pre-reduced with β-
mercaptoethanol, auto-glutathionylation was almost absent (Figure 6B). In this case, presence 
of GSTM1 and -P1 increased glutathionylation of AMPK to immunodetectable levels, also 
visible as a partial shift of AMPK to a higher molecular mass (Figure 6B). 
 
 
Figure 6. Glutathionylation of AMPK is facilitated by GST. Glutathionylation assays were performed (A) with 
AMPK 221WT (1 mM) in absence or presence of GSTM1 or -P1 (0.5 mM) and 10 mM glutathione or (B) with AMPK 
221WT (1 mM, additionally pre-reduced with β-mercaptoethanol) in absence or presence of GSTM1 or -P1 (10 
mM) and 0.1 mM glutathione. AMPK modification was detected either as a molecular mass shift of GST protein 
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in SDS-PAGE (see arrows in Ponceau protein stain, ‘‘protein’’) or by direct detection of glutathione by 
immunoblotting (‘‘glutathionylation’’). Note: As soon as glutathione is present, AMPK is almost quantitatively 
glutathionylated in (A), while additional presence of GST is needed for glutathionylation in (B). Left: 
representative data; right: quantification (mean, n = 2). 
 
We then analyzed the effect of AMPK S-glutathionylation for AMPK signaling. In vitro 
phosphorylation of AMPK 221WT at αT172 by its upstream kinase CamKKβ was identical in 
presence or absence of glutathione, and also not further modified by GSTM1 or -P1 (Figure 
7A). However, phosphorylation of the AMPK downstream substrate ACC was clearly increased 
with AMPK 221WT preparations that had been glutathionylated before in presence of 
glutathione by GSTM1 and -P1 as above, compared to controls lacking mammalian GSTs 
(Figure 7B). Activation of AMPK by CamKKβ was a prerequisite for this ACC phosphorylation. 
CamKKβ (Figure 7B) and AMPK alone (Figure S4) or combined with GSTs did not affect ACC 
phosphorylation. These results suggest that GST-dependent S-glutathionylation of AMPK in 
vitro indeed increases kinase activity in the same way as previously shown for H2O2-dependent 
AMPK glutathionylation (Zmijewski et al., 2010). 
 
 
Figure 7. AMPK glutathionylation does not affect its phosphorylation by CamKKβ, but increases 
phosphorylation of downstream substrate. (A) GSTM1 or -P1 (62.5 pmol) were pre-incubated with AMPK 221WT 
(12.5 pmol) with or without 10 mM glutathione, in presence of ATP prior to addition of CamKKβ (0.63 pmol). 
Phosphorylation assays were subjected to immunoblot analysis using anti-P-T172-α AMPK antibody. (B) AMPK 
221WT pre-activated with CamKKβ in kinase buffer with cold ATP and glutathionylated with 0,1 mM glutathione 
in presence or absence of GSTM1 or -P1, both as described above and in Figure 6, were incubated with ACC (200 
pmol) and [γ-32P]ATP. In vitro phosphorylation assays were analyzed by SDS-PAGE, Ponceau protein staining 
(lower panel) and Typhoon phosphoimager (upper panel) are shown. Left: representative data; right: 
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quantification of lanes in presence of glutathione (mean ± SD, n = 4; * = p<0.01 versus no GST). A control 
experiment lacking CamKKβ is shown in Figure S4. Note: AMPK autophosphorylation of α- and β-subunits.  
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Discussion 
The energy stress sensor AMPK can be activated by ROS and RNS, possibly via different AMP-
dependent and -independent mechanisms (Hawley et al., 2010; Xie et al., 2006; Zou et al., 
2004) and is involved in cellular redox regulation (Jeon et al., 2012) and antioxidative defense 
via induced expression of various antioxidative pathways (Colombo and Moncada, 2009; 
Kukidome et al., 2006; Wang et al., 2010). Exposure of AMPK to the strong oxidant hydrogen 
peroxide at high glutathione concentrations induces non-enzymatic S-glutathionylation of 
AMPK α- and β-subunits which in turn activates the kinase (Zmijewski et al., 2010). Our study 
adds another element to such redox regulation: activation of AMPK via GST-facilitated 
glutathionylation in the absence of exogenous oxidant that may be relevant to normal 
physiological conditions. We provide evidence that mammalian GSTM1 and -P1 can rapidly 
interact with AMPK, become enzymatically activated by this interaction, and assist in turn in 
glutathionylation and activation of AMPK as we show in vitro. 
It has previously been demonstrated that GSTM1 and -P1 were able to modulate signal 
transduction through interactions with JNK and/or other stress activated kinases ((Adler et al., 
1999; Yin et al., 2000), reviewed in (Lo and Ali-Osman, 2007)), and that this can involve GST 
phosphorylation or modification of the interacting kinase (Adler et al., 1999; Cho et al., 2001; 
Gilot et al., 2002; Lo et al., 2004; Yin et al., 2000). However, interaction with AMPK led only to 
slow and low-level phosphorylation of GSTM1 and -P1; its importance (if any) remains to be 
elucidated. By contrast, complex formation alone was sufficient to increase activity of bound 
GST and, importantly, to glutathionylate and activate AMPK under in vitro conditions where 
auto-glutathionylation is low, i.e. in the absence of strong oxidants. It is worth noting that 
protein interaction partners of GST were mostly also identified as targets for S-
glutathionylation (e.g. (Cross and Templeton, 2004; Manevich et al., 2004; Wetzelberger et 
al., 2010)). The residues glutathionylated within AMPK, α-Cys299 and α-Cys304 (Zmijewski et 
al., 2010), activate AMPK rather due to direct conformational changes as those produced by 
allosteric AMP regulation. AMPK glutathionylation did not make AMPK a better substrate for 
the upstream kinase CamKKβ, at least with the recombinant enzymes in the reconstituted in 
vitro system applied here. 
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Reversible protein modification by cysteine glutathionylation is increasingly recognized as an 
important signaling mechanism by which cells can respond effectively and reversibly to redox 
inputs (Pastore and Piemonte, 2012; Xiong et al., 2011). S-glutathionylation inhibits or 
activates a number of protein kinases (PKA, PKC, MEKK1, ASK1) and phosphatases (reviewed 
in (Pastore and Piemonte, 2012)). Although the understanding of the S-glutathionylation cycle 
is still limited, there is evidence for the participation glutaredoxins and GST isoforms, including 
GSTM1 and -P1 (Tew and Townsend, 2011; Townsend et al., 2009; Wetzelberger et al., 2010). 
GSTP1P2 knockout mice and cells expressing dead mutants of GSTP have a diminished capacity 
to S-glutathionylate proteins (Townsend et al., 2009). GSTP plays an essential role in the S-
glutathionylation of 1-cys peroxiredoxin (Manevich et al., 2004; Noguera-Mazon et al., 2006; 
Ralat et al., 2006). Even more, a glutathionylation cycle was recently described to regulate 
aldose reductase (Wetzelberger et al., 2010). Here, sequential glutathiolyation/ 
deglutathioylation is catalyzed by GSTP and GRx in vitro and in vivo, correlated with physical 
association of the reductase with either GSTP or GRx (Wetzelberger et al., 2010). Since the 
GST catalytic activity is necessary for lowering the pKa of the glutathione cysteine thiol 
(Graminski et al., 1989), altered catalytic properties as we observed with GSTM1 and -P1 in 
complex with AMPK may be relevant for the GST glutathionylation function. 
These findings fit very well into the emerging role of AMPK as a redox switch in oxidative stress 
and redox signaling. AMPK is activated by ROS/RNS via different mechanisms: impaired 
mitochondrial ATP generation will translate into increased cytosolic AMP/ATP and ADP/ATP 
ratios that activate AMPK (Hawley et al., 2010), but ROS/RNS may also directly affect upstream 
mediators and kinases (Xie et al., 2006; Zou et al., 2004) or AMPK itself by glutathionylation 
(Zmijewski et al., 2010). Activated AMPK in turn up-regulates the cellular antioxidative defense 
machinery, mainly via the FOXO3 transcription factor: manganese superoxide dismutase 
(Colombo and Moncada, 2009; Kukidome et al., 2006; Wang et al., 2010), catalase (Colombo 
and Moncada, 2009; Wang et al., 2010), thioredoxin (Colombo and Moncada, 2009; Hou et 
al., 2010), metallothioneins (Greer et al., 2007), or uncoupling protein 2 (Xie et al., 2008). 
Among AMPK-FOXO3-induced genes are also γ-glutamylcysteine synthase, the first enzyme in 
glutathione biosynthesis (Colombo and Moncada, 2009), glutathione peroxidase (Wang et al., 
2010) that uses glutathione to reduce lipid and hydrogen peroxides, as well as GSTM1 (Greer 
et al., 2007).  
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The interaction leading to GST/AMPK complexes seems to be rather specific for the GST-Mu 
and -Pi families, since it was not observed with GST-Alpha and -Omega isoforms (not shown). 
It does not involve the AMPK a-subunit, as we have recently reported for fumarate hydratase 
(Klaus et al., 2012), but the β-subunit, as also seen with several other putative mammalian 
AMPK interactors (IntAct database, (Aranda et al., 2010)) and the yeast and plants orthologs 
(Polge et al., 2008; Vincent and Carlson, 1999). Our data suggest interaction with the very N-
terminal part of the β-subunit, a domain that is fairly well conserved across the AMPK protein 
family but lacks in the solved core structures of mammalian AMPK and its yeast ortholog ((Xiao 
et al., 2011); reviewed in (Sanz, 2008)), possibly due to its high flexibility. The physical 
interaction of AMPK with GST-Sj calls for a note of caution for using GST fusion proteins in 
pull-down assays to identify AMPK interaction partners. 
GST-mediated glutathionylation and activation of AMPK may be considered a possible 
additional layer of AMPK regulation linking the energy-stress sensor to redox regulation and 
antioxidative defense. Our present data are novel in that they provide a mechanism for 
glutathionylation-dependent AMPK activation at low oxidative capacity, as compared to the 
highly oxidative conditions used in an earlier study (Zmijewski et al., 2010) which may not 
mimic peroxide concentrations generated intracellularly (Arbault et al., 1997; Pimentel et al., 
2012). Further studies have to show the specific importance of this mechanism for in vivo 
regulation of AMPK activity. 
  
 
72 Glutathion S-transferase interact with AMP-activated protein kinase 
Supplementary data 
 
 
Figure S1. The Strep-tag in Strep-GST constructs is phosphorylated by AMPK. Phosphorylation of GSTP1 (200 
pmol) and GSTM1 (40 pmol) in Strep-tagged (P1, M1) and Strep-tag-free forms (P1c, M1c) by AMPK221 (4 pmol) 
activated by CamKKβ (1 pmol). In vitro phosphorylation for 10 min at 37°C was analyzed by SDS-PAGE and 
Typhoon phosphoimager (top panel) and control Coomassie stain for protein loading (bottom panel). Control 
lanes lack AMPK221 but contain CamKKβ. 
 
 
 
 
Figure S2. Substoichiometric phosphorylation of GSTP1 by AMPK in vitro. (A) Phosphorylation time course of 
GSTP1 or ACC (200 pmol each) by AMPK221 (4 pmol) activated by CamKKβ (1 pmol). In vitro phosphorylation for 
5 to 60 min at 37°C was analyzed by SDS-PAGE and Typhoon phosphoimager. Control lanes lack AMPK221 but 
contain CamKKβ. (B) Quantification of (A) using Image Quant TL, using normalization to maximal ACC 
phosphorylation and fitting to phosphorylation enzyme kinetics. 
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Figure S3. GSTM1 and -P1 are activated in complexes with AMPK in vitro. Enzyme activity of or 20 mg GSTM1 
(A) or 30 mg GSTP1 (B) in absence or presence of 5 or 15 mg AMPK221WT at different concentrations of the 
model substrate CDNB and saturating glutathione concentrations. 
 
 
 
 
Figure S4. Increased phosphorylation of AMPK downstream substrate depends on the presence of AMPK 
activating upstream kinase CamKKβ. AMPK 221WT preactivated with CamKKβ in kinase buffer with cold ATP 
and glutathionylated with 0.1 mM glutathione in presence or absence of GSTM1 or -P1, both as described in 
Figure 6 and Figure 7, were incubated with ACC (200 pmol) and [γ-32P]ATP. In vitro phosphorylation assays were 
analyzed by SDS-PAGE, Ponceau protein staining (lower panel) and Typhoon phosphoimager (upper panel) are 
shown. Note: AMPK autophosphorylation in particular of the a-subunit. 
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Fumarate hydratase 
as AMPK substrate  
Abstract. AMP-activated protein kinase (AMPK) is 
emerging as a central cellular signaling hub involved in 
energy homeostasis and proliferation. Here we apply an 
original two-dimensional in vitro screening approach for 
AMPK substrates that combines biophysical interaction 
based on surface plasmon resonance with in vitro 
phosphorylation. By enriching for proteins that interact 
with a specific AMPK isoform, we aimed to identify 
substrates that are also preferentially phosphorylated by 
this specific AMPK isoform. Application of this screen to 
full-length AMPK α2β2γ1 and soluble rat liver proteins 
identified the tumor suppressor fumarate hydratase (FH). 
FH was confirmed to interact with and to be preferentially 
phosphorylated by the AMPKα2 isoform by using yeast-
two-hybrid and in vitro phosphorylation assays. In the 
second section we show that this phosphorylation occurs 
mainly at Ser19 in the amphiphatic N-terminal targeting 
peptide, and at a low level at Thr482 in the FH C-terminal 
domain 3. Out of some other mitochondrial proteins 
identified earlier as potential AMPK substrates by in vitro 
screening, also the pyruvate carboxylase prepeptide is 
phosphorylated by AMPK, suggesting that AMPK 
phosphorylations in prepeptides may occur more 
frequently with potential effects on mitochondrial protein 
import.  
Résumé. La protéine kinase activée par l’AMP (AMPK) est 
un point clé de l’homéostasie énergétique et de la 
prolifération cellulaire. Dans cette étude nous avons 
appliqué une approche novatrice de criblage en deux 
dimensions in vitro ciblant des substrats de l’AMPK, 
combinant interaction biophysique basée sur la méthode 
de résonance plasmonique de surface avec des tests de 
phosphorylation in vitro. En utilisant un isoforme 
spécifique de l’AMPK, nous avions pour but d’identifier des 
substrats qui seraient aussi préférentiellement 
phosphorylés par ce même isoforme. L’application de ce 
système de criblage sur l’AMPK α2β2γ1 et sur des 
protéines solubles de foie de rat ont permis l’identification 
du suppresseur de tumeur, fumarate hydratase (FH). Le 
double hybride en levure et les essais de phosphorylation 
in vitro ont confirmé que FH interagit et est phosphorylé 
préférentiellement par l’isoforme α2 de l’AMPK. Dans la 
seconde section nous montrons que c’est essentiellement 
la Ser19 qui est phosphorylée, présente en N-terminal au 
niveau du peptide signal amphiphatique. Thr482 est 
phosphorylée plus faiblement. Parmi d’autres protéines 
mitochondriales identifiées plus tôt comme potentiels 
substrats de l’AMPK dans des criblages in vitro, le 
prépeptide de la pyruvate carboxylase est phosphorylé par 
l’AMPK. Ceci suggère que la phosphorylation de 
prépeptides par l’AMPK peut arriver plus fréquemment, 
avec un rôle potentiel dans l’import mitochondrial. 
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Brunisholz, R., and Schlattner, U. (2012). A two-dimensional screen for AMPK substrates identifies tumor 
suppressor fumarate hydratase as a preferential AMPKα2 substrate. J. Proteomics 75, 3304–3313.]. I did the Co-
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Introduction 
AMP-activated protein kinase (AMPK) is member of a Ser/Thr kinase family conserved across 
the eukaryotic kingdom, including SNF1 complex in yeast and SnRK1 in plants. These kinases 
function as heterotrimeric complexes composed of one catalytic α-type subunit and two 
regulatory β- and γ-type subunits (Bouly et al., 1999; Davies et al., 1994; Jiang and Carlson, 
1997; Mitchelhill et al., 1994). Subunits of mammalian AMPK occur as different isoforms (α1, 
α2, β1, β2, γ1-3) and splice variants (of γ2 and 3), potentially generating multiple different 
heterotrimeric complexes. 
In mammals, AMPK functions mainly as an energy sensor, integrating signals from inside the 
cell, the cellular environment, and the whole organism (for reviews see (Carling et al., 2011; 
Hardie, 2007; Mihaylova and Shaw, 2011; Neumann et al., 2003a)). The activation mechanism 
involves AMP-induced conformational changes, covalent activation by the upstream kinases 
LKB1 or CamKKβ (Riek et al., 2008; Woods et al., 1996), and AMP- and ADP-dependent 
inhibition of AMPK dephosphorylation. Altered AMPK signaling has been associated with 
different human pathologies like diabetes and cancer, and the kinase is a promising drug 
target for these pathologies (Fogarty and Hardie, 2010; Steinberg and Kemp, 2009). Two of 
the major drugs used for treating diabetes type II, metformin and thiazolidinediones, activate 
AMPK (Fryer et al., 2002; Zhou et al., 2001) and many of their therapeutic effects are mediated 
by AMPK signaling (Shaw et al., 2005). The identification of LKB1, a known tumor suppressor, 
as an upstream kinase of AMPK (Woods et al., 2003) and the effect of metformin reducing 
cancer incidence (Libby et al., 2009) have generated substantial interest for the role of AMPK 
in cancer development. Activated AMPK negatively regulates cell proliferation and the cell 
cycle, mostly mediated by mTOR and p53, respectively (Alessi et al., 2006; Jones et al., 2005; 
Kimura et al., 2003). However, treatments based on a systemic activation of AMPK may not 
only be beneficial, given the largely pleiotropic effects to be expected from a growing number 
of AMPK substrates. 
Systemic activation may be avoided to some degree by targeting specific AMPK isoform 
combinations, since they show a partial tissue-specificity (Viollet et al., 2009) or may recognize 
specific substrates. However, information on putative determinants of kinase-substrate 
interaction is scarce. Few AMPK interactors have been independently verified by more than 
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one method (Polge et al., 2008; Vincent and Carlson, 1999; Woods et al., 2003), and most 
interaction data come from large-scale screening like immunoprecipitation-MS analysis with 
tagged AMPK (Ewing et al., 2007), which do even not proof direct interactions. The variable 
N-terminal region of the β-subunits has been proposed to mediate interaction of the kinase 
with its substrates in yeast (Kuramoto et al., 2007) and plants (Solaz-Fuster et al., 2006). In 
mammals, the α1 and α2 subunits were shown to exhibit subtle different substrate 
preferences when using variants of the SAMS peptide, suggesting that the two α isoforms 
could phosphorylate different substrates within the cell (Vernia et al., 2009), but this could 
not be confirmed so far for known AMPK substrates. 
To identify substrates that interact with a specific AMPK isoform combination and thus 
potentially represent preferential substrates of this AMPK species, we have set up a protocol 
involving prefractionation and a two-dimensional in vitro screening. This combines biophysical 
interaction assays using surface plasmon resonance (SPR) with in vitro phosphorylation assays 
and protein identification by mass spectrometry (MS) as successfully applied already in an 
earlier study (Tuerk et al., 2007). This approach identified the tumor suppressor fumarate 
hydratase (FH) as an interactor and preferential substrate of α2-containing AMPK complexes, 
with phosphorylation leading to enzymatic activation. 
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Materials & Methods  
Material 
AICA-Riboside (AICAR) was from Biotrend Chemicals (Zurich, Switzerland), rabbit polyclonal 
anti-P-Thr172 AMPKα and anti-His-tag antibodies from Cell Signaling Technology (Danvers, 
MA, USA), goat polyclonal anti-GSTpi and rabbit polyclonal anti-FH antibody from Abcam 
(Cambridge, UK), secondary antibodies coupled to horseradish peroxidase were from GE 
Healthcare Life Science (Buckinghamshire, UK) for rabbit IgG and Thermo Scientific (Rockford, 
USA) for goat IgG. 
 
Cloning and purification of proteins 
Plasmids pγ1β1His-α1, pγ1β1His-α1T172D, pγ1β2His-α2 and pγ1β1His-α2T172D (Neumann et 
al., 2003b) were used for bacterial expression and purification as published previously 
(Neumann et al., 2003b; Riek et al., 2009). For Y2H experiments, PCR-amplified inserts were 
introduced into Y2H vectors pCab and pDSL (Dualsystems Biotech AG, Schlieren, Switzerland). 
FH (GeneID: 24368) and fatty acid binding protein 1 (FABP1, GeneID:24360) were amplified 
from rat liver cDNA and introduced into yeast two-hybrid vectors or bacterial expression 
vectors pET-52b (+) (Merck KGaA, Darmstadt, Germany) and pGEX-4T-1 (GE Healthcare). The 
fusion constructs Strep-FH, Strep-FABP1, GST-FH, GST-FABP1, GST-ACC (plasmid kindly 
provided by G. Hardie, Univ. of Dundee, UK) (Scott et al., 2002) and GST-CamKKβ (plasmid 
kindly provided by H. Tokumitsu, Kagawa Medical University, Japan) were bacterially 
expressed and purified according to standard procedures and the tag proteolytically removed 
where necessary. For further details see the online Supplementary Material 1. 
 
Preparation and prefractionation of liver extract 
Total liver from one rat was snap-frozen in liquid nitrogen and homogenized in 15 ml ice-cold 
extraction buffer A (20 mM HEPES, pH 7.4, 100 mM NaCl, 50 μM EDTA, and anti-protease 
cocktail, 1 tablet per 50 ml solution, Roche Diagnostics, Basel, Switzerland) using a Polytron 
PT 3000 homogenizer at 24 000 rpm for 20 s. After centrifugation at 15000 g for 30 min at 4°C, 
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the supernatant was filtered through a 0.22 μm filter. Prefractionation was carried out on an 
Äkta Explorer 100 Air HPLC system (GE Healthcare). Three ml of liver extract were applied to 
a Ni-NTA column (2 ml bed volume; Qiagen) preequilibrated in buffer A. The column was then 
washed at a flow rate of 1 ml/min with 2 column volumes (CV) of buffer A. Proteins were 
eluted with imidazole buffer (20 mM HEPES, pH 7.4, 100 mM NaCl and 250 mM imidazole) 
and the first 5 ml collected. This process was repeated 3 times. Between each load, the column 
was washed with 4 CV imidazole buffer, 1 CV water, 1 CV NaOH 0.5 M and 5 CV buffer A. To 
reduce the volume, collected proteins were precipitated with 80% (w/v) ammonium sulfate 
for 2 hours at 4°C. The pellet was resuspended in 5 ml buffer A and further centrifuged at 15 
000 g for 10 min at 4 °C. The supernatant was filtered (0.22 mm filter) and applied to a 
Superdex 200 size exclusion column (separation range Mr 10 000-600 000; volume 120 ml; GE 
Healthcare) preequilibrated in buffer A. Proteins were then separated at a flow rate of 1 
ml/min and collected in 12 fractions of 5 ml each (S1 to S12) supplemented with anti-protease 
cocktail (Roche, 1 tablet per 50 ml solution) was added. 
 
Surface plasmon resonance interaction screening and yeast two-hybrid assays 
The SPR screening was performed with a BIAcore 2000 (GE Healthcare) using a NTA sensor 
chip (GE Healthcare) and as running buffer 10 mM HEPES pH 7.4, 100 mM NaCl, 50 μM EDTA 
and 0.005 % Surfactant P20. In each measurement cycle, the NTA surface was activated by a 
1 min-pulse of 500 μM NiCl2 and 50 nM His-tagged AMPK α2β2γ1 (AMPK221) was injected at 
5 μl/min until reaching 4000 response units (RU) of immobilization. An HPLC fraction was then 
injected onto the AMP221 surface at 20 μl/min for 120 s. Interacting protein was quantified 
at a reporting point 80 s after dissociation start, since the association phase was biased by an 
SPR signal caused by the chromatography sample buffer. After 120 s of dissociation, a protein–
free surface was regenerated by injection of 10 mM HEPES, pH 8.3, 150 mM NaCl, 350 mM 
EDTA and 0.005 % Surfactant P20. Binary protein-protein interactions were analyzed in vivo 
using the Cyto-Y2H system (Dualsystems Biotech) (Möckli et al., 2007) based on the split-
ubiquitin system (Johnsson and Varshavsky, 1994; Stagljar et al., 1998) (see online 
Supplementary Material 1).  
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Co-immunoprecipitation 
Strep-tagged FH (1μg) and His-tagged AMPK 221TD (1μg) were co-immunoprecipitated with 
anti-His-tag antibody (1:200) and protein G Sepharose (10% w/v) in IP buffer (30 mM Hepes 
pH 7.3, 300 mM NaCl, 6 g/l BSA, 0.5% w/v dodecylmaltoside) overnight at 4°C. Sepharose was 
washed twice (30 mM Hepes pH 7.3, 300 mM NaCl, 0.1% Tween 20) and resuspended in SDS-
PAGE sample buffer. Proteins separated by SDS-PAGE were probed for FH by immunoblotting. 
 
AMPK substrate phosphorylation screening 
AMPK phosphorylation assays were performed at 37 °C in a final volume of 25 μl containing 
12.5 μl of chromatography fractions and kinase buffer (200 μM [γ-32P]ATP (400 mCi/mmol 
ATP), 50 μM AMP, 5 mM MgCl2, 1 mM DTT and 10 mM HEPES pH 7.4), with or without 
recombinant constitutively active AMPK221 (50 pmol). The kinase reactions were stopped 
after 2 min by addition of 10 μl SDS sample buffer (105 mM Tris-HCl, pH 6.8, 4% (w/v) SDS, 
15% (v/v) glycerol, 1.2 M β-mercaptoethanol, and 0.02% (w/v) bromophenol blue), heated to 
95 °C for 5 min, and separated by SDS-PAGE. Following colloidal Coomassie staining, gels were 
air-dried and exposed to autoradiography films (GE Healthcare) for up to 2 weeks or to 
Typhoon imager (GE Healthcare). 
 
Trypsin digestion and mass spectrometry 
Radioactively labeled AMPK-specific bands were cut from the gels, in-gel trypsin-digested 
(Promega), and extracted peptides analyzed by MALDI MS and MALDI MS/MS using an 
Ultraflex TOF/TOF II (Bruker Daltonics, Bremen, Germany). Processed spectra were combined 
through BioTools software (Bruker Daltonics) to search the Uniref100 database (release 6.0), 
non-restricted to the taxonomy, using MASCOT software v. 2.0 (Matrix Science, London, UK). 
Probability-based MOWSE scores greater than 50 were considered significant. For details see 
the online Supplementary Material 2. 
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In vitro analysis of AMPK substrate phosphorylation 
To compare phosphorylation kinetics, purified FABP1, FH and ACC Strep- or GST-constructs 
(200 pmol) were incubated for 5, 10, 20, 30 and 60 min at 37°C with 200 μM [γ-32P]ATP 
(specific activity 650 mCi/mmol ATP) and AMPK221 (4 pmol) previously activated by 
incubation with 1 pmol CamKKβ for 20 min at 30°C in kinase buffer (200 μM ATP, 50 μM AMP, 
5 mM MgCl2, 1 mM DTT, 10 mM HEPES pH 7.4). To compare phosphorylation by different 
AMPK isoforms, purified Strep-FH and GST-ACC (200 pmol) were incubated for 8 min at 37°C 
in the presence or absence of 3 pmol previously activated AMPK (AMPK221, -211 or -111) in 
kinase buffer containing 200 μM [γ-32P]ATP (specific activity 650 mCi/m mol ATP). For 
negative controls, AMPK substrates were incubated with 1 pmol CamKKβ alone without 
AMPK. Kinase reactions were stopped by addition of SDS-PAGE sample buffer and subjected 
to SDS-PAGE and Typhoon phosphoimager (GE Healthcare). 
 
AMPK activation in cell culture 
HeLa cells were cultured in DMEM/F12 high glucose medium supplemented with 10% 
inactivated fetal calf serum (FCS) and 1% glutamate/streptomycine/penicillin. Endogenous 
AMPK of HeLa cells was activated by treatment with 1 mM AICAR for 1h at 37°C. Cells were 
then trypsinated, collected by centrifugation (1200 g, 5 min), and resuspended in lysis buffer 
(50 mM Tris/HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 % NP-40, 0.1 % SDS) supplemented 
with protease (Roche) and phosphatase (Thermo Scientific) inhibitor cocktail. Cells were lysed 
by sonication and insoluble material was removed by centrifugation (10 min, 10 000 g, 4°C). 
AMPK activation was verified by immunoblotting using anti P-Thr172 AMPKα antibody. 
Immunoblot against GSTpi was used as a loading control. 
 
Fumarate hydratase enzyme activity 
AMPK221 was activated by CamKKβ and incubated with GST-FH in kinase buffer for 30 min at 
37°C prior to activity measurements. Enzyme activity of FH and phospho-FH was then 
determined at 25°C by a spectrophotometric assay measuring fumarate formation (240 nm) 
in 0.1 M potassium phosphate buffer pH 7.6 using 0.5 to 8 mM malate. Data were analyzed by 
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direct fitting to Michaelis-Menten kinetics and secondary plots using SigmaPlot 10 (Systat 
Software, USA). FH activity of HeLa extracts was measured under the same conditions using 
2.5 mM malate.  
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Results 
Setup of an in vitro AMPK substrate screen 
With the rationale to use the affinity between the kinase and its substrates as an additional 
parameter in a two-dimensional screening matrix for new substrates, we set out the following 
strategy (Figure 1): starting with soluble proteins within a cell extract of rat liver, we (i) 
eliminated proteins that non-specifically interact with Ni-NTA matrix, (ii) reduced complexity 
via size exclusion chromatography, (iii) screened for fractions containing AMPK interactors by 
using Biacore SPR with His-tagged AMPK221 immobilized on an NTA sensor chip, and finally 
(iv) screened SPR-positive fractions with in vitro phosphorylation assays using constitutively 
active AMPK221. 
Preliminary experiments had revealed a high degree of non-specific protein binding to the 
NTA surface during SPR (not shown), which could be eliminated by an initial Ni-NTA 
chromatography step. Prefractionation with size exclusion chromatography on a Superdex 
200 column had the additional advantage that eluted fractions contained proteins of similar 
size. This is an important prerequisite for the subsequent SPR experiments, since the SPR 
signal directly correlates with the mass bound at the chip surface, and thus not only with the 
number but also with the size of the bound protein. The unprocessed protein chromatography 
fractions were individually analyzed by Biacore SPR on surfaces covered with AMPK221 or left 
blank (Figure 2). Fractions were considered interaction positive when 80 s after dissociation 
start the SPR response on the AMPK221 surface was still higher as compared to the blank 
surface (fractions S1, S2, S3, S4, S10, S11 and S12). Fraction S1 contained mainly aggregates 
and was discarded; all other positive fractions were subjected to phosphorylation assays with 
or without constitutively active AMPK221 and separated by SDS-PAGE (Figure 3). Nine AMPK-
specific bands could be identified in these interaction–positive fractions. 
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Figure 1. Flow chart of the in vitro screening procedure. A tissue-derived extract containing soluble proteins is 
pre-fractionated by two step column chromatography with different sorbent chemistries. Each fraction is then 
analyzed by SPR for the presence of AMPK221 interacting proteins. Positive fractions are subjected to in vitro 
phosphorylation assays for detection of potential downstream substrates. After SDS-PAGE separation and 
autoradiography, positive lanes are excised and proteins identified by mass spectrometry. 
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Figure 2. SPR interaction screening. Representative association/dissociation kinetics of different fractions from 
size exclusion chromatography injected onto immobilized AMPK221 (full lines) or empty surface (control, dotted 
lines). 
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Figure 3. Phosphorylation assay screening. SPR positive fractions were subjected to in vitro phosphorylation 
assays with or without constitutively active αT172D AMPK221 using incubation with [γ-32P]ATP for 2min at 37 
°C. Assay mixtures analyzed by SDS-PAGE and Typhoon phospho-imager revealed AMPK auto-phosphorylation 
of α and β subunits and phosphorylation of putative AMPK substrates (bands indicated by small letters). 
Phosphorylation patterns of fractions S10 and S11 were similar to S12 and are not shown. 
 
Identification of candidate substrates of AMPK 
MALDI-MS/MS mass spectrometry of AMPK-specific phospho-bands identified several 
proteins with significant MASCOTT score (Table 1, online Supplementary Material 2). Three of 
them are at least partially localized in the cytosol and are thus the most likely candidate 
substrates of AMPK in vivo. The γ-actin was already identified as a putative AMPK substrate in 
our earlier in vitro AMPK substrate screen (Tuerk et al., 2007). Fumarate hydratase (FH) and 
fatty-acid binding protein 1 (FABP1 or FABPL) are newly identified AMPK candidate substrates. 
FH occurs in identical form in mitochondria and cytosol, but has different functions in the two 
compartments (Yogev et al., 2011). FABP1, a small protein of 14.6 kDa, is the liver isoform of 
a family of nine different FABPs in mammals (Storch and Corsico, 2008). These proteins were 
analyzed for putative AMPK phosphorylation sites, either corresponding to the stringent 
consensus motif (Scott et al., 2002) or to recognition sequences identified by peptide library 
profiling (Gwinn et al., 2008). While γ-actin did not contain a stringent AMPK site and was not 
further analyzed, FH preprotein and mature protein, as well as FABP1, contained at least one 
stringent AMPK site and additional less stringent sites.  
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Table 1. Protein identification by mass spectrometry. 
Fraction Band Identified protein Accession 
no.a  
Score b Mass 
(kDa) 
No. 
of peptides 
Consensus 
sites c 
Subcellular localization 
S2 a ATP synthase subunit α P15999 281 60 5 Yes Mitochondria 
  Cytochrome P45O 2D26 P10634 150 57 3 Yes Mitochondria 
 b 3-ketoacyl-CoA thiolase P13437 210 41 6 Yes Mitochondria 
S4 f Aldehyde dehydrogenase P11884 74 54 6 Yes Mitochondria 
 g Fumarate hydratase P14408 101 54 3 Yes Cytosol and 
mitochondria 
  γ-actin P63259 104 42 2 No Cytosol 
S12 i Fatty-acid-binding protein 1 P02692 53 15 1 Yes Cytosol 
Only vertebrate proteins identified with a significant MASCOTT score (>50) and different from AMPK subunits are shown. Candidate 
substrates (highlighted in grey) were selected due to cytosolic localization and presence of stringent AMPK consensus 
phosphorylation motifs: φ(X,β)XXS/TXXXφ (φ, hydrophobic residue; β, basic residue, (Scott et al., 2002)). a UniProt accession 
number. b Probability-based MOWSE scores greater than 50 were considered significant and not a random event. c Presence of at 
least one stringent AMPK consensus site (Scott et al., 2002). 
 
FH and FABP1 preferentially interact with AMPKα2 
We next wanted to confirm whether FH and FABP1 are indeed those proteins that were 
directly interacting with AMPK221 in the first dimension and phosphorylated by AMPK221 in 
the second dimension of our screen. A cytosolic yeast two-hybrid (Y2H) assay, the Cyto-Y2H 
(Brückner et al., 2009; Möckli et al., 2007), confirmed a direct protein-protein interaction in 
vivo between FH and the α2 and β2 AMPK subunits, but not the α1 and β1 subunits (Figure 4). 
 
 
Figure 4. FABP1 and FH directly interact with specific AMPK subunits in Y2H analysis. Cytosolic Y2H analysis of 
interaction between the baits FABP1 or FH and the preys AMPK subunits (α1, α2, β1, β2) or LT (Large T Antigen 
of Simian Virus, aa 84-704; negative control). Spots represent yeast grown for 72 h at 30°C (1/10 dilution) either 
on medium selecting for the presence of bait and prey plasmids (upper row) and on medium selecting for 
bait/prey interaction (lower row). For more details see online Supplementary Material 1. 
  
Direct interaction of AMPK221 with FH could be confirmed by co-immunoprecipiation (Figure 
5). FABP1 showed the same specificity for α2, while it interacted only very weakly with both 
β1 and β2 (Figure 4). These results confirm that FH and FABP1 are true interactors of AMPK. 
Importantly, they show specific interactions with the AMPK subunits used in the initial SPR 
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screen: the AMPKα2 catalytic subunit (in case of FH and FABP) and the AMPKβ2 regulatory 
subunit (in case of FH). 
 
 
Figure 5. FH co-immunoprecipitates with AMPK221. Strep-tagged FH and His-tagged AMPK221 were 
immunoprecipitated by using anti-His antibodies, and FH detected by immunoblot analysis with anti-FH 
antibodies. LC, primary antibody IgG light chain. 
 
FH is directly phosphorylated by AMPK221 
Direct phosphorylation of FH and FABP1 by AMPK was verified by in vitro phosphorylation 
assays with purified recombinant proteins. In principle, phosphorylation in complex mixtures 
could also occur by another protein kinase which is itself activated by AMPK. FH and FABP1 
were therefore expressed in E. coli as GST- and Strep-tagged proteins. GST-FH incorporated γ-
32P in presence of CamKKβ-activated AMPK221 in a time-dependent manner (Figure 6). 
Kinetics and extend of 32P incorporation were comparable to the reference AMPK substrate 
acetyl-CoA carboxylase (ACC). Similar results were obtained with Strep-tagged FH (Suppl. Fig. 
1), showing that FH phosphorylation was not due to an interaction of AMPK with the GST-tag 
(Klaus & Schlattner, unpublished data). By contrast, FABP1 constructs were not 
phosphorylated under these conditions (not shown). Thus, the screen correctly identified FH 
as a true and direct substrate of AMPK in vitro. 
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Figure 6. FH is a direct AMPK substrate. (A) Time course of FH phosphorylation by AMPK. AMPK221 (4pmol) first 
activated by CamKKβ (1 pmol) was incubated with purified GST-FH (100pmol) or GST-ACC (positive control, 100 
pmol) for 5 to 60 min at 37°C. In vitro phosphorylation assays were analyzed by SDS-PAGE and Typhoon 
phosphoimager. (B) Quantification of the phosphorylation time course using Image Quant TL. Data is normalized 
to maximal ACC phosphorylation. Symbols: GST-ACC (○), GST-FH (●). 
 
FH is preferentially phosphorylated by α2-containing AMPK complexes 
We then wanted to know whether FH not only interacts specifically with AMPK221, but is also 
specifically phosphorylated by this AMPK isoform combination. Like above, in vitro 
phosphorylation assays were conducted with FH and ACC, using three different AMPK 
complexes: AMPK221, AMPK211, and AMPK111, all previously activated by CamKKβ. ACC 
phosphorylation served to account for different specific activities of the AMPK complexes, 
since the ACC-derived SAMS peptide is an equally good substrate for α1- and α2-containing 
AMPK complexes (Vernia et al., 2009). We first investigated the effect of different α-subunits 
on FH phosphorylation (Figure 7A). The ratio P-ACC(221)/P-ACC(111) was 1.5, while the ratio P-
FH(221)/P-FH(111) was 5.0. If normalized to ACC, FH is still 3.3 times more phosphorylated by 
AMPKα2 as compared to AMPKα1. Complexes containing different β subunits (AMPK221 and 
AMPK211) phosphorylated both ACC and FH with similar efficiency (ratios of 1.1 for P-
ACC(221)/P-ACC(211) and 0.9 for P-FH(221)/P-FH(211); Figure 7B). Thus, at least in vitro, AMPK β-
subunits have no effect on FH phosphorylation. These results strongly suggest that AMPK 
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isoform composition can determine preference for specific substrates. FH interacts with 
AMPKα2 and is preferentially phosphorylated by α2-containing complexes. Although FH also 
interacts with the β2-subunit, this does not affect phosphorylation efficiency. 
 
 
Figure 7. AMPK isoform composition affects FH phosphorylation. (A) AMPK221 phosphorylates FH more 
efficiently than AMPK111. (B) AMPK221 and AMPK211 phosphorylate FH and ACC with similar efficiency. 
Conditions: 3 pmol AMPK221, -211 or -111 first activated by CamKKβ (1 pmol) were incubated with purified FH 
or ACC (200 pmol) for 8 min at 37°C. In vitro phosphorylation assays were analyzed by SDS-PAGE and Typhoon 
phosphoimager.  
 
FH phosphorylation by AMPK increases its enzyme activity in vitro and in vivo 
We have finally addressed the effect of FH phosphorylation on its enzymatic function, which 
catalyzes the reversible hydration/dehydration of fumarate to malate. Enzyme kinetics of FH 
were determined before and after in vitro phosphorylation by CamKKβ-activated AMPK221, 
using malate as substrate and measuring fumarate formation by spectrophotometry. FH 
phosphorylation led to a 37 % increase in kcat whereas the apparent Km remained almost 
unaffected (Figure 8; Table 2).  
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Figure 8. AMPK-mediated phosphorylation affects enzymatic catalysis of FH. Enzyme activity of phosphorylated 
(○) and non-phosphorylated (●) FH at different concentrations of malate, measured as described in material and 
methods. The direct fit to original data (large graph) and Lineweaver-Burk plot (insert graph) are shown. The 
derived catalytic constants are given in Table 2.  
 
Table 2. Phosphorylation by AMPK activates FH. Enzyme kinetic parameters of recombinant FH before and 
after phosphorylation with AMPK221 activated by CamKKβ. 
 Vmax 
(U mg-1) 
kcat 
(s-1) 
Km 
(malate) (mM) 
kcat/ Km 
(mM-1 s-) 
FH 32,9 ± 0,4 110,0 ± 1,3 4,2 ± 0,1 26,2 
P-FH 45,1 ± 1,4 150,8 ± 4,7 4,6 ± 0,3 32,8 
Measurements with variable concentrations of malate at 25°C (see figure 8). Enzyme activity is given in U, equivalent to 1 
μmol/min. Catalytic efficiency is calculated as kcat/ Km. Results are given as means ± SE (n=2) of two independent 
phosphorylation experiments. 
 
 
To investigate whether AMPK could also affect FH activity in vivo, we examined the effect of 
AMPK activation by its pharmacological agonist AICAR on FH activity in HeLa cells. Treatment 
of HeLa cells with 1 mM AICAR for 1 h led to a strong increase in AMPK αThr172 
phosphorylation (Figure 9A). This AMPK activation led to an average increase in FH activity by 
31.3 ± 6.4 % (Figure 9B). Similar results were obtained by activating AMPK with the Abbott 
compound A-769662 (not shown). 
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Figure 9. Pharmacological AMPK activation increases FH enzyme activity in HeLa cells. (A) Treatment of HeLa 
cells with 1 mM AICAR for 1 h increases AMPK activity as shown by immunoblotting for P-αThr172 AMPK with 
glutathione S-transferase pi (GST) as loading control. (B) FH activity in HeLa cells increases after AMPK activation 
as measured spectrophotometrically using malate as substrate (for details see material and methods). One 
representative experiment of three independent activation experiments is shown. 
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Discussion 
The original two-dimensional in vitro screen for protein kinase substrates presented here 
combines biophysical interaction based on SPR with phosphorylation assays. Our data provide 
proof of principle that such a screening protocol can reveal AMPK substrates that are 
phosphorylated in an AMPK isoform-specific manner. We identified FH (or fumarase) as a 
novel AMPK substrate, and show that mainly the α2-subunit of AMPK is involved in FH 
interaction and recognition, as well as in FH phosphorylation. This phosphorylation increases 
FH enzymatic turnover in vitro and in vivo. 
SPR technology has so far not been used to explore kinase/substrate interaction for screening 
of novel kinase substrates. It has only been applied as high-throughput readout device to 
measure interactions between phosphorylated kinase substrates and anti-phospho antibodies 
(Takeda et al., 2010). Highthoughput procedures have also been developed to screen for 
AMPK activators or inhibitors (e.g. (Anderson et al., 2004)). We show here that SPR can detect 
AMPK interactors in complex protein mixtures when different conditions are satisfied: (i) 
availability of highly pure, active kinase, as we have established by polycistronic bacterial 
expression of full-length AMPK complex (Neumann et al., 2003b); (ii) reversible, high density 
immobilization of the kinase on the chip surface for repeated use with fresh protein (e.g. by 
using Ni-NTA); (iii) the use of prefractionated extracts as source of soluble protein to reduce 
complexity; and in particular (iv) prior removal of proteins with non-specific affinity to the chip 
surface (especially relevant for Ni-NTA). We have assembled these conditions in a protocol 
(Figure 1) that provides useful data for AMPK and soluble liver proteins. The resolving power 
of the screen could be further improved by using multidimensional prefractionation (e.g. by 
additional ion exchange chromatography) or detection approaches (e.g. 2D-PAGE of 
interaction-positive fractions). 
From SPR-positive fractions, FH and FABP1 were identified as direct AMPK221-interacting 
proteins. Another FABP family member, the epidermal FABP5, and FH were also part of AMPK-
containing complexes in an earlier large-scale anti-bait co-immunoprecipitation study using 
AMPK-β1 (Ewing et al., 2007). However, here we show that both proteins exclusively interact 
with subunits used in our SPR screen: the α2- and (in case of FH) the β2-subunits. In addition, 
recombinant FH, but not FABP1, was also phosphorylated by AMPK in vitro. Possibly, FABP1 
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phosphorylation by AMPK requires additional factors (i.e. fatty acids) or secondary 
modifications missing in the bacterially expressed FABP1 but present in endogenous liver 
protein. Phosphorylation of FH constructs by AMPK221 occurred with kinetics and a degree of 
32P-incorporation per mol of protein that were similar to the well characterized AMPK 
substrate ACC. Like for FH/AMPK interaction, FH was phosphorylated predominantly by 
complexes containing the α2-subunit as compared to α1-complexes. This is one of the first 
reports showing a clear preference of mammalian AMPK complexes for one of its substrates 
(Vernia et al., 2009). Such substrate specificity may contribute to tissue- and compartment-
specific AMPK signaling whose mechanisms are so far largely unsolved. 
FH or fumarase is encoded by a single gene, but dual-targeted to mitochondria and cytosol 
(reviewed in (Yogev et al., 2011)). As studied in yeast, after cleavage of the signal peptide in 
mitochondria, identical mature FH variants relocate in a metabolically regulated process 
either to the mitochondrial matrix or to the cytosol. In humans or yeast, cytosolic FH (cFH) 
represents about half of the cellular FH pool and is the likely substrate of AMPK in vivo (Yogev 
et al., 2011). While mitochondrial FH is well known for its participation in the tricarboxylic acid 
cycle (TCC), converting fumarate into malate, the role of cFH is emerging only more recently. 
Recent research is driven by the tumor suppressor function of FH which suggests that 
metabolic signals can regulate carcinogenesis (reviewed in (Raimundo et al., 2011)). Cancer 
incidence is linked to cFH inhibition and/or the resulting cytosolic fumarate accumulation, 
which may act via different mechanisms. These include induction of pseudohypoxia via 
stabilization of HIF-1α (O’Flaherty et al., 2010), signaling via serum responsive factor 
(Raimundo et al., 2009), up-regulation of antioxidant-response element-controlled genes (Ooi 
et al., 2011; Tong et al., 2011), or inhibition of DNA damage response (Yogev et al., 2010). In 
the latter mechanism, cellular stressors leading to DNA damage, induce cFH translocation to 
the nucleus, where its enzymatic activity is required to activate the DNA repair machinery, 
thus avoiding genomic instability. Our study together with literature data suggest that 
phosphorylation and activation of cFH by AMPK could play an important role in this sequence 
of events. AMPK signaling is known to respond to DNA damage and genotoxic stress 
transmitted via p53 and the p53 targets Sestrin1 and Sestrin2 (Budanov and Karin, 2008) or 
the cellular damage sensor ataxia-telangiectasia mutated protein (ATM) (Alexander et al., 
2010). Furthermore, the nuclear functions of AMPK are mediated by α2-complexes (α1-
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complexes are not localizing to the nucleus) (Salt et al., 1998), exactly the isoform that 
preferentially phosphorylates cFH. 
In summary, we provide proof of concept that combining classical in vitro AMPK 
phosphorylation assays with SPR-based AMPK-protein interaction screening can not only 
identify novel AMPK substrates but also enrich for AMPK isoform-specific substrates. The 
newly identified AMPK substrate FH is exclusively interacting with and preferentially 
phosphorylated by α2-containing AMPK complexes. Both phosphorylation and activation of 
FH could contribute to the tumor suppressor function of FH. 
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Introduction  
AMP-activated protein kinase (AMPK) plays a central role in sensing and regulating energy 
homeostasis at the cellular, organ and whole-body level (Carling et al., 2012; Hardie, 2011; 
Hardie et al., 2012; Steinberg and Kemp, 2009). By regulating enzyme activity in metabolic 
pathways and transcription, it exerts pleiotropic control of metabolism and other physiological 
functions like cell growth, shape, motility and proliferation, including higher level functions 
such as appetite control. These functions suggested the kinase as a potential drug target for 
treating diabetes type II or cancer (Fogarty and Hardie, 2010; Viollet et al., 2009; Zhang et al., 
2009). Kinase activation is triggered by a diverse array of external (e.g. hormones, cytokines, 
nutrients) and internal signals (e.g. AMP, ADP) linked to limited energy availability and other 
stress signals in physiological and pathological situations. The complex activation mechanism 
involves covalent phosphorylation of the α-subunit and allosteric binding of AMP or ADP to 
the γ-subunit.    
In vitro screening that we carried out for novel substrates of AMPK repeatedly identified 
proteins that localize to mitochondria, in particular the mitochondrial matrix, like e.g. 
fumarate hydratae (fumarase, FH) (Klaus et al., 2012; Tuerk et al., 2007). Although the 
existence of different protein kinases within the mitochondrial compartment is emerging 
(Acin-Perez et al., 2009; Aponte et al., 2009; Padrão et al., 2013), AMPK has not yet been 
clearly localized with this organelle. An alternative possibility would be regulation of 
mitochondrial import of nascent protein that occurs already in the cytosol. It has been shown 
that phosphorylation of serine, threonine or tyrosine residues can either inhibit or promote 
mitochondrial targeting of nascent proteins, depending on the phosphorylated site and the 
nature of the targeting mechanism (Dasari et al., 2006; Robin et al., 2002, 2003). This would 
render subcellular localization dependent on dynamic signaling processes. Several studies 
provided evidence for phosphorylation within an N-terminal targeting sequence of 
mitochondrial proteins that reduces import efficiency (Chua et al., 2003; Lee et al., 2006; 
Merrill et al., 2013). 
Here we examined in more detail the in vitro phosphorylation of rat mitochondrial FH and 
show that this secondary modification occurs mainly in the cleavable prepeptide at Ser19 and 
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only at a much lower level at Thr482. Out of other mitochondrial matrix proteins that our 
studies suggested as AMPK substrate candidates ((Klaus et al., 2012; Tuerk et al., 2007) and 
unpublished data), also the prepeptide of pyruvate carboxylase is AMPK-phosphorylated. 
Such phosphorylations, if occurring in vivo, must happen already in the cytosol before 
mitochondrial import, and may thus affect import efficiency.  
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Materials and Methods 
Vectors 
Plasmid pγ1β2His-α2AMPK was used for bacterial expression and purification as we have 
published previously (Neumann et al., 2003; Riek et al., 2009). FH (GeneID 24368) was 
amplified from rat liver cDNA and introduced into bacterial expression vector pET-52b (+) to 
obtain N-terminally tagged FH. Vectors for GST-ACC domain and GST-CamKKβ were kindly 
provided by G. Hardie (Univ. of Dundee, UK) (Scott et al., 2002) and H. Tokumitsu (Kagawa 
Medical University, Japan), respectively.  
 
Site-directed mutagenesis of fumarate hydratase by sequence and ligation-independent 
cloning 
FH plasmids were amplified by PCR using T4 DNA phusion polymerase (Thermo Scientific) and 
mutagenic primers listed in Table 1. After PCR amplification, 20 U DPN1 (New England BioLabs) 
were added to the reaction and the mixture was incubated at 37°C for 1 h to digest the 
template. Plasmid DNA was then purified by Nucleospin Extract II (Machinery-Nagel). 1 µg 
DNA was treated with 0.5 U T4 DNA polymerase (Invitrogen) in a 20 µl reaction mixture at 
22°C for 30 min giving the exonuclease activity of T4 DNA polymerase 20 bp at both 3’ end of 
the PCR product will be digested, forming sticky end between the two extremities of the PCR 
product to further recirculation of the plasmid. The reaction was stopped by purification with 
Nucleospin Extract II (Macherey-Nagel). Finally, 600 ng DNA, 2µl T4 DNA ligase buffer and 1µl 
T4 DNA ligase (New England BioLabs) were used in 20 µl reaction volume at room temperature 
for 2h for ligation. A 5µl aliquot of the annealing mix was used to transform 100 µl of 
competent MachT1 bacteria which were plated on Ampicillin plates. The sequence of all 
clones was verified by sequencing.  
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Table 1. Primers used for generating FH point mutations 
 
The sequence of the mutated amino acid is highlighted in grey; fw, forward primer; rev, reverse primer. 
 
Expression and purification of GST-tagged proteins 
All GST fusions protein constructs were transformed into competent BL21-Codon Plus (DE3)-
RIL E. coli cells (Stratagene) and incubated overnight on LB agar containing 100 µg/ml 
ampicillin and 30 µg/ml chloramphenicol. Cultures were grown in LB containing antibiotics at 
37°C with shaking until OD (600 nm) 0.7-0.9. Cells were then cooled down to 30°C and protein 
expression was induced for 4 hours with 2 mM isopropyl β-D-thiogalactopyranoside (IPTG) 
(Eurobio). Cells were harvested and suspended in lysis buffer: PBS (phosphate buffer saline) 
with complete EDTA-free protease inhibitor cocktail (Roche). After sonication, insoluble 
material was removed by centrifugation (40000 xg, 40 min at 4°C). Supernatant was applied 
to a Gluthatione Sepharose matrix (Qiagen) packed column, the column was washed with PBS, 
and proteins were eluted with 10 mM L-gluthatione reduced (Sigma-Aldrich) in 50 mM Tris-
HCL, pH 8. 
 
In vitro phosphorylation assays 
Purified GST-tagged FH proteins (200 pmol each), including WT and mutants S19A, S43A, 
S155A, S233A, T482A, T482V, T482V, T482G and N-terminally truncated FH (amino acids 1-
Mutation  Primers sequences : 5’ → 3’ 
S19A Fw GTCGCTTCCCGCGGGTCCCCGCCGCCGGTGCTGTATTGTCAGGGGAAGCG 
Rev GGCGGGGACCCGCGGGAAGCGAC 
S43A Fw TCTATACGGAAGGAATTTTGCGCCGCTGCCATTCGCACGACG 
Rev GCGCAAAATTCCTTCCGTATAGAATACGACACC 
S155A Fw TGAATGTAAATGAAGTGATCGCCAACAGGGCAATCGAAATGCTAGG 
Rev GGCGATCACTTCATTTACATTCATGTTCGTCTGG 
T233A Fw TAAAAATTGGGCGGACTCATGCGCAGGACGCTGTCCCTCTTACTCTT 
Rev CGCATGAGTCCGCCCAATTTTTATGAC 
T482A Fw ACGGATCCACCTTAAAGAAAGCGGCTATTGAACTTGGCTATCTCACAG  
Rev CGCTTTCTTTAAGGTGGATCCGTTCTTGTG 
T482D Fw ACGGATCCACCTTAAAGAAAGACGCTATTGAACTTGGCTATCTCACAG 
Rev GTC TTTCTTTAAGGTGGATCCGTTCTTGTG 
T482G Fw ACGGATCCACCTTAAAGAAAGGGGCTATTGAACTTGGCTATCTCACAG 
Rev CCCTTTCTTTAAGGTGGATCCGTTCTTGTG 
T482V Fw ACGGATCCACCTTAAAGAAAGTGGCTATTGAACTTGGCTATCTCACAG 
Rev CACTTTCTTTAAGGTGGATCCGTTCTTGTG 
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41), as well as GST-tagged ACC domain (control) were incubated for 30 min at 37°C with 200 
µM [γ-32P]ATP (specific activity 6000 Ci/mmol ATP) and AMPK221 (4 pmol) previously 
activated by incubation with 1 pmol CamKKβ for 20 min at 30°C in kinase buffer (50 µM AMP,  
5 mM MgCl2 , 1 mM DTT, 10 mM HEPES pH 7.4). For negative controls, AMPK substrates were 
incubated with 1 pmol CammKKβ without AMPK. Kinase reactions were stopped by addition 
of Laemmli buffer and subjected to SDS-PAGE and autoratiography by Typhoon 
phosphoimager (GE Healthcare).  
 
Mass spectrometry  
Phosphorylated samples were prepared with freshly purified AMPK221 to avoid the presence 
of glycerol normally needed for long term AMPK storage. FH-WT (100 pmol) was incubated 
for 30 min at 37°C with 2 pmol AMPK221 previously activated by incubation with 1 pmol 
CamKKβ for 20 min at 30°C in kinase buffer. As negative controls, ACC domain and FH-WT 
were incubated with 1 pmol CammKKβ without AMPK. The samples were conserved at 4°C. 
Samples were dried and solubilized in 20 µl of ammonium bicarbonate (50 mM) before 
performing a reduction of disulfide bonds, an alkylation of thiols and trypsin digestion. 
Aliquots of the digest were either used directly for mass spectrometry analysis or 
phosphopeptides were enriched using the Pierce kits TiO2 Phosphopeptide Enrichment or Fe-
NTA Phosphopeptide enrichment (Thermo Scientific) and then purified with Graphit Clean-up 
kit (Thermo Scientific). Of each aliquot, 10 pmol were subjected to nanoLC-MS/MS using an 
ESI-QTrap mass spectrometer (4000QTRAP, AB Sciex) directly connected to a nano-
chromatography system (3000 Ultimate nanoLC, Thermo Fischer). Bioinformatics analysis for 
identification of (phospho)peptides/proteins was performed using ProteinPilot 4 software 
(ABSciex) with both Paragon and Mascot algorithms and Swissprot (Rattus norvegicus species) 
as protein database. Validation of phosphopeptides was considered when their identification 
led to a high confidence level, i.e. confidence level >95% for Paragon algorithm and p<0.05 for 
Mascot algorithm. 
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Results 
Fumarate hydratase contains different putative AMPK phosphorylation sites 
Bioinformatics analysis of the full length sequence of rat mitochondrial FH suggested three 
AMPK sites, Ser19, Ser43 and Thr233, which correspond to the stringent AMPK 
phosphorylation motif. This motif is X,XXS/TXXX, where  is a hydrophobic residue 
(mostly M, V, L, I or F),  is a basic residue (R, K or H) and the parentheses indicate that the 
order of residues at the P-3 and P-4 positions is not critical (Dale et al., 1995).  
We then performed LC-MS/MS analysis of in vitro phosphorylated full-length FH for 
unbiased identification of phosphosites, with or without additional enrichment of 
phosphopeptides (Table 2). Different experiments revealed either predominant 
phosphorylation in the sequence of the mature enzyme (Ser43, Ser155 and Thr482) or in the 
mitochondrial prepeptide (Ser19). The Ser43 site was identified at lower confidence, but 
retained for further analysis since it occurred in both phosphopeptide enrichment procedures. 
Ser155 and Thr482 both do not conform to a stringent AMPK motif (Dale et al., 1995); 
however, the latter may correspond to a less stringent AMPK motif as based on a peptide 
screen (Gwinn et al., 2008). 
 
Table 2. Phosphorylation sites identified by mass spectrometry 
Phospho- Phosphorylation Identified phosphorylated peptides  
site motif sequence 
Without enrichment 
phosphopeptide enrichment with 
  TiO2 FeNTA 
S19 RRFPRVPSAGAVLS V17-R33 V17-R33  ND 
S43 PNVVRMASQNSFRI - P36-R48 N37-R48 
G21-R48 
P36-R48 
S155 MNVNEVISNRAIEM M148-K169 - - 
T482 NGSTLKETAIELGY N475-K501 
K480-K501 
- - 
The stringent AMPK motif is X,XXS/TXXX is hydrophobic;  is basic (Dale et al., 1995). Bold Peptides in 
bold letters were identified with a high degree of confidence (>99%) via the paragon algorithm. ND, not 
determined. 
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AMPK phosphorylates fumarate hydratase mainly at Ser19 
To unambiguously identify the FH phosphoresidues on the basis of the bioinformatic and MS 
data, all valid candidate Ser and Thr sites were mutated into a non-phosphorylatable alanine 
(Figure 1). Different mutations in the sequence of the mature enzyme, Ser43, Ser155 and 
Thr233, did not affect phosphorylation as compared to FH wild-type (WT). The T482A 
mutation reduced phosphorylation levels. This reduction was confirmed in some other Thr482 
mutants (T482D, T482G and T482V) even if this phenomenon was less exacerbated in those 
mutants (Figure 1A). Surprisingly, the most important effect on phosphorylated level was 
observed on Ser19 in the N-terminal targeting peptide of FH that is cleaved after 
mitochondrial import (Figure 1B). Also in a truncation mutant lacking this targeting peptide 
(N-terminal 41 amino acids), phosphorylation by AMPK was strongly reduced.  
 
 
Figure 1. In vitro phosphorylation of fumarate hydratase wild type and mutant proteins. Mitochondrial FH wild-
type (WT) together with (A) point mutants S43A, S155A, T233A, T482A, T482D, T482G, and T482V, or (B) 
truncated WT protein lacking the mitochondrial targeting peptide (amino acid 1-41, ΔWT) or point mutation 
S19A, as well as an acetyl-CoA carboxylase domain (ACC, positive control) were subjected to a standardized in 
vitro phosphorylation assay using AMPK221 heterotrimeric complex activated by CamKKβ (see Materials and 
Methods).  
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AMPK phosphorylates the prepeptide of pyruvate carboxylase 
Mitochondrial prepeptides are amphiphatic and contain numerous hydrophobic and basic 
residues which are essential in the stringent AMPK motif X,XXS/TXXX (Dale et al., 1995). 
We therefore hypothesized that AMPK could also phosphorylate other mitochondrial 
prepeptides, at least in vitro. All mitochondrial matrix proteins suggested in our earlier studies 
as putative AMPK substrates ((Klaus et al., 2012; Tuerk et al., 2007) and unpublished data) 
were thus analyzed for potential AMPK phosphorylation sites. The AMPK motif was detected 
in addition to fumarate hydratase also in citrate synthase (CS) and pyruvate carboxylase (PC), 
when alanine and glycine were allowed as hydrophobic residues (Table 3). Less stringent forms 
of the AMPK motif (Gwinn et al., 2008) were found in several other mitochondrial matrix 
proteins (not shown). We then tested phosphorylation of synthetic CS and PC prepeptides in 
the same in vitro phosphorylation assay as used for FH. Heavy incorporation of 32P label was 
observed in the prepeptide of PC, not of CS (Figure 2). 
Table 3. Putative AMPK phosphorylation sites in mitochondrial prepeptides 
Protein Uniprot Name localization Prepeptide Prepeptide sequence 4 
Fumarate hydratase 1 P14408 FUMH M, C 1-41 MNRAFCLLARSRRFPRVPSAGAVLSGEAATLPRCAPNVVRMASQN… 
Citrate synthase 2 O75390 CISY M 1-27   MALLTAAARLLGTKNASCLVLAARHASASST… 
Pyruvate carboxylase 3 P11498 PYC M 1-20              MLKFRTVHGGLRLLGIRRTSTAPAASPNVR… 
[1] Klaus et al. 2012 (Klaus et al., 2012); [2] Tuerk et al 2007 (Tuerk et al., 2007); [3] Ramirez (2010) thesis Université de 
Grenoble no. 00641109; [4] Black letters indicate the N-terminal prepeptide, bold letters indicate the sequence used in in vitro 
phoisphorylation assays, colors indicate key residues in the AMPK motif X,XXS/TXXX is hydrophobic;  is basic (Dale et 
al., 1995). Localization: M, matrix; IM, intermembrane space; C, cytosol. 
 
 
 
Figure 2. In vitro phosphorylation of mitochondrial 
prepeptides. Synthetic peptides corresponding to 
prepeptides of human citrate synthase (CS) or 
pyruvate carboxylase (PC), together with ACC domain 
(positive control) were subjected to a standardized in 
vitro phosphorylation assay using AMPK221 
heterotrimeric complex activated by CamKKβ (see 
Materials and Methods). Note autophosphorylation 
of AMPKα and –β subunits. 
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Discussion 
Several in vitro screens that we performed in recent years identified mitochondrial proteins, 
most in the matrix space, as candidates for AMPK substrates ((Klaus et al., 2012; Tuerk et al., 
2007) and unpublished data). However, no relevant phosphorylation site has been reported 
so far for these proteins. Here we further analyzed the mitochondrial isoform of rat fumarate 
hydratase that we recently described as being phosphorylated by AMPK in vitro (Klaus et al., 
2012). We identify Ser19 in the cleavable mitochondrial target peptide of FH as the main 
phosphorylated residue, and Thr482 as a putative secondary site.        
Our MS analysis clearly pinpoints Ser19 as the by far most predominant site, thus responsible 
for the near stoichiometric phosphorylation of FH that we have observed earlier (Klaus et al., 
2012). Although phosphorylation in the prepeptide is surprising at first glance, it could be 
physiologically relevant. Several studies have shown that phosphorylation within an N-
terminal mitochondrial targeting sequence reduces protein import efficiency (Chua et al., 
2003; Lee et al., 2006; Merrill et al., 2013). The amphiphatic cleavable presequences carry a 
net positive charge that is important for translocation into the negatively charged 
mitochondrial matrix by an electrophoretic mechanism (Neupert and Herrmann, 2007). 
Phosphorylation within this sequence reduces or neutralizes this positive charge and can 
retain the protein in the cytosol, leading to persistent cytosolic localization or degradation of 
the enzyme (Chua et al., 2003; Lee et al., 2006; Merrill et al., 2013). For example, 
phosphorylation of Ser9 and Ser22 in cNMP phosphodisesterase by PKC effectively inhibits 
targeting to the mitochondrial matrix and retains the protein in the cytosol (Lee et al., 2006). 
Also the actin-binding protein cofilin phosphorylated at Ser3 by LIM kinase is cytosolic, while 
dephosphorylation during apoptisis triggers mitochondrial import (Chua et al., 2003). 
Similarly, phosphorylation of so-called cryptic mitochondrial targeting signals, for example 
present in proteins with bimodal targeting to different compartments (Avadhani, 2011), can 
affect mitochondrial localization as in case of the cytochrome P450 family 
(Anandatheerthavarada et al., 1999; Dasari et al., 2006) or GSTA4-4 (Robin et al., 2003). 
Phosphorylation of Thr482 occurs only at low levels in vitro, but a regulatory role in vivo cannot 
be excluded. The site is well exposed at the protein surface and situated in the C-terminal 
domain 3 of FH (Figure 3) which may have regulatory functions. Interestingly, this domain is 
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phosphorylated at multiple threonine and tyrosine residues in mouse liver (see (Villén et al., 
2007) and www.phosphosite.org). 
 
Figure 3. Phosphorylation sites in the fumarate hydratase domain 3. Tetrameric molecular structure of human 
fumarate hydratase (3E04, monomers in green and blue colors) showing the localization of the minor AMPK site 
Thr485 identified here (red, Thr482 in rat) within the domain 3 (C-terminal 65 residues). This domain habors also 
other Tyr (orange) and Thr (pink) phosphorylation sites reported elsewhere ((Villén et al., 2007) and 
www.phosphosite.org). Phosphorylated amino acids are given in spacefill representation. Structure prepared by 
WebLabVierwer Pro 4.0. 
 
In conclusion, we unambiguously identify an AMPK phosphorylation site in the prepeptide of 
rat FH that targets the protein to mitochondria. Further studies will have to show whether this 
modification alters mitochondrial FH import.  
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NRDP1 – high level 
expression of full-
length protein and 
analysis of its 
interaction with 
AMPK 
 
 
Abstract. NRDP1, an E3 ubiquitin ligase, has been 
shown to interact with AMP-activated protein kinase 
(AMPK) in cytosolic split-protein yeast-two hybrid 
screens (Y2H). Here we developed a method to 
produce NRDP1 full-length protein at high yield by 
avoiding formation of inclusion bodies. Recombinant 
NRDP1 can be phosphorylated by AMPK in vitro, but 
does not ubiquinate AMPK in HEK293 cells. Cellular 
overexpression of AMPK in HeLa cells increases 
NRDP1 proteasomal degradation, suggesting that 
AMPK affects cellular steady state levels of NRDP1 
and thus NRDP1 functions.     
 
Résumé. Un crible cytosolique de double hybride en 
levure (Y2H) a montré que l’E3 ubiquitine ligase 
NRDP1 interagit avec la protéine kinase activée par 
l’AMP (AMPK). Nous avons alors développé une 
méthode afin de produire la protéine NRDP1 à haut 
rendement en évitant la formation de corps 
d’inclusions. La protéine recombinante NRDP1 peut 
être phosphorylée par l’AMPK in vitro, en revanche 
elle n’ubiquitine pas l’AMPK dans les cellules 
HEK293. La surexpression d’AMPK dans les cellules 
HeLa augmente la dégradation de NRDP1 via le 
protéasome, ce qui suggère que l’AMPK affecte le 
niveau basal de NRDP1 et donc ses fonctions.   
 
 
Research of this part was partially conducted in the group of Dr. Pascual Sanz, IBV, CSIC, Valencia, Spain. 
A manuscript based on this part [Zorman, S., Roma-Mateo, C., Sanz, P., Schlattner, U., High level 
expression and AMPK complex formation of E3 ubiquitin ligase NRDP] is submitted to Protein Expression 
and Purification.  
I was involved in all experiments, data analysis and manuscript writing.  
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Introduction 
The neuregulin receptor degradation protein 1 (NRDP1) is part of the E3 ubiquitin ligase family 
that is essential for the ubiquitination of proteins. This secondary protein modification, mostly 
known to target proteins to the proteasome for degradation (Hershko and Ciechanover, 1992) 
is among the most frequent in eukaryotes and occupies a pivotal role in regulating cell 
signaling and homeostasis (Dikic et al., 2009). The conjugation of an ubiquitin (Ub) moiety to 
a substrate protein serves as a recognition element for effector proteins. However, protein 
ubiquitination extends far beyond the well-known proteasome-linked protein degradation. It 
is critical for processes such as endocytosis, DNA repair, DNA damage tolerance, protein kinase 
regulation, autophagy, multivesicular bodies biogenesis or NF-кB activation and transcription 
(Dikic et al., 2009). Given the broad spectrum of ubiquitination events and substrates, it is not 
surprising that this modification is also involved in pathologies ranging from cancer to 
neurodegenerative disorders and infectious diseases, such as HIV (Weissman, 2013). Thus, 
there is intense interest in targeting enzymes involved in ubiquitination. 
 
The ubiquitination system  
Ub is a small, monomeric protein of 76 residues that is highly conserved in all eukaryotic 
organisms (except 3 amino acids, the sequence is identical between yeast and human 
proteins) (Ozkaynak et al., 1987). The lack of evolutionary divergence suggests that the entire 
sequence is functionally important. The conjugation of Ub to a substrate protein has been 
elucidated in detail by Avram Hershko & Aaron Ciechanover (Hershko and Ciechanover, 1998). 
It requires three enzyme subfamilies: E1, E2, and E3. ATP-dependent ubiquitin-activating 
enzyme E1 is a unique isoform in most organisms. It generates an activated E1-bound Ub able 
to be transferred to a cysteine in the active site of an E2 Ub conjugating enzyme. There are 
roughly 40 different E2 enzymes in mammals, working in conjunction with accessory E3 
proteins. Ubiquitin-protein ligase E3, the last effector of the machinery, provides substrate 
specificity. By formation of E2-E3 complexes, E3 will transfer the Ub from E2 to a Lys ɛ-amino 
group of its target substrate protein, thereby forming an isopeptide bond. Mammalian cells 
contain over 600 type of E3 enzymes (Weissman, 2013), each of which mediating the 
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ubiquitination of a specific set of substrate proteins and thereby alter their fate or function. 
The known E3 enzymes form two unrelated families: the HECT domain E3 (homologous to 
E6AP-C-terminus) and the RING finger E3 (really interesting new gene) (Ardley and Robinson, 
2005). The HECT E3 enzymes have a 350 residue HECT domain that mediates E2 binding and 
catalyzes the ubiquitination reaction, and a unique N-terminal domain that interacts with its 
target substrate proteins. The ubiquitin moiety is first transferred from E2 to E3 before it is 
attached to the substrate. RING finger-containing E3s have a RING finger domain of 40 to 60 
residues at their N-terminal tail which is thought to mediate a variety of protein-protein 
interactions and catalyzes a direct transfer of ubiquitin from E2 to a substrate protein (Figure 
1). 
In one round of ubiquitinylation, Ub is either directly bound to a lysine residue of a substrate 
protein, or to a lysine residue of protein-linked Ub, thus forming a polyUb chain. Ub has 7 
internal Lys residues in positions 6, 11, 27, 29, 33, 48 and 63. Earlier studies suggested that 
only Lys48 was involved in the formation of Ub chains (Chau et al., 1989; Dammer et al., 2011), 
More recent studies showed that homogeneous chains could be also based on linkage of Lys6, 
11, 27, and 29 (Dammer et al., 2011), and also Lys 33 (Bedford et al., 2009)and Lys 63 (Saeki 
et al., 2009). In addition, there are heterogeneous chains based on different internal linkages 
(Kirkpatrick et al., 2006), and more than one Ub can be linked to a proceeding Ub, thus creating 
branched Ub polymers (Kim et al., 2007).  These different Ub structures are recognized by an 
Ub-binding domain (UBD) on the effector proteins. The entire Ub polymer structure is critical 
to condition the fate of the target protein (Husnjak and Dikic, 2012). This pattern seems to be 
a complex language which needs a better understanding to decode the numerous signals 
generated by these different chains and to discover the mechanisms that underlie the 
diversity of encoded functions. 
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Figure 1. Enzymatic reactions involved in the ubiquitination of proteins. The ubiquitin-activating enzyme E1 
binds ubiquitin to activate it for transfer to ubiquitin-conjugation enzyme E2. E2 is forming a complex with 
ubiquitin-ligase E3 which ubiquitinates substrate proteins and confers substrate specificity. The exact mechanism 
differs between the two E3 families, the HECT-domain E3 (left) and the ring finger-domain E3 enzymes (right).  
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The E3 ubiquitin ligase NRDP1 
NRDP1 was first described in 2001, but only few publications are referring to it so far. This 
RING finger E3 ubiquitin ligase shows an ubiquitous expression in human adult tissues, with 
highest levels in heart, skeletal muscle and brain (Diamonti et al., 2002). Four different 
functions of NRDP1 have been described in literature: 
1/ NRDP1 interacts with the cytoplasmic tail of ErbB3 (Bouyain and Leahy, 2007) receptor, 
thus stimulating Erb3 ubiquitination and degradation by the proteasome (Qiu and Goldberg, 
2002; Sweeney and Carraway, 2004). ErbB3 is a component of the EGF receptor family that 
regulates cell survival, proliferation and differentiation. Overexpression of ErbB receptors is 
associated with the development of different types of human cancer (Berger et al., 1988; 
Gullick, 1996; Hynes, 2007; Press and Lenz, 2007; Sharma and Settleman, 2009).   Moreover, 
human NRDP1 and ErbB3 genes co-localize at the chromosomal locus 12q13 which is 
frequently rearranged in human tumors (Abdullah et al., 2001), and NRDP1 is even lost in 
certain mammary tumors (Yen et al., 2006), both suggesting a putative role of NRDP1 in tumor 
progression via increased Erb signaling. Degradation of ErbB via NRDP1 would thus be an 
attractive target for cancer therapy.  
2/ NRDP1 binds and catalyzes the ubiquitination of BRUCE, a member of the IAP (inhibitor of 
apoptosis proteins) family, thus targeting it to proteasomal degradation as shown by NRDP1 
overexpression (Qiu et al., 2004) and siRNA knock-downs (Qiu et al., 2004). Such BRUCE 
degradation is critical for the initiation of apoptosis (Bartke et al., 2004).  
3/ NRDP1 interacts with and regulates the stability of parkin, another E3 ubiquitin ligase. Loss 
of function in parkin causes accumulation and aggregation of its substrates and and inhibits 
mitophagy, leading to death of dopaminergic neurons in Parkinson disease (Mo et al., 2010; 
Yu and Zhou, 2008; Zhong et al., 2005).  
 4/ Finally, NRDP1 activity seems to be dependent on its antagonist USP8 (deubiquitinating 
enzyme 8) which is stabilizing both, NRDP1 and its target substrates, by deubiquitination 
(Avvakumov et al., 2006; De Ceuninck et al., 2013; Wu et al., 2004). This is important, since 
autoubiquitination of NRDP1 causes high cellular turnover of this protein (Qiu and Goldberg, 
2002; Wu et al., 2004). The balanced reciprocal cross regulation between NRDP1 and USP8 
thus decides about the fate of both proteins and their substrates. 
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NRDP1/AMPK interaction 
An unbiased yeast-two-hybrid (Y2H) interaction screen performed in our laboratory has 
revealed another potential regulation of NRDP1: an interaction with the AMP-activated 
protein kinase (AMPK). AMPK is a key sensor and regulator of energy metabolism and 
represents a signaling hub in a large network that maintains cellular and organism energy 
homeostasis (Hardie and Carling, 1997; Winder and Hardie, 1999). AMPK is regulating its 
substrates by activatory or inhibory phosphorylations at serine or threonine residues. 
Activated AMPK is increasing the ATP-generating catabolism and reduces ATP-consuming 
anabolism. Among the various additional functions mostly related to spare cellular energy 
expenditure is the reduction of protein synthesis and cell growth. This is mediated by 
inhibition of the mammalian target of rapamycin complex 1 (mTORC1) pathway.  
 
In this study, we report on the identification of AMPK as an NRDP1 interactor by two different 
Y2H screens. An NRDP1/AMPK interaction may have different, non-exclusive functional roles: 
(i) NRDP1 could be a putative substrate of AMPK, (ii) AMPK could be a putative substrate of 
NRDP1, or (iii) the interaction alone could affect NRDP1 or AMPK functions. Scaffolding, 
affecting conformation, stabilized or unstabilized one or both proteins. 
To study the NRDP1/AMPK interaction in vitro, we established an efficient bacterial expression 
and purification protocol for full-length NRDP1. Recombinant protein used for in vitro assays, 
together with cellular overexpression systems, revealed an effect of the NRDP1/AMPK 
interaction on NRDP1 stability, independent of an observed low level NRDP1 phosphorylation 
by AMPK. 
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Materials & Methods  
Cloning 
NRDP1 (E3 ubiquitin-protein ligase NRDP1, Accession no. BC032637) was amplified from 
vector pCMV-SPORT6 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) with NRDP1-
fw (CAATGTATTGGCCATTACGGCCATGGGGTATGATGTAACCCGTTTC) and NRDP1-rev 
(CAATACATTGCAGGCCGAGGCGGCCCCTATCTCTTCCACGCCATGCGCAAATAT) primers 
containing sfi1 sites and introduced into yeast two-hybrid (Y2H) vectors pCab and pDSL 
(Dualsystems Biotech AG,  Schlieren, Switzerland) for Y2H experiments or in bacterial 
expression vector pGEX-4T-1 (GE-Healthcare Life Sciences, Pittsburgh, PA, USA), all plasmids 
containing Sfi1 sites (more details can be found  in the PhD thesis of A. Bruckner/Grenoble 
University). All construct were verify by sequencing (GATC-Biotech, Konstanz, Germany). The 
fusion constructs GST-NRDP1, GST-ACC (plasmid kindly provided by G.Hardie, Univ. of Dundee, 
UK) and GST-CamKKβ (plasmid kindly provided by H. Tokumitsu, Kagawa Medical University, 
Japan) all with GST-tag at n-terminal of the protein, were bacterially expressed as below. 
 
Yeast-two-hybrid 
Cytosolic yeast two-hybrid (Y2H) systems based on reconstitution of split proteins have been 
used for protein-protein interaction screening and pairwise protein-protein interaction 
analysis. The Cyto-Y2H (Möckli et al., 2007) (Dualsystems Biotech, Schlieren, Switzerland) is 
based on the split-ubiquitin system (Johnsson and Varshavsky, 1994; Stagljar et al., 1998). The 
membrane-anchored bait is fused to a reporter cassette composed of the C-terminal half of 
ubiquitin and the artificial transcription factor LexA-VP16, whereas the prey is fused to the N-
terminal half of ubiquitin. Bait/prey interaction leads to ubiquitin reconstitution and cleavage 
by ubiquitin-specific proteases that liberate the transcription factor for classical 
transcriptional read-out. In contrast to the published ER-membrane-anchored (Ost4P) bait, 
we apply here a novel version using a plasma membrane anchor (Aβ-domain, transmembrane 
domain of the Type 1 membrane protein APP). Cloning procedures using Sfi1 sites, 
transformation of yeast cell line NMY51 (MATa his3delta200 trp1-901 leu2-3,112 ade2 
LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-lacZ (lexAop)8-ADE2 GAL4) and yeast spotting were 
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described earlier (Möckli et al., 2007). Selective media lacked either tryptophan and leucine 
(SD-WL) to control the presence of bait and prey plasmid, or additionally adenine and histidine 
(SD-AHWL) for protein interaction analysis. Spotted plates were incubated 72 h at 30°C. The 
Split-Trp is based on the split-protein sensor Trp1p (Tafelmeyer et al., 2004). A C-terminal part 
of Trp1p (CTrp) is fused to bait subunits and an N-terminal part of Trp1p (NTrp) is fused to 
prey. Upon interaction of bait and prey, active Trp1p is reconstituted from both domains, thus 
allowing growth of yeast strain CRY1 (MATa ura3-1 trp1-1 his3-11,15 leu2-3,112 ade2-1 can1-
100 GAL) on medium lacking tryptophan. CRY1 transformation and spotting were similar as 
above. Selective media either lacked uracil and leucine (SD-UL, controls) or additionally 
tryptophan (SD-UWL, protein interaction analysis). Spotted plates were incubated up to 9 days 
at 27°C.  
The Cyto-Y2H was used to screen a human brain cDNA library (preys) for interactors of the N-
terminal domain of AMPK- β1 and - β2 subunits (∆β1, ∆β2 amino acids 1-54 as baits). This 
domain was chosen to avoid interactions with other AMPK subunits, and because it has been 
identified as candidate AMPK interaction domain. About 6.2 × 106 and 3.4 × 106 clones were 
screened. Plasmids containing the cDNA sequence of putative interaction partners were 
extracted and reintroduced together with the corresponding ∆β -encoding bait vector into the 
reporter yeast strain in order to confirm the interaction. Reproducible interactors were 
sequenced and clones containing in-frame coding sequence ot known as false positives 
(Dualsystems, personal communication) were retained. To verify NRDP1/AMPK interactions, 
paired Y2H assays were performed using ∆β1 and ∆β2, full-length β1 and ∆β, as well as α1 and 
α2 subunits as baits and full-length NRDP1 as a prey. Interaction of GST with an unrelated bait, 
Large T antigen (Simian virus) was used as negative control. 
  
Expression and purification of GST-fusion protein 
All the GST fusions protein constructs were transformed into competent E. coli BL21-Codon 
Plus (DE3)-RIL cells (Stratagene, La Jolla, CA, USA) and incubated overnight on LB agar 
containing 100 µg/ml ampicillin and 30 µg/ml chloramphenicol. Cultures were routinely grown 
in standard LB medium containing antibiotics (100 µg/ml ampicillin and 30 µg/ml 
chloramphenicol) at 37°C in Erlenmeyer flasks with constant shaking until O.D. (600nm) 0.7-
  
134 E3 ubiquitin ligase NRDP1 – high level expression of full-length protein and interaction with AMPK 
0.9 (if not indicated otherwise). Cells were then cooled down to 30°C and protein expression 
was induced for 4 hours (if not indicated otherwise) with 2mM isopropyl β-D-
thiogalactopyranoside (IPTG, Eurobio). Cells were centrifuged at 4000 g, 30 min at 4°C, 
harvested and suspended in PBS lysis buffer (phosphate buffer saline: 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). After 3x15s sonication at 85% of manual 
powered, insoluble material was removed by centrifugation (40000 g, 40 min at 4°C). All 
supernatant was applied by gravity flow to a 5 ml Gluthation Sepharose matrix (binding 
capacity up to 1g/ml, Qiagen, Hilden, Germany) self-packed in a column (diameter 1 cm). The 
column was washed with 3x5 column volumes PBS and proteins were eluted with 10 ml of 10 
mM reduced L-glutathione (Sigma-Aldrich) in 50 mM Tris-HCl, pH 8. Ten µl of each elution 
fraction were mixed with Laemli sample buffer, separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE, 12% acrylamide), and stained with Coomassie. Protein 
concentrations were determined according to Bradford (Bradford, 1976) with the Biorad 
microassay (Biorad, Reinach, Switzerland) and BSA as standard. 
 
Protein expression in bioreactor 
GST-NRDP1 fusion protein constructs were transformed into competent E. coli BL21-Codon 
Plus (DE3)-RIL cells (stratagene, La Jolla, CA, USA) and incubated overnight on LB agar 
containing 100 µg/mL ampicillin and 30 µg/mL chloramphenicol. Precultures (30 mL) were 
grown in LB containing antibiotics at 37°C until O.D600. 1. Bacteria were harvested by 
centrifugation and added to second preculture of 300 mL complement M9 medium (6.8 g/L 
Na2HPO4.7H2O, 3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl) containing antibiotics (100 µg/mL 
ampicillin and 30 µg/mL chloramphenicol), and grown overnight at 37°C and constant shaking. 
Cells were centrifuged (4000 g, 30 min at 4°C), resuspended in 20 mL M9 and injected with a 
100 mL-syringe (sterile) into the bioreactor (Minifors, Infors HT) containing 3 L of complement 
M9 medium with antibiotics (100 µg/mL ampicillin and 30 µg/mL chloramphenicol). Bioreactor 
conditions were maintained constant at pH 7.4, 37°C and stirring speed of 500 rpm. Cells were 
grown until O.D600. 8, cooled down to 16°C, and expression was induced by 2 mM IPTG 
(Eurobio, Courtaboeuf, France). Cells were harvested by centrifugation and treated as 
described above. 
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To follow bacteria growth, sample were taking every hour and O.D was measured at 600 nm.  
 
In vitro analysis of AMPK substrate phosphorylation kinetics 
Purified GST-ACC and GST-NRDP1 (200 pmol) were incubated for 5, 10, 20 and 40 min at 37°C 
with 200 µM [γ-32P] ATP (specific activity 6000 Ci/mmol ATP) and AMPK221 (4 pmol) 
previously activated by incubation with 1 pmol CamKKβ for 20 min at 30°C in kinase buffer (50 
µM AMP, 5mM MgCl2, 1mM DTT, in 10 mM HEPES pH 7.4). For negative controls, AMPK 
substrates were incubated with 1 pmol CamKKβ without AMPK. Kinase reactions were 
stopped by addition of Laemli buffer and subjected to SDS-PAGE (12%) with Coomassie 
staining and analysis by Typhoon phosphoimager (GE Healthcare). 
 
In vitro analysis of AMPK substrate phosphorylation stoichiometry 
Different concentrations of purified GST-ACC and GST-NRDP1 (25, 50, 100, 200 pmol) were 
incubated 40 min at 37°C with 200 µM [γ-32P] ATP (specific activity 6000 Ci/mmol ATP) and 
AMPK221 (4 pmol) previously activated by incubation with 1 pmol CamKKβ for 20 min at 30°C 
in kinase buffer. For negative controls, AMPK substrates were incubated with 1 pmol CamKKβ 
without AMPK. Kinase reactions were stopped by addition of Laemli buffer and subjected to 
SDS-PAGE. After Coomassie staining, the bands corresponding to the substrates (around 60 
kDa) were cut and incubated in 5 ml scintillation solution and subjected to measurements in 
a liquid scintillation counter (Packard). 
 
Sample preparation for mass spectrometry analysis  
To find NRDP1 phosphorylation(s) site(s) by AMPK, GST-ACC, GST-NRDP1 (300 pmol) were 
incubated for 1 h at 37°C with 6 pmol of freshly purified AMPK-221 (to avoid the presence of 
glycerol needed for long term AMPK storage) previously activated by incubation with 3 pmol 
CamKKβ for 20 min at 30°C in kinase buffer. As negative controls, GST-ACC and GST-NRDP1 
were incubated with 3 pmol CamKKβ without AMPK. The samples were conserved at 4°C.  
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Mass spectrometry to detect phosphosite(s) 
Samples were dried and solubilized in 20 µL ammonium bicarbonate (50 mM), trypsin-
digested. Part of them were enriched either in Pierce TiO2 Phosphopeptide Enrichment 
(Thermo Scientific) or in Pierce Fe-NTA Phosphopeptide enrichment kit (Thermo Scientific) 
then purified with Graphit Clean-up kit (Thermo Scientific). 30 pmol of each assay were 
injected in LC-MS/MS.  The analyses were proceed by a 4000QTrap mass spectrometer. 
Phosphopeptide identification was realized with ProteinPilot 4 (ABSciex) using Paragon and 
Mascot algorithms.  
 
Cell culture conditions 
Human embryonic kidney (HEK293) cells, were grown in DMEM supplemented with 100 
units/ml penicillin, 100 µg/mL streptomycin, 2 mM glutamine, 10% inactivated fetal bovine 
serum (FBS, GIBCO). Hepitheloid cervix carcinoma (HeLa) cells, were cultured in DMEM/F12 
high glucose medium supplemented with 10% inactivated fetal calf serum (FCS) and 1% 
glutamate/streptomycine/penicillin.  
 
Analysis of in vivo ubiquitination 
HEK293 cells cultured as describe above were transfected with one or several of the following 
plasmids (all gently provided by Pascual Sanz, IBV, Valencia, Spain): pCMV-His6xUbiq 
(encoding a modified ubiquitin, tagged in n-terminal with 6 His residues); pCMVmyc (encoding 
the different AMPK subunits α2, β2, and γ1 all tagged in N-terminal with myc), pcDNA3-HA-
NRDP1 (encoding N-terminally HA-tagged NRDP1), by using the Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacturer’s instructions.  After 36 h of transfection, medium 
was removed and cells were frozen in liquid nitrogen, then scrapped in lysis buffer A (6 M 
guanidinium-HCl, 0.1 M sodium phosphate, and 0.1 M Tris-HCl, pH 8.0). To purify His-tagged 
proteins, 4 mg protein of a clarified extract (CE; centrifuged at 12000 g for 15 min) was 
incubated in 100 µl of TALON resin (Clontech) in the presence of 10 mM imidazole, for 3 h at 
room temperature on a rocking platform. The resin was then successively washed with 2 mL 
each of buffer B (buffer A plus 10 mM imidazole), buffer C (buffer B but with 8 M urea instead 
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of 6 M guanidin-HCL), and four more times with buffer C adjusted to pH 6.0. Bound proteins 
were eluted with 50 µl of 2X Laemli’s sample buffer and analyzed by Western blotting using 
appropriated antibodies. 
 
AMPK or ubiquitin overexpression in cell culture  
HeLa cells were transfected with one or several of the following plasmids (kindly provided by 
Pascual Sanz, IBV, Valencia, Spain): pCMV-myc (encoding the different AMPK subunit α2, β2, 
and γ1), pCMV-His6xUbiq (encoding a modified ubiquitin tagged with 6 His residues), and 
pCMV-His6xUbiqK48R or pCMV-HisxUbiqK63R (encoding mutated ubiquitin variants, were 
Lys48 and Lys63 is replaced by an arginine, by using the Lipofectamine 2000 reagent 
(Invitrogen) according to the manufacturer’s instructions. 24 h after transfection, medium was 
removed and cells were frozen in liquid nitrogen. To extract proteins, HeLa cells were lysed in 
Tris-buffer (10 mM pH7 containing complete with EDTA-free protease inhibitor cocktail tablet 
(Roche), sonicated 3 X 10 s and centrifuged at 12000 g for 15 min at 4°C. 
 
Proteasome inhibition in cell culture 
HeLa cells were cultured as described above. Inhibitor MG132 (Sigma, Saint Louis, MO, USA)  
prepared in DMSO at 4 µM final concentration was added four hours before the medium was 
removed and cells were frozen in liquid nitrogen. Proteins were extracted as described above. 
 
Immunoblotting 
50 µg of total protein from the clarified extracts prepared as described above were analyzed 
by SDS-PAGE (12%) and Western blotting using appropriate antibodies: anti-myc (Sigma-
Aldrich, diluted at 1/2000); anti-HA (Invitrogen, diluted at 1/1000); anti-NRDP1 (Bethyl dilute 
at 1/1000); anti-tubulin (Abcam diluted at 1/1000). All membranes were revealed at room 
temperature with ImageQuant CAS4000 CDD camera (GE Healthcare).  
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Results 
Yeast-two-hybrid screening reveals an interaction between NRDP1 and AMPK   
A Y2H screen using the AMPK- β1 and - β2 N-teminal domains (∆β1, ∆β2 amino acids 1-54) as 
baits and a brain cDNA library as preys identified NRDP1 as a putative AMPK interactor. The 
applied novel cytosolic, split-ubiquitin-based system (Cyto-Y2H, (Möckli et al., 2007)) detects 
protein-protein interactions in a cytosolic environment, with bait and prey anchored to the 
plasma membrane, and uses a very sensitive transcriptional read-out that detects also weak 
or transient interactions. The identified NRDP1 clone contained the C-terminal domain of 
NRDP1, which also associates with receptor tyrosine-protein kinase ErbB3 to trigger its 
degradation (Diamonti et al., 2002; Yen et al., 2006).  
  
 
Figure 2. Cyto-Y2H reveals interaction of NRDP1 with AMPK β-subunits. Representative results of a cyto-Y2H 
assay to analyze interaction of AMPK-∆β subunits with the C-terminal domain of NRDP1 (amino acids 136-316). 
Presence of bait and prey plasmids are verified on selective media (SD-WL). Bait/prey interaction leads to 
reconstitution of ubiquitin and a transcriptional readout allowing growth on medium lacking in addition adenine 
and histidine (SD-AHWL). Spots represent yeast grown for 48h at 30°C. Δβ: N-terminal domain of AMPK β-subunit 
used for Y2H screening. For more details see Material and Methods. 
 
The NRDP1/AMPK interaction was then confirmed by different paired Y2H assays. First, in 
Cyto-Y2H, the identified NRDP1 clone interacted with both ∆β1 and ∆β2 subunits, (Figure 2). 
In another cytosolic Y2H assay, the Split-Trp-Y2H, protein-protein interaction reconstitutes an 
enzyme in tryptophane biosynthesis, allowing a direct readout that is more proportional to 
interaction strength (Figure 3). This assay confirmed interaction of NRDP1 with both truncated 
and full-length β subunits although interaction seemed to be less strong with full-length β1. 
When α-subunits were tested in this Y2H assay, NRDP1 interacted weakly with α2 and more 
strongly with α2TD (a constitutive active α2 mutant), but not with α1.  
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Figure 3. Split-Trp Y2H confirms interaction between NRDP1 and AMPK β subunits but also α2 subunit.  
Representative results of a Split-Trp-Y2H assay to analyze interaction of AMPK subunits with full-length NRDP1. 
Bait/prey interaction leads to reconstitution Trp1P essential for tryptophan synthesis, thus allowing growth on 
medium lacking tryptophan (SD-UWL). Spots represent yeast grown for 9 days at 27°C. α1, α2, β1, β2: AMPK 
subunits; α2TD: constitutive α subunit; Δβ: N-terminal domain of AMPK β-subunit used for Y2H screening. For 
more details see Material and Methods. 
 
Production of NRDP1 full-length protein 
Since our goal was to proceed with in vitro characterization of the NRDP1/AMPK interaction 
without prior knowledge of the involved domain(s), our primary aim was to produce 
recombinant full-length NRDP1. Previous publications have shown the difficulties to produce 
full-length NRDP1 (Wu et al., 2004), although it is a cytosolic and thus an a priori soluble 
protein. So far, only a C-terminally truncated version (amino acids 134 to 317) could be 
produced at low quantities (Qiu and Goldberg, 2002). We thus generated a NRDP1 construct 
carrying a GST-tag at the N-terminus for bacterial expression.   
 
Bacterial expression in shaking flask cultures  
First, a standard protocol for production of GST-tagged protein was applied, where bacteria 
were grown at 37°C until O.D600. 1 before expression was induced by IPTG (2 mM) for 4 h at 
30°C. Under these conditions, a predominant band at the size of full-length GST-NRDP1 
(around 60 kDa) appeared in E. coli lysates, reaching a maximum after about 3 hours (Figure 
4). Further bands between 25 and 50 kDa also increased during induction, possibly as a 
consequence of proteolytic degradation or incomplete translation.  
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Figure 4. Effect of expression time on 
quantity and quality of expressed 
NRDP1 (expression at 30°C). 
Expression profile of NRDP1 at 30°C 
after induction by IPTG (2 mM). 
Coomassie staining of a SDS-PAGE gel. 
Culture of BL21 bacteria transformed 
with pABGSTn-NRDP1 was done in 400 
ml LB. At O.D. 1, expression was 
induced with IPTG for 4 hours at 30°C. 
20 µL aliquots were taken at different 
expression time (0-4 h). M: molecular 
mass markers.  
  
However, when soluble protein of these expressions was subjected to affinity purification, full-
length GST-NRDP1 around 60 kDa occurred only as minor band as compared to the lower 
molecular mass bands (Figure 5), in particular the 23 kDa band that corresponds to the size of 
the GST-tag domain. A commercial protease inhibitor mix in the lysis buffer did not improve 
this result and was therefore not added in further experiments. The yield of these purifications 
reached only 0.12 mg/L, a too low value considering the small fraction of full-length protein 
in this preparation. Further analysis of lysate preparation revealed that it is not the sonication 
procedure itself that degrades NRDP1, but the presence of mainly insoluble full-length NRDP1 
that remains in the pellet after sonication (Figure 6). Thus, recombinant full-length NRDP1 
tends to form insoluble inclusion bodies in E. coli.  
 
 
 
 
Figure 5. Quantity and quality of purified 
NRDP1 (expression at 30°C). Elution 
profile of the NRDP1 peak from a 
glutathione sepharose column. 
Coomassie staining of a SDS-PAGE gel. 
Induction of expression at O.D. 1 for 4 
hours at 30°C. Bacterial lyses buffer: PBS 
pH.7.4 complemented with 20% glycerol 
and 1% Triton X-100. 2, 3, 4, 5, 6, 7, 8: 
NRDP1 peak elution fractions; NRDP1: 
full-length NRDP1; *: main band, possibly 
corresponding to a NRDP1 degradation 
product.     
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Figure 6. Full-length NRDP1 in 
soluble and insoluble fractions 
(expression at 30°C). Coomassie 
staining of a SDS-PAGE gel. 
Induction of expression at O.D. 1 
for 4 hours at 30°C. The bacteria 
were lysed in PBS pH 7.4, 20% 
glycerol and 1% Triton X-100, 
sonicated 7x10 s and centrifuged 
40 min at 25000 g.  NRDP1: full-
length NRDP1. 
 
 
Inclusion bodies are the consequence of incorrect or insufficient protein folding. We therefore 
modified the expression protocol by (i) repeating 4 times the sonication-centrifugation step, 
(ii) inducing expression at different O.D., and (iii) using growth at only 25°C to slow down the 
bacterial metabolism Repeated sonication rather solubilized preferentially the contaminating 
lower Mr bands in expressions induced at O.D. 0.8 and grown at 25°C and was not retained 
(Figure 7). 
Then, expression was induced at 25°C at different moments during growth: late lag phase 
(O.D. 0.5), exponential phase (O.D. 0.8) and early stationary phase (O.D. 1.5). The soluble 
fractions were directly applied to a glutathione Sepharose column to compare purity (Figure 
8) and protein yield. All these expressions increased protein yield by about 3-fold as compared 
to expressions at 30°C. In addition, expressions induced at O.D. 0.8 and 1.5 each increased 
protein yield by another 10% each, and these two preparations also contained a higher 
fraction of full-length NRDP1 as compared to early induction (O.D. 0.5) (Figure 8). Thus, late 
expression appears to be preferable for maximal quantity and quality of full-length NRDP1. 
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Figure 7. Full-length NRDP1 in soluble 
and unsoluble fractions (expression at 
25°C). Coomassie staining of a SDS-PAGE 
gel. Induction of expression at O.D. 0.8 
for 4h at 25°C. Protein extraction by 
consecutive sonication-centrifugation 
steps. Supernatants (supernatant 1 to 4) 
as well as resuspension of corresponding 
pellets in lysis buffer (pellet 2, 3 and 4) 
are shown. M: molecular mass markers; 
NRDP1: full-length NRDP1. 
 
 
 
 
 
Table 1. Effect of temperature and induction time point on the yield of purified NRDP1  
O.D. 1.0 0.5 0.8 1.5 4.3 
Temperature 30°C 25°C 25°C 25°C 10°C 
Expression  4h 4h 4h 4h 16h 
Yield (mg protein/L) 0.12 0.30 0.35 0.39 0.71  
 
 
 
 
Figure 8. Effect of induction time 
point on quality of purified NRDP1 
(expression at 25°C).  NRDP1 elution 
profiles from a glutathione Sepharose 
column using E. coli lysates from 
different induction growth phases. 
Coomassie staining of a SDS-PAGE 
gel. The expression was induced at 
O.D. 0.5, 0.8 or 1.5 at 25°C for 4 h. The 
fractions collected after purification 
represent the NRDP1 elution peaks. 
NRDP1: full-length NRDP1. 
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Since lower temperature seemed to be the major factor driving production of soluble full-
length NRDP1, bacteria were grown at 10°C and expression time was concomitantly increased 
to reach stationary phase as optimized above (Figure 8). 
 
 
 
 
Figure 9. Effect of low-temparture 
expression at 10°C on quality of 
purified NRDP1. Elution profile of a 
glutathione Sepharose column. 
Coomassie staining of a SDS-PAGE gel. 
Expression was inducted at O.D. 4.3 at 
10°C for 16 h. 1 to 8: fractions 
representing the NRDP1 elution peak; 
NRDP1: full-length NRDP1. 
 
 
Under these conditions, protein yield doubled to 0.71 mg/L as compared to expressions at 
25°C (table 1). Also purity seemed to improve slightly, although there still remained 
contaminating bands (Figure 9). Thus, late induction combined with very slow expression at 
10°C clearly increased production of soluble full-length NRDP1.  
 
Bacterial expression of NRDP1 in a bioreactor 
A bioreactor allows control of bacterial growth conditions by regulation of nutriment, pO2, pH 
and temperature of the medium. Such controlled conditions require however the use of a 
minimal medium which prolongs the lag phase as compared to complete LB medium. 
With NRDP1-transfected bacteria, a 2 L-bioreactor allowed to reach O.D. 27 (Figure 10) instead 
of O.D. 4 in batch culture.   
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Figure 11. Effect of bioreactor 
expression on quality of purified 
NRDP1. Elution profile of a 
glutathione Sepharose column 
following production in 
bioreactor. Coomassie staining of 
a SDS-PAGE gel. Expression was 
inducted at O.D. 8 at 16°C for 12 
h. 1 to 7: fractions representing 
the NRDP1 elution peak; pellet: 
insoluble protein after first 
sonication step, flow through: 
protein not binding to the 
column.  
  
 
According to the data obtained in batch culture, expression was induced at the rather high 
O.D. of 8, corresponding to early exponential growth phase, and continued for 12 h at the low 
temperature of 16°C. Full length NRDP1 was mostly soluble and appeared in the pellet only at 
low levels (Figure 11). The yield was 3.1 mg/L, meaning that a single run of the bioreactor 
followed by a single purification step yielded 6.2 mg of protein  
 
 
Figure 10. Typical bacterial growth curve in the bioreactor. Samples were taken every hour and O.D. was measured 
at 600 nm.  
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14
O
.D
. [
6
0
0
 n
m
]
Time [h]
  
145 E3 ubiquitin ligase NRDP1 – high level expression of full-length protein and interaction with AMPK 
NRDP1 is directly phosphorylated by AMPK 221 
With recombinant protein we first tested whether NRDP1 could be directly phosphorylated 
by AMPK. An in vitro phosphorylation assay revealed that NRDP1 can be directly 
phosphorylated by AMPK 221 in a time-dependent manner, although at low levels (Figure 12). 
Incorporation of 32P into NRDP1 calculated by phosphoimager and scintillation counter 
reached about 30-40% of what was seen with the AMPK reference substrate acetyl-CoA 
carboxylase (ACC). Also the time course of NRDP1 phosphorylation was much slower than with 
ACC, reaching maximal activation only after 20 minutes (as compared to <5 min with ACC).  
 
 
 
Figure 12. NRDP1 is a direct AMPK 
substrate in vitro. (A) Time course of 
NRDP1 phosphorylation by AMPK. AMPK 
221WT (4 pmol) first activated by CamKKβ 
(1 pmol) was incubated with purified 
NRDP1 (200 pmol) or ACC (positive 
control, 200 pmol) for 5 to 40 min at 37°C. 
In vitro phosphorylation was analyzed by 
SDS-PAGE and Typhoon phosphoimager. 
(B) Quantification of the phosphorylation 
time course using ImageJ. Data are 
normalized to maximal ACC 
phosphorylation. (C)  Incorporation of 32P 
into ACC and NRDP1 by AMPK. Assay as 
above, but using varying amounts of 
purified NRDP1 or ACC (50-200 pmol) and 
analyzing bands in SDS-PAGE by 
scintillation counting. Lines and values of 
a linear regression fit is indicated. 
 
      
 
In silico analysis of the NRDP1 sequence identified Ser77 as a putative AMPK phosphorylation 
consensus sequence. However, mass spectrometry of in vitro phosphorylated NRDP1 did not 
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yield conclusive data. Thus, the significance of the observed phosphorylation remains to be 
shown. 
 
AMPK is not ubiquinated by NRDP1 
We therefore tested whether the NRDP1/AMPK complex could serve NRDP1 to ubiquitinate 
AMPK. We compared the effect of overexpression of two E3 ubiquitin ligases, NRDP1 and 
MDM2, on AMPK 221 ubiquitination in HEK293 cells. MDM2 served as a negative control for 
unspecific ubiquitination induced by ubiquitin and ubiquitin ligase overexpression. 
Experiments with both E3 ubiquitin ligases revealed AMPK γ1 as a highly ubiquitinated subunit, 
while AMPK α2 was ubiquitinated only at a low level and AMPK β2 seemed not to be 
ubiquitinated under these conditions (Figure 13). Ubiquitination by NRDP1 was however 
identical or even lower as with MDM2 control, indicating that NRDP1 is not a specific ubiquitin 
ligase of AMPK subunits in HEK293 cells. The AMPK/NRDP1 interaction would thus have no 
function in AMPK ubiquitination.   
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Figure 13. AMPK is not ubiquitinated by NRDP1. In 
vivo ubiquitination assay using overexpression of 
proteins (+) in HEK293 cells and corresponding control 
experiments for construct expression. (A) Pull-down 
for His-tagged ubiquitin with Ni-NTA resin analyzed by 
Western blot for AMPK subunits with anti-Myc Ab. (B) 
Overexpression of AMPK subunits (α2, β2, γ1) analyzed 
by Western blot with anti-Myc Ab. (C) Overexpression 
of E3 ubiquitin ligase (NRDP1 and MDM2) analyzed by 
Western blot with anti-HA and anti-MDM2 Ab. 
 
B
 
 C
 
 
HA-NRDP1 
HA-NRDP1 HA-NRDP1 
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NRDP1 proteasome targeting inactive ubiquitination of both lysine 48 and 63 
Independent of NRDP1/AMPK complexes, NRDP1 is rapidly auto-ubiquitinated for 
proteasomal degradation, but it is unknown how this occurs. We therefore applied a similar 
ubiquitination assay but using ubiquitin constructs mutated at specific lysine residues to 
address this question (Figure 14). Overexpression of ubiquitin wild-type in HeLa cells induced 
degradation of full-length NRDP1 via the proteasome since this decrease could be rescued by 
the proteasome inhibitor MG132. In case of overexpressed ubiquitin mutants K48R and K63R, 
unable to link ubiquitin moieties to Lys48 or Lys63, respectively, partial degradation in absence 
of MG132 still occurred. This result suggests that both lysine residues are involved to target 
NRDP1 to the proteasome.  
  
 
Figure 14. Ubiquitination NRDP1 topology for it proteasome degradation. Representative Western blot for 
NRDP1 levels in HeLa cells overexpressing wild-type or mutant (K48R, K63R) ubiquitin in absence or presence of 
protease inhibitor MG132. One representative out of four experiments is show. 
 
 
AMPK decreases NRDP1 levels 
We finally tested whether the high NRDP1 turnover due to auto-ubiquitination is modulated 
by AMPK (Figure 15). Two genuine NRDP1 bands can be detected in HeLa cells with NRDP1-
specific antibody (https://www.bethyl.com): a full-length NRDP1 at 36 kDa and a short form 
of NRDP1 (sNRDP1) at around 30 kDa. Overexpression of individual AMPK subunits (α,β or γ) 
had no significant impact on the levels of the two NRDP1 forms. However, co-expression of all 
three subunits supposed to form heterotrimeric complex decreased full-length NRDP1 levels 
by about 30%. 
 
NRDP1 
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B 
 
Figure 15. Overexpressions of AMPK221 decreases NRDP1 levels. (A) Representative Western blot of NRDP1 
levels (bottom) under conditions of AMPK subunit overexpression (top) in HeLa cells for 24 h, Anti-myc Ab is used 
to verify overexpression of myc-tagged AMPK subunits α2, β2 and γ1 . NRDP1, full-length NRDP1; sNRDP1, lower 
Mr NRDP1. (B) Western blot quantification of full-length NRDP1 from four independent experiments by Image J, 
normalized to the level of tubulin.*p<0.05 versus ctl; n=4. 
 
 When expressing increasing levels of AMPK heterotrimer, levels of full-length NRDP1 
decreased, while sNRDP1 rather increased (Figure 16). These data suggest that sNRDP1 results 
from NRDP1 degradation and that AMPK/NRDP1 interaction plays a role in regulating cellular 
NRDP1 levels. 
To further test this hypothesis, we applied the proteasome inhibitor MG132 which reduces 
degradation of ubiquitin-conjugated proteins.     
In presence of MG132, as expected, NRDP1 levels increased in both controls and AMPK221 
overexpressing HeLa cells (Figure 17). Importantly, the decrease of NRDP1 by AMPK221 
overexpression is rescued by MG132 to levels comparable to control, suggesting that an 
AMPK-induced NRDP1 degradation via the proteasome pathway is operating here.  
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A 
 
Figure 16. Full-length NRDP1 levels are inversely 
correlated with AMPK levels. (A) Representative 
Western blot of AMPK221 and NDRP1 levels in HeLa 
cells transfected with different amounts of AMPK 
vector. Anti-myc Ab is used to verify overexpression 
of myc-tagged AMPK subunits α2, β2 and γ1 NRDP1, 
full-length NRDP1; sNRDP1, lower Mr NRDP1. (B) 
Western blot quantification of full-length NRDP1. (C) 
Western blot quantification of sNRDP1 Data in (B) 
and (C) were obtained by ImageJ, normalized to 
tubulin and AMPK control (0 µg AMPK plasmid). 
*/°p<0.05 versus 0 µg and 1 µg, respectively; n=4. 
B                         NRDP1 expression 
 
 
C                        sNRDP1 expression 
 
 
 
 
 
 
 
Figure 17. Induction of NRDP1 degradation by AMPK via proteasome. Representative Western blot of full-
length NRDP1 in HeLa cells overexpressing AMPK221, Cells were treated for 4h with MG132 (4µM) before lysis 
and analysis of NRDP1 levels by Western blot. One representative out of four experiments is show. 
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AMPK activity is not required for NRDP1 degradation 
AMPK-induced NRDP1 degradation could involve the above described NRDP1 
phosphorylation. We therefore overexpressed AMPK221 wild type (wt) or dominant negative 
AMPK221 mutant (T172A, an α2 subunit that cannot be activated). Both AMPKs (wt and 
T172A) caused a similar, significant degradation of NRDP1 (Figure 18). Thus, the kinase activity 
of AMPK is not required for NRDP1 degradation. 
 
 
 
 
Figure 18. Kinase activity of AMPK is not required for NRDP1 degradation. (A) Representative Western blot of 
NRDP1 levels (bottom) under conditions of overexpressing AMPKwt or dominant negative AMPK mutant (top) in 
HeLa cells for 24 h, Anti-myc Ab is used to verify overexpression of myc-tagged AMPK. (B) Western blot 
quantification of full-length NRDP1 by Image J, normalized to the level of tubulin.  *p<0.05 versus ctl; n=4   
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Discussion 
NRDP1 is an E3 ubiquitin ligase for which information is still scarce. Here we provide a bacterial 
expression protocol that yields as much as 3.1 mg/L full-length NRDP1 for in vitro studies. 
Further, we present evidence for a direct interaction of NRDP1 with the energy sensor and 
regulator AMPK.  This interaction involves the C-terminal domain of NRDP1 (amino acids 136 
to 317) and the N-terminal tail of AMPK β-subunits (amino acids 1 to 54). Complex formation 
increases NRDP1 turnover, independent of low-level phosphorylation by AMPK, but vice versa 
does not induce specific ubiquitination of AMPK by NRDP1. 
In the first part of this study, we describe highly efficient conditions for bacterial expression 
and purification of full-length NRDP1. So far, bacterial production of this protein was 
hampered by predominant formation of insoluble protein in bacterial inclusion bodies (Wu et 
al., 2004). Only a C-terminally truncated version (amino acids 135 to 317 aa) could be prepared 
at a satisfying yield (Qiu and Goldberg, 2002). In E.coli, host protein misfolding is not 
uncommon. It may result from premature termination of translation, failure of a newly 
synthesized chain to reach a correct conformation or loss of structural integrity triggered by 
environmental stress (Baneyx and Mujacic, 2004). Attempts to correlate the probability of 
inclusion body formation with particular properties of the recombinant protein, the 
expression system, or the host cell have for the most part been unsuccessful (Schein, 1990). It 
seems that overproduction by itself is sufficient to induce formation of inclusion bodies of 
cytosolic proteins (Gribskov and Burgess, 1983). Based on this finding a kinetic model was 
proposed that shows that the yield of native protein depends only on the rate of folding, the 
rate of aggregation, and the rate of protein synthesis (Kiefhaber et al., 1991). This model 
implies that the yield of native protein increases with a decreasing rate of protein expression. 
Thus, reducing growth rate by slowing down metabolism increases yield of native, soluble 
protein (Cabilly, 1989; Kopetzki et al., 1989; Schein, 1990). In our batch culture experiments, 
a decreased in expression temperature from 30°C to 10°C had the most pronounced effect, 
leading to a 6-fold higher yield of soluble full-length NRDP1. Induction at a later growth phase 
also slightly increased yield, but mainly had a positive effect by reducing co-purifying low 
molecular mass contaminants. This may be also due to more growth-limiting conditions 
(nutrient deprivation, acidification etc.). Up-scaling batch cultures to a bioreactor further 
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increased yield by at least 4-fold. Apparently, controlled bioreactor conditions provide all the 
benefits of slowing down metabolism by growth at 16°C, while avoiding potential 
disadvantages of batch cultures by keeping all growth conditions constant. Efficiency and 
reproducibility of a bioreactor culture thus allows maximum yield for a given volume of 
medium, particularly important in case of an expensive additions (e.g. carbon-14 labeled 
medium).  
In the second part of the study, we concentrated on the interaction of NRDP1 with AMPK that 
we have detected and confirmed by Y2H analysis. In an attempt to identify a functional role 
of this interaction, we primarily analyzed phosphorylation and ubiquitination events. Although 
NRDP1 can be phosphorylated by AMPK in vitro, it appeared to be a poorer substrate as 
compared to the AMPK reference substrate ACC, seen by both kinetic and stoichiometric 
measurements. Mass spectrometry (MS) did neither reveal any phosphorylated residue. The 
in vivo significance of NDRP1 phosphorylation remains to be clarified. 
Vice versa, in HEK293 cells, AMPK was not specifically ubiquinated by NRDP1, although it is 
known that AMPK can be ubiquitinated in vivo (Zungu et al., 2011) and some involved E3 
ubiquitin ligase have been identified (e.g. WWP1 and malin) (Lee et al., 2013; Moreno et al., 
2010). However, NRDP1 is also heavily autoubiquitinated, resulting in proteasomal 
degradation and concomitant high turnover rate (Wu et al., 2004) which are the key regulators 
of cellular activity of this protein. Our data with HeLa cells suggest that NRDP1/AMPK 
interaction accelerates proteasomal NRDP1 degradation. First, In vivo AMPK overexpression 
reduces levels of full-length NRDP1 while increasing levels of a shorter NRDP1 species, 
probably a first product of NRDP1 degradation. Second, such reduced NRDP1 levels do not 
occur when proteasomal protein degradation is inhibited. AMPK-dependent proteasomol 
NRDP1 degradation does not involve putative NRDP1 phosphorylation, since it occurs also 
with inactive AMPK. A similar regulation has been reported for other E3 ubiquitin ligases. 
Auto-ubiquitination and proteasomal degradation of certain inhibitor of apoptosis (IAP) is 
stimulated by interaction with SMAC/DIABLO (Dueber et al., 2011; Varfolomeev et al., 2007).  
The role of AMPK in NRDP1 autoubiquitination may involve activating conformational 
changes, a NRDP1 scaffolding function (bringing different NRDP1 proteins close to each other), 
or disrupting interaction of NRDP1 with ubiquitin carboxyl-terminal hydrolase 8 (USP8), a 
major stabilizing NRDP1 protein (Avvakumov et al., 2006). 
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 One consequence of AMPK-dependent NRDP1 degradation would be increased levels of 
known NRDP1 substrates like ErbB3. ErbB3 is the first effector of the ErbB3-PI3K-Akt-TSC2-
mTOR cascade, whose activation leads to cell survival, proliferation and differentiation, but 
also higher susceptibility for certain types of cancer (Gwinn et al., 2008; Inoki et al., 2003). 
Thus, formation of AMPK/NRDP1 complexes would activate ErbB3 signaling and proliferation 
which could be in contradiction with the well-described AMPK tumor suppressor effect, but 
since few years it clearly appear that AMPK also play a role in helping tumor cell survival 
(Banko et al., 2011; Frigo et al., 2011; Laderoute et al., 2006).       
This work establishes a link between AMPK and NRDP1. However, more research is needed to 
fully clarify its functional significance. 
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associated 
proteins VAMP2 
and VAMP3 – a 
role in exocytosis? 
 
Abstract. AMP-activated protein kinase (AMPK) and 
the vesicle-associated membrane proteins VAMP2 
and VAMP3 are involved in exocytotic translocation 
of e.g. nutrient transporters GLUT4 and CD36 to the 
cell surface to increase glucose and fatty acid uptake, 
respectively. The exact molecular mechanism is still 
unclear. We found that VAMP2 and VAMP3 both 
interact with AMPK by using yeast two hybrid (Y2H) 
approaches, co-immunoprecipitation, pull-down and 
surface plasmon resonance (SPR). VAMP does not 
serve as AMPK substrate, but could be a scaffold for 
AMPK to recruit it to exocytotic vesicles. In support 
of this, we show direct AMPK/VAMP interaction of 
medium affinity as typical for reversible interactions, 
and the presence of putative AMPK substrates in 
exocytotic vesicles. The mapped AMPK and VAMP3 
interaction domains enabled the generation of an 
inhibitory construct. This construct is able to 
decrease AMPK-VAMP interaction in vitro and will be 
suitable for in vivo applications, in particular to study 
effects on the translocation of GLUT4 and CD36. 
 
Résumé. La protéine kinase activée par l’AMP 
(AMPK) ainsi que les protéines membranaires 
associées aux vésicules VAMP2 et VAMP3 sont 
impliquées dans l’exocytose et la translocation des 
transporteurs de nutriments à la surface cellulaire, 
tels GLUT4 et CD36 qui permettent respectivement 
l’entrée de glucose et d’acides gras dans la cellule. Le 
mécanisme moléculaire reste pour le moment 
indéfini. Par un système de double hybride en 
levures nous avons découvert que VAMP2 et VAMP3 
interagissent avec l’AMPK, résultats confirmés 
également  par co-immunoprécipitation, pull-down 
et résonance plasmon de surface. VAMP n’est pas un 
substrat de l’AMPK, mais pourrait être une protéine 
de recrutement (scaffold) d’AMPK vers les vésicules 
exocytotiques. Allant dans ce sens, nous avons 
montré qu’AMPK et VAMP interagissent de façon 
directe avec une affinité moyenne, typique des 
interactions réversibles. Nous avons aussi montré la 
présence de substrats putatifs de l’AMPK dans des 
vésicules exocytotiques. La détermination du 
domaine d’interaction entre AMPK et VAMP3 a 
permis la production d’une construction inhibant 
leur interaction. Cette construction est capable de 
diminuer l’interaction AMPK-VAMP in vitro et 
adaptée pour des expériences in vivo, en particulier 
pour étudier son effet sur la translocation de GLUT4 
et CD36. 
 
I was involved in all experiments following the yeast-two hybrid and VAMP phosphorylation assays data 
analysis and manuscript writing.  
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Introduction  
Vesicular transport mediates a continuous exchange of components between membrane 
enclosed distinct compartments. Since cells segregate proteins into separate membrane 
domains by assembling a special protein coat (which is a cage of protein covering the cytosolic 
face, (Kirchhausen, 2000)), a transport mechanism is necessary that extracts specific 
components from a compartment for delivery to another one. Transport vesicles will dock to 
the target membrane and fuse with it to deliver their cargo (Bonifacino and Glick, 2004). These 
vesicles are classified according to their origin and type of cargo (Rothman and Wieland, 1996). 
Vesicle-stored cargo could be a chemical element as neurotransmitter (synaptic vesicle), 
hormone (endocrine tissue), but also receptors or transporters present at the vesicular 
membrane which will incorporate into the target membrane during membrane fusion.   
To ensure an orderly flow of vesicular traffic, transport vesicles must be highly selective in 
recognizing the correct target membrane to fuse with. A vesicle is likely to encounter many 
potential target membranes because of the large diversity of membrane systems. To select 
the correct one, all transport vesicles display surface markers ensuring targeting specificity 
(Pfeffer, 1999). Target membranes display the complementary receptors that recognize the 
appropriate vesicle markers. However the precise mechanism for the specificity of this crucial 
process is still not entirely clear; it depends on two major types of proteins: Rab proteins that 
direct the vesicle towards the correct target membrane for a preliminary docking (Grosshans 
et al., 2006), and the soluble NSF attachment receptor (SNARE) proteins that catalyze the 
fusion of the lipid bilayers (Jahn and Scheller, 2006), (Figure 1).  
Rab proteins are the largest subfamily of monomeric GTPases with over 60 known members 
(Grosshans et al., 2006). Each Rab protein is associated with one or more membrane enclosed 
organelles, and each one of these organelles has at least one Rab protein on its cytosolic 
surface. Thus Rab proteins are ideal molecular markers for identifying membrane types and 
guiding vesicular traffic between them. Finally, Rab proteins bind to proteins called Rab 
effectors, which facilitate vesicle transport, membrane tethering, and fusion (Mizuno-
Yamasaki et al., 2012; Pfeffer, 2012).  
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SNARE proteins are transmembrane protein that catalyze the membrane fusion reactions in 
vesicular transport (Jahn and Scheller, 2006). Once a transport vesicle has been tethered to 
its target membrane, complementary sets of v-SNAREs and t-SNAREs, respectively found on 
vesicle membrane and target membranes (McNew et al., 2000), will be able to form 
complexes (Sutton et al., 1998). The resulting SNARE complexes lock the two membranes 
together and mediate membrane fusion by bringing the lipid bilayers of two membranes close 
enough so that they can join (Fasshauer, 2003). SNAREs also provide an additional layer of 
specificity, helping to ensure that only correctly targeted vesicles fuse (Scales et al., 2000).  
 
 
Figure 1. Process preceding membrane fusion. Tethering: Rab effector proteins tether a vesicle via interaction 
with active Rab protein (Rab-GTP) located on the vesicle membrane. Docking: the v-SNARE and t-SNARE assemble 
into a four-helix bundle forming a trans-SNARE complex. Fusion: Formation of multiple trans-SNARE complexes 
between vesicle and target membrane catalyzes the fusion of the two apposed lipid bilayers. 
   
Fusion does not always immediately follow v-SNARE- t-SNAREs pairing. In fact, to allow for 
additional regulation, fusion is delayed until e.g. secretion of cargo is triggered by a specific 
intra- or extracellular signal (Varlamov et al., 2004). These will cause the release of inhibitory 
proteins that prevent the complete zipping-up of the SNARE complexes. Rab proteins and Rab-
effectors are involved in the release of such SNARE inhibitory proteins (Pfeffer, 1999). 
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The vesicle-associated membrane proteins VAMP2 (or synaptobrevin) and its closest homolog 
VAMP3 (or cellubrevin) are two major members of the v-SNARE family. They are both involved 
in many exocytotic processes as e.g. neurotransmitter release from synaptic vesicles in neuron 
synapses (Mochida, 2000; Procino et al., 2008; Sai et al., 2013), or cell surface expression of 
nutrient transporters such as glucose transporter GLUT4 and long chain fatty acid (LCFA) 
transporter CD36. The latter occurs by translocation of storage vesicles from intracellular 
stores to the plasma membrane, followed by membrane fusion that inserts the transporters 
into the cell membrane (Holman and Cushman, 1994; Karylowski et al., 2004; Martin et al., 
1998; Schwenk et al., 2010). This is the rate-limiting step for cellular uptake of glucose and 
fatty acids, the predominant substrates for cellular energy conversion into ATP. Fusion of 
GLUT4 storage vesicles (GSVs) with the plasma membrane to trigger glucose uptake can occur 
insulin-dependent, e.g. under hyperglycemic conditions (Lizunov et al., 2005) in different 
peripheral organs, or insulin-independent, e.g. after physical exercise in muscle (Hayashi et 
al., 1997).   
The AMP-activated protein kinase (AMPK) is a key sensor and regulator of cellular energy 
homeostasis (Hardie and Carling, 1997). AMPK is activated to maintain cellular ATP level, 
increasing ATP-producing pathways while decreasing ATP-consuming pathways (Carling, 
2005; Hardie et al., 2006). Thus it is strongly implicated in transformation of the two major 
cellular sources of free energy, carbohydrates and fatty acids. Among many others, it regulates 
the cellular uptake of these nutriments. AMPK is implicated in exercise-induced GLUT4 and 
CD36 translocation to the plasma membrane (Kurth-Kraczek et al., 1999; Luiken et al., 2003; 
Webster et al., 2010). However the exact mechanism of how AMPK regulates GLUT4/CD36 
translocation is not entirely clear. 
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Figure 2. Regulation of glucose uptake by AMP-activated protein kinase (AMPK). Exercise activates AMPK by a 
multiple pathways. Activated AMPK causes direct or indirect phosphorylation of the Akt substrate AS160 
(Geraghty et al., 2007; Treebak et al., 2006). AS160 interacts with IRAP (insulin-regulated aminopeptidase) (Park 
et al., 2012; Peck et al., 2006), a marker of Glut4 storage vesicles (GSV), which interacts itself directly with glucose 
transporter 4 (GLUT4) (Martin et al., 1997; Ross et al., 1996). Phosphorylation of AS160 triggers translocation of 
GSV to the plasma membrane, leading to incorporation of GLUT4 into the latter and increased glucose uptake.  
 
Both insulin-dependent and -independent pathways of GLUT4 translocation seem to involve 
Akt substrate of 160 kDa (AS160) (Cartee and Wojtaszewski, 2007; Sakamoto and Holman, 
2008; Zaid et al., 2008). This downstream effector protein is anchored to the GSV via cargo 
proteins like insulin-regulated amino peptidase (IRAP) (Larance et al., 2005), (Figure 2). AS160 
is a Rab GTPase-activating protein (RabGAP) that keeps the corresponding Rab in an inactive, 
GDP bound state (Mîinea et al., 2005). In response to insulin, AS160 is phosphorylated at 
Thr642 and other sites by protein kinase B/Akt (Baus et al., 2008; Kane et al., 2002). This leads 
to binding of AS160 to inhibitory 14-3-3 protein that relieves AS160 inhibition of Rab, thus 
triggering Rab-mediated GSV translocation and docking to the plasma membrane, where 
VAMP proteins initiate membrane fusion process (Sano et al., 2003). VAMP2 was identified in 
GSV membranes already in 1992 (Cain et al., 1992), later also VAMP3 and VAMP5 were 
implicated in translocation of GLUT4 and CD36 (Schwenk et al., 2010). The exocytotic process 
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thus finally leads to cell surface localization of GLUT4, CD36, IRAP and other cargo membrane 
proteins (Martin et al., 1997; Ross et al., 1996). More recently, AS160 was found 
phosphorylated by several protein kinases other than Akt. It has been suggested as a 
downstream effector of AMPK in response to exercise/contractile activity. The 
pharmacological AMPK-activator AICAR increases AS160 phosphorylation and contraction-
mediated AS160 phosphorylation is impaired in α2-AMPK knock-out (KO) and knock-down 
mice (Treebak et al., 2006). During post-exercise recovery in vivo, increased muscle AMPKα2 
activity correlates with AS160 phosphorylation state and muscle glucose uptake (Dreyer et al., 
2008). Consistent with this, AS160 has been shown to be phosphorylated by AMPK in vitro at 
Ser570 and Ser588 (Geraghty et al., 2007). Even though less is known for CD36 trafficking, 
there seems to be much similarity to GLUT4, suggesting a very similar mechanism (Schwenk 
et al., 2010). 
In the present study, we describe an interaction between AMPK and VAMP2 and -3 that we 
originally discovered in a yeast-two-hybrid (Y2H) screen for interacting proteins of the AMPK 
β-subunit and that we confirmed by co-immunoprecipitation, pull-down and surface plasmon 
resonance (SPR) with full-length AMPK complexes. We show that interaction does not involve 
VAMP phosphorylation by AMPK, but that VAMP may rather serve as a scaffold to recruit 
AMPK to exocytotic vesicles e.g. involved in cell surface expression of nutrient transporters 
like CD36 or GLUT4. In support of this, we show direct AMPK/VAMP interaction of medium 
affinity as typical for reversible interactions, and the presence of putative AMPK substrates in 
exocytotic vesicles. Finally, we map the involved interaction domains and present data on an 
inhibitory construct that is able to decrease AMPK-VAMP interaction in vitro.    
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Materials & Methods 
Yeast-two-hybrid assay: Cyto-Y2H  
Cytosolic yeast-two-hybrid (Y2H) systems based on reconstitution of split proteins have been 
used for protein interaction screening. The cytoY2H (Möckli et al., 2007) (Dualsystems Biotech, 
Schlieren, Switzerland) is based on the split ubiquitin system (Johnsson and Varshavsky, 1994; 
Stagljar et al., 1998). The membrane-anchored bait is fused to a reporter cassette composed 
of the C-terminal half of ubiquitin half and the artificial transcription factor LexA-VP16 
whereas the prey is fused to the N-terminal half of ubiquitin. Bait/prey interaction leads to 
ubiquitin reconstitution and cleavage by ubiquitin-specific protease that liberate the 
transcription factor thus leading to a classical transcriptional read-out. While the original 
system used an ER-membrane anchor (Ost4P) for the bait, we applied here a version that uses 
a plasma membrane anchor (Aβ-domain). Cloning procedures using Sfi1 sites, transformation 
of yeast cell line NMY51 (MATa his3delta200 trp1-901 leu2-3,112 ade2 lys2: (lexAop)4-HIS3 
ura3: (lexAop)8-ADE2 GAL4) with the lithium acetate method (Gietz and Woods, 2006) and 
yeast spotting were performed as described earlier (Möckli et al., 2007). Different dilutions (1, 
1/10, 1/100, 1/1000) of overnight yeast cultures were spotted on selective medium lacking 
tryptophan and leucine (SD-WL) for growth verification and on medium lacking tryptophan, 
leucine, adenine, and histidine (SD-AHWL) for protein interaction analysis. In some cases up 
to 5 mM 3 Amino-triazole (3-AT; Applichem, Darmstadt, Germany) was added to increase 
selection stringency (see also Y2H cDNA library screening procedures). The spotted plates 
were incubated 48-72 h at 30°C. 
The Cyto-Y2H was used to screen a human brain cDNA library (preys) for interactors of the N-
terminal domain of AMPK- β1 and - β2 subunits (∆β1, ∆β2; amino acids 1-54 as baits). This 
domain was chosen to avoid interactions with other AMPK subunits, and because it has been 
suggested as a putative AMPK interaction domain. A 3-AT concentration of 2.5 mM was 
determined by a pilot screen testing autoactivation by using empty library vector. About 6.2 × 
106 and 3.4 × 106 clones were screened. Plasmids containing the cDNA sequence of putative 
interaction partners were extracted and reintroduced together with the corresponding ∆β -
encoding bait vector into the reporter yeast strain in order to confirm the interaction. 
Reproducible interactors were sequenced and clones containing in-frame coding sequence 
 
169 AMPK interacts with vesicle associated proteins VAMP2 and VAMP3 – a role in exocytosis? 
and not known as false positives (Dualsystems, personal communication) were retained. To 
verify VAMP2,3/AMPK interactions, paired Y2H assays were performed using ∆β1 and ∆β2, 
full-length β1 and ∆β, as well as α1 and α2 subunits as baits and VAMP2,3 as a prey. Interaction 
with an unrelated bait, Large T antigen (Simian virus), was used as negative control. 
 
Yeast-two-hybrid assay: Split-Trp-Y2H 
The Split-Trp Y2H is based on the split-protein sensor Trp1p (Tafelmeyer et al., 2004). A C-
terminal part of Trp1p (CTrp) is fused to bait subunits and an N-terminal part of Trp1p (NTrp) 
is fused to prey. Upon interaction of bait and prey, active Trp1p is reconstituted from both 
domains, thus allowing growth of yeast strain CRY1 (MATa ura3-1 trp1-1 his3-11,15 leu2-3,112 
ade2-1 can1-100 GAL) on medium lacking tryptophan. CRY1 transformation and spotting were 
similar as above. Selective media either lacked uracil and leucine (SD-UL, controls) or 
additionally tryptophan (SD-UWL, protein interaction analysis). Spotted plates were incubated 
up to 9 days at 27°C.  
 
Expression and purification of GST-fusion protein 
All the GST fusions protein constructs were transformed into competent E. coli BL21-Codon 
Plus (DE3)-RIL cells (Stratagene, La Jolla, CA, USA) and incubated overnight on LB agar 
containing 100 µg/ml ampicillin and 30 µg/ml chloramphenicol. Cultures were routinely grown 
in standard LB medium containing antibiotics (100 µg/ml ampicillin and 30 µg/ml 
chloramphenicol) at 37°C in Erlenmeyer flasks with constant shaking until O.D. (600nm) 0.7-
0.9 (if not indicated otherwise). Cells were then cooled down to 30°C and protein expression 
was induced for 4 hours (if not indicated otherwise) with 2mM isopropyl β-D-
thiogalactopyranoside (IPTG, Eurobio). Cells were harvested by centrifugation at 4000 g, 30 
min at 4°C, harvest and suspended in lysis buffer: PBS (phosphate buffer saline: 137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH7.4). After 3x15s sonication at 85% of manual 
powered, insoluble material was removed by centrifugation (40000 g, 40 min at 4°C). All 
supernatant was applied by gravity flow to a 5ml Gluthation Sepharose matrix (binding up to 
1 g/mL) (Qiagen, Hilden, Germany) self-packed in a column (diameter 1cm). The column was 
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washed with 3x5 column volumes of PBS and proteins were eluted with 10 ml of 10 mM L-
glutathione reduced (Sigma-Aldrich) in 50mM Tris-HCl, pH 8. Ten µl of each elution fraction 
were mixed with Laemli sample buffer, separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE, 12% acrylamide), and stained with Coomassie. Protein concentrations were 
determined according to Bradford (Bradford, 1976) with the Biorad microassay (Biorad, 
Reinach, Switzerland) and BSA as standard. 
 
Preparation of synaptic vesicles 
Synaptic vesicles were obtained from Wistar rat forebrains by differential centrifugation and 
a density gradient procedure (Whittaker et al., 1964). Rat forebrains were homogenized in 
sucrose buffer (0.32 M sucrose, 4 mM HEPES pH 7.4) and separated into fraction P1 (nuclei, 
large myelin fragments, tissue debris), P2 (mitochondria, synaptosomes, small myelin 
fragments, some microsomes) and S2 (microsomes, some small mitochondria and 
synaptosomes, and soluble proteins). The synaptosomal fraction (P2) was washed two times 
with sucrose buffer and re-suspended in water (2 ml/mg tissue) to disrupt synaptosomal 
membranes and liberate synaptic vesicles. Synaptic vesicles were then purified on a 
discontinuous sucrose density gradient composed of 20 mL 0.6 M sucrose, 5 mL 0.4 M sucrose 
and 5 mL sample. After centrifugation for 2 h at 53500 g (4°C), vesicles were located in the 0.4 
M sucrose phase. Enrichment of synaptic vesicles was verified by immunoblotting using anti-
VAMP2 antibody (1:3000, Pierce Biotechnology, Rockford, IL, USA). All protein concentrations 
of biological samples were determined using the BCA Protein Assay Kit according to provider’s 
instruction (Thermo Scientific, Rockford, IL, USA).  
 
In vitro analysis of AMPK phosphorylation on VAMP2/3 and synaptic fractions 
AMPK 221TD was activated by incubation in kinase buffer (200 µM ATP, 50 µM AMP, 5 mM 
MgCl2, 1 mM DTT, in 10 mM HEPES pH 7.4) for 20 min at 30°C. Purified GST-ACC (200 pmol) 
and GST-VAMP2 (200 pmol), GST-VAMP3 (200 pmol), synaptosomal proteins (20 µg) and 
vesicular proteins (1.3 or 2.6 µg) were incubated for 2-8 min at 37°C with 200 µM [γ-32P] ATP 
(specific activity 6000 Ci/mmol ATP) in presence or absence of 221TD (30 pmol) previously 
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activated by incubation with 1 pmol CamKKβ for 20 min at 30°C in kinase buffer. Kinase 
reactions were stopped by addition of Laemli buffer and subjected to SDS-PAGE (12%) with 
Coomassie staining and analysis by Typhoon phosphoimager (GE Healthcare). 
 
Co-immunoprecipitation of AMPK and VAMP2 
VAMP2 was immunoprecipitated from synaptic vesicle fractions (20 µg protein) incubated 
with 1 µg recombinant His-tagged AMPK (221TD) using anti-His-tag antibody (1:200, 2366, Cell 
Signaling Technology, Danvers, MA, USA) and protein A sepharose (10%) in IP-buffer (10 mM 
HEPES pH 7.3, 100 mM NaCl, 6 g/L BSA, 0.5 % dodecylmaltoside) overnight at 4°C. The 
Sepharose was washed 4 times with wash-buffer (10 mM HEPES pH 7.3, 100 mM NaCl, 0.1 % 
Tween 20), re-suspended in SDS-PAGE sample buffer, and the solubilized denatured proteins 
were subjected to SDS-PAGE and immunoblotting using anti-VAMP2 antibody (1:3000, Pierce 
Biotechnology, Rockford, IL, USA). 
 
Co-pull down of AMPK and VAMP2 
20 µg vesicle fraction were incubated with or without 1 µg recombinant His-tagged AMPK 
(221TD) overnight at 4°C in IP-buffer containing 10 mM imidazole and 10 % nickel-
nitrilotriacetic acid (NTA) Sepharose (Qiagen, Hilden, Germany). The Sepharose was washed 5 
times with wash-buffer containing 10 mM imidazole and proteins bound to the Sepharose 
beads were directly re-suspended and denatured  in SDS-PAGE sample buffer and subjected 
to SDS-PAGE and immunoblotting, using anti-VAMP2 antibody as above.  
 
Cloning of VAMP3 and AMPK constructs 
Truncated constructs of VAMP 3 (Q15836) were amplified from vector pDSL20-V3 obtained in 
our Y2H screen library (Dualsystems Biotech AG, Schlieren, Switzerland) using PCR with 
specific primers (Table 1).  
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Table 1. Primers used for amplification of VAMP3 clones. 
VAMP3 fw CAATGTATTGGCCATTACGGCCATGTCTACAGGTCCAACTGCTGC 
rev CAATACATTGCAGGCCGAGGCGGCCCCTGAAGAGACAACCCACACGATG 
SNARE-domain fw CAATGTATTGGCCATTACGGCCATGAGACTTCAGCAGACACAAAATC 
Rev CAATACATTGCAGGCCGAGGCGGCCCCCTTCCACCAATATTTCCTCTTC 
Ct-V3 Fw CAATGTATTGGCCATTACGGCCGACGCACTGCAGGCAGGCGCTTCTCAA 
Rev CAATACATTGCAGGCCGAGGCGGCCCCTGAAGAGACAACCCACACGATG 
Nt-V3 Fw CAATGTATTGGCCATTACGGCCATGTCTACAGGTCCAACTGC 
rev CAATACATTGCAGGCCGAGGCGGCCCCCTTGCAATTCTTCCACC 
Green:sfi1 restriction enzyme site/ Bold: hybridization site 
 
Amplified PCR sequences containing Sfi1 sites on 3’ and 5’ ends of the coding sequence were 
introduced into yeast two-hybrid (Y2H) vectors pCab and pDSL20 (Dualsystems Biotech AG, 
Schlieren, Switzerland) containing two additional Sfi1 sites for Y2H experiments.  
The Nter-GBD domain of AMPK β2 comprising the N-terminal VAMP interaction domain 
(amino acids 1-71) and the glycogen binding domain (amino acids 72-168) was PCR-amplified 
(Table 2) to be inserted into bacterial expression vector pAB52s (derived from pET52b(+), 
Novagen, by insertion of a second Sfi1 site and a N-terminal Strep-tag in the coding sequence), 
and in vector pcDNA3.1(-) (Invitrogen) for eukaryotic expression.  
Table 2. Primers used for PCR-amplification of Nter-GBD β2 AMPK domain.  
To be inserted in pAB52s 
 fw Sfi1 CAATGTATTGGCCATTACGGCCATGGGAAACACCACCAGCGA 
rev Sfi1 CAATACATTGCAGGCCGAGGCGGCCCCCTATAACTTTAAAGCATCGAACACCTCAAAATCA 
To be inserted in pcDNA3.1 
 fw Hind3 CAATGTATTCTCGAGATGGGAAACACCACCAGCGA 
rev Xho1 CAATACATTGCAAAGCTTCTATAACTTTAAAGCATCGAACACCTCAAAATCA 
Green: restriction enzyme site/ Bold: hybridization site 
 
Expression and purification of Strep-GBD Nter β2 domain 
The fusion protein construct Strep-GBDNter β2 domain was transformed into competent E.coli 
BL21-Codon Plus (DE3)-RIL cells (Stratagene) and incubated overnight on LB agar containing 
100 µg/ml ampicillin and 30 µg/ml chloramphenicol. Cultures were grown in LB containing 
antibiotics at 37°C with shaking until OD (600 nm) 0.7-0.9. Cells were then cooled down to 
30°C and protein expression was induced for 4 hours with 2 mM isopropyl β-D-
thiogalactopyranoside (IPTG, Eurobio). Cells were harvested and suspended in lysis buffer: PBS 
(phosphate buffer saline) with complete EDTA-free protease inhibitor cocktail (Roche). After 
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sonication, insoluble material was removed by centrifugation (40000 g, 40 min at 4°C). The 
supernatant was applied to a Strep Tactin Superflow column (Merck KGaA, Darmstadt, 
Germany) and Strep-fusion proteins were purified according to the purification protocol 
provided by the manufacturer.  
 
In vitro activation of AMPK by CamKKβ 
AMPK221 (4 pmol) was activated by incubation with 1 pmol CamKKβ for 20 min at 30°C in 
kinase buffer (200 µM ATP, 50 µM AMP, 5 mM MgCl2, 1 mM DTT, in 10 mM HEPES pH 7.4).  
 
Surface plasmon resonance  
Binding of inactive AMPK221 to the soluble, cytosolic domain of VAMP2 (amino acids 1-94, 
kind gift of Rothman lab, Yale University, USA) was analyzed by surface plasmon resonance 
(SPR) with a Biacore T100 instrument (GE Healthcare). The SPR signal is expressed in arbitrary 
response units (RU) which are proportional to the amount of material bound at a sensorchip 
surface. All experiments were carried out at 25°C in running buffer containing 10 mM HEPES 
(pH 7.4), 50 mM K-acetate, and 0.005 % Surfactant P20 (GE Healthcare), using stock solutions 
of VAMP2 domain (3.34 mg/mL in 25mM HEPES pH7.8 containing 100 µM TCEP, 200 mM KCl, 
10% glycerol and 400 mM Imidazole) and AMPK221 (3.1 mg/ml in phosphate buffer 50 mM 
pH8 containing 50 mM NaCl, 250 mM imidazole. Soluble VAMP2 domain was randomly 
immobilized on a carboxy-methylated dextran sensorchip (CM5; GE Healthcare) using routine 
covalent amine coupling according to the manufacturer’s instructions. Control lanes were only 
treated with amine coupling reagents without protein. A defined immobilization level of 
VAMP2 domain was achieved by multiple injections of VAMP2 onto the activated chip at a 
flow rate of 5 µl/min. AMPK association and dissociation kinetics (300 s each) were recorded 
at a flow rate of 30 µl/min. The initial baseline was recovered by injection of 150 μl 0.5 M NaCl. 
For determination of binding parameters, 400 RU VAMP2 were immobilized. AMPK221 stock 
solution, inactive or activated in vitro by CamKKβ, were diluted into running buffer to different 
concentrations (7.5 and 12.5 μM) just prior to injection. At lower or higher AMPK 
concentrations there was an unacceptable signal/noise ratio, possibly because AMPK became 
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unstable or bulk refractive index change was too important, respectively. Binding curves of 
inactive or active AMPK with VAMP2 domain were calculated as the difference between 
VAMP2-containing channels and control channels. Kinetic data were subjected to a global fit 
with a simple Langmuir 1:1 kinetics (Biacore software, GE Healthcare). The affinity KD 
(dissociation equilibrium constant) was derived from rate constants as KD = koff / kon.  
For competition binding experiments, 900 RU VAMP2 were immobilized, and the buffer of 
AMPK221 stock solution was exchanged against Biacore running buffer by 20 concentration-
dilution cycles using a Amicon-30 device (Merck Millipore). A constant concentration of 4 μM 
AMPK221 was pre-mixed with a concentration series (0, 1, 2, 4, 8, and 16 μM) of AMPK β-
subunit N-terminal domain (AMPK-βN; stock solution of 0.4 mg/ml in Tris-buffer 50 mM pH8). 
Control-corrected AMPK221 binding levels at a reporting point 150 s after injection were 
recalculated into percentage of bound AMPK221 vs. AMPK-βN using a calibration curve based 
on their different molecular mass (135 kDa vs. 20 kDa) and assuming a fixed number of binding 
sites shared by both proteins (Figure 3). These data were fitted to a sigmoidal dose-response 
curve using using Sigma Plot 10.0 (Systat Software).  
 
 
Figure 3. Calibration curve for competition binding assay of AMPK221/VAMP2 interaction and AMPK-βN as 
competitive inhibitor. Data given in Figure 13 were recalculated into percentage of bound AMPK221 vs. AMPK-
βN based on their different molecular mass (135 kDa vs. 20 kDa) and assuming a single binding site shared by 
both proteins. For further details see Materials & Methods. 
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Membrane fusion assay 
Full length t-SNARE and v-SNARE protein expression and purification were performed as 
described (Parlati et al., 1999; Weber et al., 1998). All lipids for proteoliposome preparation 
were obtained from Avanti Polar Lipids. For white vesicles, 100 µL of a 15 mM premixed lipid 
solution in chloroform (POPC (1-plamitoyl, 2-oleoyl phosphatidylcholine):DOPS (1,2-dioleoyl 
phosphatidylserine), in an 85:15 mol ratio), and for fluorescent (red) donor vesicles 100 µL of 
a 3 mM premixed lipid solution in chloroform (POPC (1-plamitoyl, 2-oleoyl 
phosphatidylcholine):DOPS (1,2-dioleoyl phosphatidylserine):rhodamine-DOPE (1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine: PE-NBD (phosphatidylethanolamine), in a 82:15:1.5:1.5 
mol ratio), were dried down in 10x75 mm glass test tubes by a gentle stream of nitrogen (15 
min), and any remaining traces of chloroform were then removed under vacuum for 1 h, 
leaving a pure lipid film.  Then t-SNARE (SNAP25) (200 lipids/FLT) is added to the white lipid 
film and volume adjusted with 1% octyl-β-D-glucopyranoside (OG) in buffer A (25 mM Hepes-
KOH (pH7.4), 3 M KCl, 10% glycerol, 1 mM DTT) in order to have a final solution of 500 µL 
(3mM lipids), and v-SNARE (VAMP2) (40 lipids/FLV) is added to the red lipid film and volume 
adjusted with OG 1% in buffer A in order to have a final solution of 100 µL (3 mM lipids). In 
both cases, the lipids were dissolved by gentle agitation for 15 min at room temperature. 
Vesicles were then formed from these samples by rapid dilution followed by extensive dialysis 
as follows. While vortexing vigorously, the sample was diluted with twice the sample volume 
of buffer A (at room temperature), thereby diluting the detergent OG below its critical micellar 
concentration and promoting vesicle formation. Then detergent was removed by dialysis (in 
Spectrapore 6-8 kDa cut-off dialysis tubing) against 3 L of buffer overnight at 4°C (2-3 mL/min). 
For free protein removal, 1.5 mL of t-liposomes were mixed with 1.5 mL of HistoDenz 80% and 
poured into a MLS50 Beckman centrifuge tube (5 mL UltraClear) and overlayed with 1.5 mL of 
30% HistoDenz and 900 µL of buffer A. This was centrifuged 5 h at 46000 g, and twice 240µL 
were collected from each tube (~ 6.25 mM lipids). In analogy, 300 µL of v-liposomes were 
mixed with 300 µL of HistoDenz 80% and poured into a MLS50 Beckman centrifuge tube (0.8 
mL UltraClear) and overlaid with 100 µL of HistoDenz 30% and 75µL of buffer A. This was 
centrifuged 5 h at 46000 g, and twice 40 µL were collected from each tube (~ 7.5 mM lipids). 
Standard fusion assays were performed in white 96-well FluoroNunc plates (Nunc). 45 µL 
unlabeled t-liposome (white) were prewarmed in the plate at 37°C in presence or absence of 
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AMPK, then 5 µL of labeled v-liposomes (red) were added. The plates were then placed in the 
Fluorimeter (Fluoroskan II, Labsystems) equilibrated to 37°C. NBD fluorescence was followed 
with filters set at 460nm (excitation, half band width 25 nm) and 538 nm (emission, half band 
width 25 nm). NBD fluorescence was monitored every minute for 140 min. To obtain 
maximum intensity of fluorescence for normalization, 10 µL n-Dodecyl-β-maltoside (10%) was 
added.  
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Results 
Yeast-two-hybrid screen for AMPK interactors identifies VAMP3 
Putative interaction partners of the N-terminal domain of AMPK β-subunits (∆β) were 
identified in a Y2H screen using a human brain cDNA library. The applied novel split-ubiquitin 
cyto-Y2H system (Möckli et al., 2007) detects protein-protein interactions occurring in the 
cytosol. It is coupled to a transcriptional read-out that allows growth on nutrient-deficient 
medium that detects also weak or transient interactions. About 6.2 × 106 and 3.4 × 106 clones 
were screened for AMPK-∆β1 and -∆β2 subunits, respectively, yielding 102 primary interacting 
clones, including 38 that reproducibly interacted with ∆β in paired Y2H assays as compared to 
a negative control, the unrelated bait Simian virus large T antigen (Table 3). Sequencing 
confirmed 5 clones containing in-frame coding sequences not known or not supposed to be 
false positives in Cyto-Y2H (Dualsystems, personal communication) and corresponding to 
different proteins (Table 4). Sequencing of these clones identified mainly transmembrane 
proteins, including the vesicle associated membrane protein (VAMP) family member 3.    
Table 3: Cyto-Y2H screen for interactors of AMPK β1 or β2 N-terminal domain in a human cDNA library. 
 Δβ1 Δβ2 
Library human brain cDNA library human brain cDNA library 
Transformation efficiency 2.2x105clones/ug library 1.2x105clones/ug library 
Clones, total number ca. 6.2x106 ca. 3.4x106 
Clones, selected on SD-AHTL 69 33 
Clones, bait dependent 1 26 12 
Clones, selected 2 4 different 2 different        
1) Clones interacting with Δβ but not with LT. 2) Clones with in-frame CDS not corresponding to known false positives, 
corresponding to different proteins. In addition, known interactors of APP were excluded, since the transmembrane domain 
of APP is used as a membrane anchor in the Cyto-Y2H screen.  
 
Table 4. Putative AMPK interactors identified in the Cyto-Y2H screen. 
Bait Gene name Encoded protein 
SwissProt 
entry 
Identified part 
(amino acids) 
∆β2 VAMP3 Vesicle-associated membrane protein 3 Q15836 22-80 
∆β2 C14orf1 Probable ergosterol biosynthetic protein 28 Q9UKR5 1-140 
∆β1 NRDP1/RNF41 E3 ubiquitin-protein ligase Nrdp1 Q9H4P4 136-316 
∆β1 JWA/ARL6IP5 JWA protein or PRA1 family protein 3 O75915 1-188 
∆β1 CLDND1 Claudin domain-containing protein 1 Q9NY35 203-253 
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VAMP 2 and 3 are interacting with AMPK beta 
We further concentrated on VAMP proteins because of the apparent functional link between 
vesicle exocytosis and  AMPK activation. We first checked whether VAMP3 can interact with 
both ∆β constructs and also with full-length β-subunits, and whether such interactions are 
preserved in the highly homologous VAMP2 isoform. VAMP3 indeed interacted with both 
truncated and full-length β1 and β2, but not with isolated SNARE domain common to all 
VAMPs (amino acids 31-91 in VAMP2, 14-74 in VAMP3). All these interactions were conserved 
in VAMP2 (Figure 4). These results were confirmed by an independent Y2H assay, the Split-
Trp system (data not shown), as well as co-immunoprecipitation and pull-down of VAMP2 
from synaptic vesicles by heterotrimeric full-length AMPK (Figure 5). 
 
Figure 4. Two major VAMP isoforms interact with the AMPK β-subunit. Paired Cyto-Y2H was performed with 
∆β1, ∆β2, β1 and β2 as baits and VAMP2 or 3 (V2, V3) or the shared SNARE domain (SN, VAMP2 amino acids 31-
91) as preys. Presence of bait and prey plasmids are verified on selective media (SD-WL). Bait/prey interaction 
leads to reconstitution of ubiquitin and a transcriptional readout allowing growth on medium lacking in addition 
adenine and histidine (SD-AHWL). Spots represent yeast grown for 72h at 30°C. Negative controls: LT, Large T 
Antigen of Simian Virus (aa 84-704) and empty prey vector (---). Positive controls: AMPK -β dimerization. For 
more details see Materials and Methods. 
 
 
Figure 5. AMPK/VAMP2 interaction is confirmed by immunoprecipitation and pull-down. (A) Immuno-
precipitation of VAMP2 from purified synaptic vesicles with added constitutively active AMPK αT172D-Hisβ2γ1 
(221TD) using anti-His-tag antibody. (B) Pull-down of VAMP2 from purified synaptic vesicles by added 221TD 
using Ni-NTA Sepharose. VAMP2 was detected by immunoblot analysis with anti-VAMP2 antibody. 
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VAMP is not a substrate for AMPK 
For further in vitro assays, the soluble N-terminal domains of VAMP2 and -3 fused to an N-
terminal GST-tag (GST-ntVAMP3, GST-ntVAMP2) were produced in E. coli and purified. When 
these proteins were subjected to an in vitro phosphorylation assay, neither of both VAMPs 
was phosphorylated (Figure 6). The same negative results were obtained when Strep-
ntVAMP3 or a constitutive active AMPK 221TD mutant were used in such in vitro experiments 
(data not shown). Thus, at least the soluble, N-terminal VAMP domain is not an AMPK 
substrate. This coincides with the lack of any consensus AMPK phosphorylation recognition 
sites in both VAMP2 and VAMP3 (Prosite Scan for [MLIFV]-[XRKH]-[XRKH]-X-X-[ST]-X-X-X-
[MLIFV];  (Dale et al., 1995; Scott et al., 2002)). 
 
 
Figure 6. VAMPs are not AMPK substrates. AMPK 221WT (4 pmol) previously activated by CamKK (1 pmol) was 
incubated with GST-ntVAMP3 or GST-ntVAMP2 (200 pmol) or with GST-ACC (100 pmol) for 8 min at 37°C. In vitro 
phosphorylation assays were analyzed by SDS-PAGE and Typhoon phosphoimager. Note the AMPK 
autophosphorylation of α and β subunits. 
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VAMP is not directly regulated by AMPK-binding  
Since the v-SNARE VAMPs did not serve as an AMPK substrate, we hypothesized that the 
interaction alone could affect VAMP-mediated membrane fusion. In an in vitro assay for 
SNARE-complex induced membrane fusion, we tested whether addition of AMPK affects 
fusion of two vesicle populations containing either the v-SNARE VAMP2 or a t-SNARE SNAP25 
(Figure 7). However, the interaction of VAMP2 and AMPK did not affect SNARE-complex 
function in membrane fusion.  
 
 
Figure 7. AMPK/VAMP interaction does not affect vesicle fusion. Mixing of two vesicle populations containing 
either v-SNARE (VAMP2) or a t-SNARE (SNAP25) together with NBD- and rhodamine-labelled lipids leads to 
SNARE-mediated vesicle fusion, dilution of the fluorescent labels and thus loss of FRET between NBD and 
rhodamine. This is monitored by the increase in NBD fluorescence at 538 nm.  Grey and black symbols represent, 
respectively, membrane fusion in absence and in presence of AMPK. For further details see Materials & Methods. 
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Determination of the AMPK-VAMP interaction domain 
Since VAMPs were not phosphorylated by AMPK, we considered the possibility that they could 
act as scaffolding proteins to recruit AMPK to exocytotic vesicles, which could facilitate 
phosphorylation of vesicle-bound AMPK substrates. In support of this model, we could detect 
AMPK together with at least two putative AMPK substrates in a purified fraction of synaptic 
vesicles from rat brain (Figure 8, see arrow in B). 
 
 
Figure 8. AMPK and putative AMPK substrates in synaptic vesicles. (A) Representative immunoblots showing 
that AMPK is present in synaptosome fractions and can be activated. Synaptosomes were treated (+) or not (-) 
with AMPK activator A-769662 for 30 min at 37°C. Immunoblotting of 50 μg synaptosomal proteins probed with 
anti-phospho-ACC, anti-P172 AMPK (Ponceau staining as loading control) or anti-total AMPK antibodies. (B) In 
vitro phosphorylation assay for AMPK substrates. AMPK 221TD (30 pmol) was incubated with synaptic vesicles 
(2.6 or 1.3 µg) for 2 min at 37°C. In vitro phosphorylation assays were analyzed by SDS-PAGE and Typhoon 
phosphoimager. Note the AMPK autophosphorylation of α and β subunits. 
 
To further tackle such scaffolding function of VAMPs, we mapped the interaction domains 
situated in VAMP3 and the AMPK β2 subunit by applying Y2H analysis to different VAMP3 and 
AMPK β2 truncation constructs. Y2H data revealed that the very N-terminal domain of AMPK 
β (Δβ1/2, amino acids 1-54) is sufficient for interaction with full-length VAMP3 (Figure 9). 
However, the N-terminal truncation construct ∆1-54β2 is still able to interact with VAMP3, and 
N-terminal truncation up to the glycogen-binding domain (amino acid 72; construct ∆1-72β2) is 
necessary to suppress the interaction (Figure 9). These results clearly show that the entire N-
terminal sequence of AMPK β2 (amino acids 1-72) can interact with VAMP, and that sequences 
1-54 and 55-72 are sufficient for this interaction.  
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AMPK-β2 subunit constructs 
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Figure 9. Mapping of the AMPK-β2 domain interacting with VAMP2. Paired Cyto-Y2H was carried out as 
described in Figure 4. AMPK β2 subunit constructs used: β2, full length subunit; Δβ2, N-terminal amino acids 1-54; 
∆1-53β2, C-terminal amino acids 54-272;∆1-71β2, C-terminal amino acids 72-272; GBD, glycogen binding domain; 
α/γ-SBS , C-terminal α/γ-subunit binding sequence. (+) proteins interact, (-) no interaction between proteins, 
(ND) not determined. 
 
The mapping occurred to be more complex for VAMP. The VAMP3 clone identified in the 
original Y2H screen corresponds to a truncated version comprising amino acids 22-80, thus 
spanning a large part of the SNARE domain (amino acids 14-74). However, isolated SNARE 
domain did not interact with AMPK-β1/-β2 (Figure 4) or did so only more weakly with AMPK-
β2 and somewhat more weakly (Figure 10). 
We therefore checked separately the C-terminal 50 amino acids of VAMP3 bearing the 
transmembrane domain and a minor part of the SNARE domain, as well as the VAMP3 C-
terminal 14 amino acids which are VAMP-isoform-specific (Figure 10). No interactions were 
detectable with these constructs. Thus, the SNARE domain (in particular the region between 
amino acids 22 and 50) is necessary, but it does not seem to be sufficient for interaction.  Most 
likely, the SNARE domain requires the context of a more extended VAMP structure, as in case 
of the identified Y2H clone (amino acids 22-80), possibly for reaching a proper folding.  
We finally also tested VAMP interaction with the catalytic subunits α1, and α2. VAMP 3 
interacted with AMPK catalytic subunit α2, but not with the α1 isoform (Figure 10B). AMPK-α1 
and -α2 have only 74% sequence homology which may explain these differences. The AMPK γ 
subunit does not correctly express in yeast and cannot be used in Cyto-Y2H.  
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Figure 10. VAMP3 interaction with AMPK. (A) Mapping of the VAMP3 domain interacting with AMPK β1 and β2. 
Paired Cyto-Y2H was carried out as described in Figure 4. (+) proteins interact, (-) no interaction between proteins 
(see (B)). (B) Interaction of VAMP3 with different AMPK subunits. Paired Cyto-Y2H with different AMPK subunits 
or Large T (LT) as negative control (baits) and VAMP3 constructs (preys). Spots represent yeast grown for 48h at 
30°C on selective medium lacking tryptophan, leucine, adenine, and histidine (SD-AHWL). Different VAMP 
constructs used: V3, full-length VAMP3; SNARE, common SNARE domain of VAMP proteins (amino acids 14-74); 
Ct-V3, C-terminal 50 amino acids of VAMP3 bearing a part of the SNARE domain and the C-terminal 
transmembrane domain (TMD); Nt-V3, VAMP3 N-terminal 14 amino acids; α1, α2,, , β1, β2, AMPK subunits; α2 TD, 
a constitutively active AMPK subunit. 
 
Determination of AMPK-VAMP binding kinetics 
To further verify a function of VAMP in recruiting AMPK to transport vesicles, we applied 
surface plasmon resonance (SPR) spectroscopy to (i) test whether AMPK/VAMP interaction is 
direct, (ii) measure the kinetic and equilibrium binding parameters, and (iii) analyze how to 
experimentally interfere with AMPK/VAMP interaction. 
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Figure 11. Surface plasmon resonance identifies interaction of AMPK221 with VAMP2. Representative SPR 
traces of association (contact) and dissociation phase of 7.5 and 12.5 μM AMPK221 with soluble VAMP2 domain 
(thin lines). Global fitting of traces to 1:1 Langmuir kinetics (bold lines) and the corresponding residuals (below) 
are given. Data were recorded at 25°C and 30 μl/min flow rate. The calculated interaction parameters are: 
ka=2.5·102 M-1 s-1, kd=2.2·10-3 s-1, and KD=8.5·10-6 M. For further details see Materials & Methods. 
 
For SPR, we used an immobilized soluble N-terminal VAMP2 domain (amino acids 1 to 94) and 
injected AMPK221 heterotrimer in the flow (Figure 11). The data show that AMPK and VAMP 
interact directly with an affinity constant (KD) of 8.5µM. This rather low affinity argues for a 
more transient type of interaction, although in vivo additional factors may increase this 
affinity. We further tested whether VAMP interaction is different between AMPK in an active 
or inactive conformation by activating AMPK with CamKKβ prior to SPR experiments (Figure 
12). Activation of AMPK caused a slightly faster association rate without affecting dissociation, 
thus increasing affinity.  
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Figure 12. Surface plasmon resonance identifies differences between active and inactive AMPK in VAMP2 
interaction. Representative SPR traces of association (contact) and dissociation phase (thin lines) of AMPK at 
12,5 μM, either activated in vitro by CamKKβ (top trace) or inactive (bottom trace), with soluble VAMP2 domain. 
Data were recorded at 25°C and 30 μl/min flow rate. Traces were fitted individually to 1:1 Langmuir kinetics (bold 
lines) and the corresponding residuals (below) are given. The calculated interaction parameters are: ka=4,5·102 M-
1 s-1, kd=1,5·10-3 s-1, and KD=3,2·10-6 M (for active AMPK), and ka=2,5·102 M-1 s-1, kd=1,8·10-3 s-1, and KD=7,4·10-6 M 
(for inactive AMPK). For further details see Materials & Methods. 
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Inhibition of AMPK-VAMP interaction 
In the next step, we wanted to disrupt the interaction between VAMP and AMPK. Based on 
the mapping of the interaction domains (Figure 9 and Figure 10), we decided to generate an 
AMPK β2 construct comprising the N-terminal VAMP interaction domain (amino acids 1-71) 
and the glycogen binding domain (amino acids 72-168). This construct should be able (i) to 
fold correctly (with the GBD domain being successfully crystallized), (ii) to competitively inhibit 
the AMPK/VAMP interaction, while (iii) being unable to interact with α- and γ-subunits.  In a 
competition assay, using again soluble VAMP domain immobilized at the chip surface, we co-
injected both, AMPK221 complex and AMPK-βN domain. The assay clearly showed a decrease 
in AMPK221 binding with increasing concentrations of AMPK-βN in the lower micromolar 
range (Figure 13).   
 
Figure 13. Competition binding assay of AMPK221/VAMP2 interaction and AMPK-βN as competitive inhibitor. 
Representative SPR traces of association (contact) phase with 4 μM AMPK221 and (from top to bottom) 0, 1, 2, 
4, 8, or 16 μM AMPK-βN. Data were recorded at 25°C and 30 μl/min flow rate. For further details see Materials 
& Methods. 
 
The percentage of bound AMPK was then calculated from the binding response by correcting 
for bound AMPK-βN (which has much lower molecular mass) and assuming a fixed number of 
binding sites shared by both proteins. These data were fitted to a sigmoidal dose-response 
curve (Figure 14). They demonstrate that at an equimolar concentration of 4 μM of both 
proteins, AMPK221 and AMPK-βN, the interaction is inhibited by about 35%. Inhibition 
reaches 80% at higher AMPK-βN concentrations. Possibly, the remaining AMPK-βN-resistant 
AMPK/VAMP interaction is due to the interacting α subunit (Figure 10). The SPR study allowed 
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us to confirm a direct interaction between AMPK221 and VAMP2 that can be inhibited by a 
AMPK-βN construct. 
 
 
Figure 14. AMPK221 β-subunit N-terminal domain competes with AMPK221 for VAMP2 binding. Competition 
binding assay showing the effect of AMPK221 β-subunit N-terminal domain (AMPK-βN) on AMPK221/VAMP2 
interaction. SPR binding kinetics of 4 μM AMPK221 to soluble VAMP2 domain were determined as a function of 
the presence of 0, 1, 2, 4, 8, or 16 μM AMPK-βN. Reporting points taken at 150 s of association from Figure 13 
were used for calculation of data presented here. For further details see Materials & Methods. 
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Discussion  
One of the most interesting putative AMPK interactors identified in our Y2H assays were 
members of the large VAMP family, VAMP2 and VAMP3, both essential players in exocytosis. 
Localized at different intracellular storage vesicles, they are involved in their correct sorting 
and fusion with specific target membranes (Mochida, 2000; Procino et al., 2008; Sai et al., 
2013). Regulation of many of these exocytotic processes seems to involve also AMPK. The 
most prominent example is cell surface expression of the nutrient transporters GLUT4 
(glucose uptake) and CD36 (fatty acid uptake), playing a central role in regulating glucose and 
lipid uptake (Heather et al., 2013; Holman and Cushman, 1994; Karylowski et al., 2004). 
However, also the release of neurotransmitters like glutamate from synaptic vesicles in 
synapses is controlled by AMPK (Cunningham et al., 2012). In this study we provide insight 
into the molecular properties of the AMPK/VAMP interaction, and develop tools to further 
study its functional role in vitro and in vivo. Taken together with published data, our study 
suggests an AMPK scaffolding function for VAMP2 and VAMP3.  
The interaction between AMPK and VAMP2/3 found in Y2H assays was confirmed by multiple, 
independent interaction assays, including co-immunoprecipitation, pull-down and SPR. Thus 
the VAMP/AMPK interaction has been established in vivo. We could also map the interaction 
domains to a central portion of VAMP3 and more precisely to the N-terminal 72 amino acids 
of the AMPK β-subunit. In addition, an N-terminal AMPK-β domain was able to competitively 
inhibit AMPK/VAMP interaction in SPR assays. This domain could thus be used to disturb 
VAMP/AMPK interaction in vivo to study e.g. effects on exocytosis. Addition of the GBD-β 
domain (73-168 amino acids) which is an autonomously folding domain should help to 
correctly structure the entire N-terminal AMPK-β domain of 168 amino. 
There is ample evidence that both interaction partners, AMPK and VAMP2/3, are acting 
sequentially in the same signaling pathway of exocytosis. However, so far they have been 
involved at very different stages. In the best studied case, which is the exocytosis of GLUT4-
containg storage vesicles (GSV), AMPK acts upstream by phosphorylating AS160 at Ser570/588 
to trigger GSV release and translocation to the cell surface, the key event in exercise-
stimulated glucose uptake. In contrast, VAMP2 and VAMP3 seem to act very much more 
downstream in the docking and membrane fusion processes. Our data however suggest that 
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both proteins have a more intimate role to play here. This role does not include direct 
regulation of VAMPs by AMPK. As our in vitro data suggest, VAMPs are neither a direct 
substrate of AMPK nor are they regulated in their membrane fusion activity by bound AMPK. 
By contrast, VAMPs may represent a type of scaffolding protein that allows recruitment of a 
fraction of AMPK to the surface of storage vesicles. In support of this, our SPR experiments 
confirmed a direct interaction between both proteins with an affinity in the lower µM-range, 
increasing when AMPK was activated. Such affinities are typical for interactions mapped at 
the surface of GSVs, such as the interaction between the RabGAP AS160 and the insulin 
regulated amino peptidase (IRAP; Park et al., 2012). Interestingly, the GLUT4-interacting IRAP 
is like VAMP a transmembrane protein (Martin et al., 1997; Ross et al., 1996), and both may 
share a common functional feature: they represent scaffolds to recruit the “true” signaling 
molecules, AS160 and AMPK, respectively, to the storage vesicles.  
We would thus propose a model (Figure 15) in which VAMP2 and VAMP3 have an additional 
role at the initiation step of exocytosis. By interacting with AMPK or even more the activated 
form of AMPK, they would bring the kinase in close vicinity of its substrate AS160 for triggering 
downstream exocytosis. This concept may be generally true for exocytotic translocation 
processes which involve VAMP2 and VAMP3 as v-SNAREs. In addition to GLUT4 and CD36 
translocation to the plasma membrane, this could also concern the release of 
neurotransmitters from synaptosomes, which involves VAMP2-containing storage vesicles 
and possibly also activation by AMPK (Cunningham et al., 2012). In support of this, we found 
that synaptic vesicles (i) contain considerable amounts of AMPK, (ii) contain different putative 
AMPK substrates that could act similar to AS160, and (iii) fuse with the synaptosome 
membrane for glutamate release depending on the AMPK activation state (not shown).  
In summary, our data support formation of transient AMPK/VAMP complexes in vitro and in 
vivo. They suggest a role of VAMP2 and VAMP3 upstream of vesicle docking and membrane 
fusion, in form of a scaffolding function that recruits AMPK to storage vesicles for 
phosphorylation of vesicle-located substrates such as AS160. It has still to be tested whether 
such a model applies in vivo, either in case of nutrient transporter externalization or 
neurotransmitter release. Such experiments will employ the N-terminal AMPK β2-construct 
for which we have shown competitive inhibition of the AMPK/VAMP interaction. Its 
expression in cells should for example reduce AS160 phosphorylation and GLUT4 or CD36 
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appearance at the cell surface. It also remains to be established whether this novel function 
of VAMPs is a general feature of exocytotic processes. 
 
Figure 15. VAMP as a scaffold to recruit AMPK to glucose storage vesicles. Exercise causes AMPK activation. 
Interaction of AMPK with the VAMP scaffold then recruits AMPK transiently to the vicinity of its substrate AS160, 
anchored via the IRAP scaffold to the same GSVs. Thus, AMPK could easily phosphorylate AS160, which triggers 
translocation of GSVs to the plasma membrane, integration of cargo like GLUT4 and IRAP into the plasma 
membrane, and finally an increase in glucose uptake.  
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Conclusions and outlook  
During the three-year work on this thesis, over 4000 articles have been published about 
AMPK. Although some of them identified new AMPK interaction partners and substrates (Liu 
et al., 2013; Um et al., 2013; Zhang et al., 2012), few have applied large scale screening to 
characterize the AMPK signaling network (Banko et al., 2011; Thali et al., 2010). This thesis 
provides confirmation and further functional characterization of several novel AMPK 
interaction partners and substrates which emerged from two large scale screens performed 
in the laboratory. First, a two dimensional in vitro screen combining surface plasmon 
resonance (SPR) with in vitro phosphorylation assays allowed identification fumarate 
hydratase (FH) as new putative AMPK substrate. Second, split-ubiquitin based cytosolic yeast 
two-hybrid (Y2H) systems combined with complementary interaction methods (split-Trp1 
based Y2H, co-immunoprecipitation, SPR) led to the identification of two protein interaction 
partners of AMPK: E3 ubiquitin-ligase NRDP1 and vesicle-associated membrane proteins 2 and 
3 (VAMP2/3). Finally, glutathione S-transferase (GST) was found to interact with AMPK during 
our interactomics research on AMPK. The kinase was pulled-down with recombinant proteins 
fused to a GST-tag and we could show that GST alone is sufficient to interact with AMPK. 
During this thesis, several of these putative AMPK interaction partners and substrates could 
be characterized in more detail, in particular concerning their functional role in the AMPK 
signaling network. 
 
Analysis of the AMPK interactome 
New protein interaction partners of the AMPK complex were identified in two large scale 
screening interactomic strategies: (1) A novel procedure combining SPR and phosphorylation 
assay, which revealed new AMPK-interacting substrates such as FH. (2) A cyto-Y2H screen for 
new interactions partners of AMPKβ1 and AMPKβ2, which led to identification of five putative 
AMPK protein interaction partners. The latter approach seems particularly interesting since it 
is not limited to AMPK substrates. Most work in this thesis was done with two candidates that 
emerged from this screen: NRDP1 and VAMP3.  
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Both screens yielded less candidates than anticipated. Probably, this relates to the high 
stringency that we applied, but also screening protocols could be improved. All investigated 
proteins occurred to be true positive interaction candidates. Our approach also indicates that 
high throughput interactomic methods, although giving valuable new insight, should be 
followed by targeted studies to verify the actual relationships e.g. between two interaction 
partners in a complex network. This may reveal very different roles of a given interaction, 
going from pure scaffolding functions to different kinds of mutual modifications involving one 
or both interacting proteins.       
 
Glutathione S-transferase (GST)  
The GST of Schistosoma japonicum (GST-Sj) commonly used as GST-tag, and the rat GST 
isoforms GSTM1 and GSTP1 were shown to interact with heterotrimeric AMPK via the N-
terminal domain of the AMPK β-subunit in initial Y2H assays. Here we have confirmed the 
interaction between AMPK and GST by several independent procedures, such as pull-down 
and co-immunoprecipitation, SPR and Y2H. We have further investigated possible functions 
of this interaction, including putative phosphorylation and activation of GST by AMPK or 
glutathionylation and activation of AMPK by GST. We could show that formation of a 
GST/AMPK complex slightly increases GST activity and in turn GST glutathionylates AMPK, 
which increases AMPK activity. Such S-glutathionylation of AMPK leading to non-canonical full 
activation of AMPK under certain conditions could represent an additional layer of AMPK 
regulation. It would link AMPK signaling to redox regulation and position AMPK as a redox 
sensor. It has previously been shown in vivo that under highly oxidative conditions AMPK is 
glutathionylated and activated (Zmijewski et al., 2010). Here, we demonstrate in vitro that 
already under mildly oxidative conditions, GSTM1 and –P1 are able to catalyze AMPK 
glutathionylation. It is well established that reversible protein modification by 
glutathionylation could play a protective role against irreversible protein thiol oxidation which 
is usually associated with permanent loss of protein function and leads to protein degradation 
(Giustarini et al., 2004). Thus glutathionylation of AMPK in mildly oxidative conditions could 
be important for protecting AMPK. Further work should be done to demonstrate the 
significance of AMPK glutathionylation in vivo and to confirm the role of GST in this 
mechanism. To analyze the importance of AMPK glutathionylation, GST inhibitors like 
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ethacrynic acid (EA) or the peptidomimetic glutathione analog TLK199 ([γ-glutamyl-S-
(benzyl)cysteinyl-R-phenyl glycine diethyl ester]) (Tew, 2007) could be used in cells in vivo 
under different oxidative conditions, followed by pull-down of glutathionylated proteins and 
Western blot analysis to detect AMPK.  
 
Fumarate hydratase (FH) 
Among the five putative AMPK substrates found by combining SPR and in vitro 
phosphorylation screening, fumarate hydratase (FH) was confirmed by co-
immunoprecipitation and in vitro phosphorylation assays as AMPK interactor and substrate. 
FH phosphorylation by AMPK also affects its activity in vitro and in HeLa cells. However, after 
thorough phosphosite analysis by mass spectrometry (MS) and site-directed mutagenesis it 
appears that FH is primarily phosphorylated at serine 19 located in the cleavable 
mitochondrial transit or targeting peptide. FH is encoded by one unique nuclear gene and 
could be localized both to mitochondria or to cytosol (Yogev et al., 2011), and in mammals 
only the mitochondrial form contains the transit peptide. Phosphorylation of FH in the 
targeting peptide could thus affect its mitochondrial translocation and reduce the amount of 
mitochondrial FH. Activation of FH due to phosphorylation, as we initially observed, has to be 
reconsidered, since the phophorylatable residue is not present in the mature protein. 
Production of an antibody against phosphorylated serine 19 could provide a tool to study this 
process in vivo, but since lifetime of the native protein containing the targeting peptide is 
probably short, the phosphorylation may be difficult to observe. In addition, overexpression 
of wild type and S19A mutant FH could already give information on mitochondrial import 
efficiency by observation of FH localization (e.g. accumulation of FH-S19A in the cytosol). 
 
E3 ubiquitin-ligase NRDP1 (NRDP1) 
We describe here the first successful production of full-length NRDP1 protein. Previous 
attempts always yielded insoluble protein (Wu et al., 2004). We have also noticed the 
formation of a large proportion of inclusion bodies during NRDP1 production, but could reduce 
their formation and increase yield of soluble protein by reducing the temperature during 
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expression and applying bioreactor conditions. Bioreactor production yielded 3.1 mg of 
soluble NRDP1 protein per liter of culture.    
Y2H analysis led to detection and confirmation of an interaction between NRDP1 and AMPK, 
and allowed to identify the C-terminal domain of NRDP1 and the N-terminal tail of the AMPK 
β-subunit as interaction domains. In an attempt to clarify the functional consequences of this 
interaction, we primarily analyzed phosphorylation and ubiquitination events. Ubiquitination 
assays in HEK293 cells showed that even though AMPK can be ubiquitinated in vivo (Zungu et 
al., 2011), this is no specific function of NRDP1. In contrast, NRDP1 is phosphorylated in vitro, 
but the low level as compared to the AMPK reference substrate acetyl-CoA carboxylase (ACC) 
makes it uncertain whether this is of physiological relevance.  
Considering the high NRDP1 turnover rate caused by its strong autoubiquitination leading to 
proteasomal degradation, we have finally also investigated the effect of AMPK on cellular 
NRDP1 levels. We could show that in HeLa cells in vivo, AMPK overexpression reduces levels 
of NRDP1 by increasing its proteasomal degradation, probably via enhanced NRDP1 
autoubiquitination, independent of phosphorylation by AMPK. These results suggest a role of 
AMPK in NRDP1 turnover, which might be due to (i) activating conformational changes within 
NRDP1, (ii) a NRDP1 scaffolding function of AMPK which recruits several NRDP1 proteins close 
to each other, or (iii) a role for AMPK in disrupting NRDP1 interactions with ubiquitin carboxyl-
terminal hydrolase 8 (USP8), a major stabilizing NRDP1 protein  (Avvakumov et al., 2006). At 
present, our work suggests a functional link between AMPK and NRDP1. However more work 
is needed to understand its putative function in NRDP1 down-regulation. 
Immunocytochemistry combined with confocal microscopy could be used to analyze NRDP1 
localization in situations of AMPK overexpression. In addition work should be done to analyze 
the impact of NRDP1 downregulation on its targets.   
  
Vesicle associate membrane protein (VAMP) 
Interaction of VAMP2 and VAMP3 with AMPK was first shown by us in Y2H assays, and then 
confirmed by pull-down, co-immunoprecipitation and SPR. However VAMPs occurred not to 
be AMPK substrates. Further work on functional consequences of VAMP/AMPK interaction 
was less straight forward, since activity of VAMPs is relatively difficult to assess due to the fact 
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that VAMPs have no simple enzymatic activity but cellular sorting functions. To be able to 
investigate VAMP/AMPK interaction, we have mapped the interaction domain with the idea 
to disrupt the interaction in vivo and to analyze the effect at the cellular level.  
Based on the mapping of the interaction domain, we decided to generate an AMPK β2 
construct comprising the N-terminal VAMP interaction domain (amino acids 1-71) and the 
glycogen binding domain (amino acids 72-168), that we call the AMPK-βN domain. SPR 
confirmed the interaction between VAMP and AMPK and in addition demonstrated that the 
AMPK-βN domain is able to competitively inhibit the interaction. In vitro, a membrane fusion 
assay involving VAMP2 and its in vivo partner t-SNARE (SNAP25) showed that the AMPK/VAMP 
interaction does not interfere with the final VAMP-mediated fusion of vesicles with the plasma 
membrane, indicating that the role of VAMPs in AMPK interaction may be situated further 
upstream.  
AMPK and VAMP2/3 are both implicated in translocation of glucose transporter GLUT4 and 
the long chain fatty acid (LCFA) transporter CD36 to the plasma membrane (Kurth-Kraczek et 
al., 1999; Martin et al., 1998; McGee et al., 2003; Schwenk et al., 2010; Webster et al., 2010). 
The mechanism of how AMPK regulates the translocation of these nutrient transporters is not 
entirely elucidated to date, and the interaction between VAMP and AMPK could be a major 
key to understand it. Therefore, the hypothesis should be tested whether VAMP represents a 
scaffold for AMPK, recruiting it to exocytotic vesicles. This would facilitate phosphorylation of 
AMPK substrates at the vesicle surface, such as AS160 (at serine 570 and 588 (Geraghty et al., 
2007)), to induce vesicle transfer to the cellular periphery. According to this model, 
overexpression of AMPK-βN domain in eukaryotic cells should inhibit AMPK/VAMP 
interaction, reduce AS160 phosphorylation and thus reduce translocation of CD36 or GLUT4, 
observable by combining immunohistochemistry and confocal microscopy.   
In addition to its implication in GLUT4 and CD36 translocation, AMPK/VAMP interaction could 
be of importance for other exocytotic processes that involve VAMP2 or VAMP3 like e.g. 
neurotransmitter release, and possibly also for other VAMPs that have not been tested for 
AMPK interaction. Such scaffolding mechanisms are relevant for understanding the role of 
AMPK localization which was first thought to be diffuse within the cytosol. AMPK secondary 
modifications have already been shown to localize AMPK in certain cellular compartment 
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(McGee et al., 2003; Oakhill et al., 2010; Suzuki et al., 2007); here we present a mechanism by 
which AMPK may be localized at specific sites via its interaction with another protein. 
 
Novel AMPK interactors in the context of the known AMPK signaling network 
The analysis of the four putative AMPK interacting proteins, GSTM1/GSTP1, FH; NRDP1 and 
VAMP2/VAMP3 confirmed all four as actual AMPK interactors, although the roles of the 
interactions seem to be very different in the four cases examined. The only interactor that is 
clearly downstream of AMPK is FH. Phosphorylation of FH within the mitochondrial targeting 
sequence strongly suggests a role of AMPK in FH translocation into mitochondria. Changing 
the charge of the transit peptide could influence its ability to pass through the mitochondrial 
membrane (part 4, p.79). Another interactor, GSTM1/GSTP1, is clearly upstream of AMPK, 
since it glutathionylates and activates the kinase. GST-facilitated-glutathionylation of AMPK 
adds a novel layer of complexity to AMPK activation, depending on the cellular redox state 
(part 3, p.49). The two other candidates, which were identified in the Y2H screen, NRDP1 and 
VAMP2/3, turned out not to be classical substrates. NRDP1 presents an example of a “cross-
talk” protein; this cross-talk would affect cellular levels of NRDP1 (part 5, p.123). Finally, 
VAMP2/VAMP3 (part 6, p.157) may function as scaffold protein to recruit AMPK, thus possibly 
adding yet another layer of complexity to AMPK signaling by introducing specific cellular 
localization of AMPK. This interaction proposes a novel model for the role of AMPK in 
regulating nutrient uptake.  
Taken together, the studies give new insight into regulation and role of AMPK and open 
several new perspectives for research in AMPK signaling.   
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Conclusions et perspectives 
Durant les trois ans qu’a duré ce travail de thèse, plus de 4000 articles en lien avec l’AMPK ont 
été publiés. Même si quelques-uns ont permis l’identification de nouveaux interacteurs et 
substrats de l’AMPK (Liu et al., 2013; Um et al., 2013; Zhang et al., 2012), peu ont appliqué des 
criblages à grande échelle afin de  caractériser les voies de signalisation de l’AMPK (Banko et 
al., 2011; Thali et al., 2010). Cette thèse a permis la confirmation ainsi que la caractérisation 
fonctionnelle de nouveaux partenaires d’interactions et substrats de l’AMPK provenant de 
deux criblages interactomique sans à priori réalisé dans le laboratoire. Premièrement, un 
criblage in vitro à deux dimensions combinant résonance plasmon de surface (SPR) avec des 
essais de phosphorylation in vitro a permis l’identification de nouveaux substrats putatifs de 
l’AMPK tel que la fumarate hydratase (FH). Par la suite, un système de double hybride 
cytosolique en levure (Y2H, basé sur une split-ubiquitine) combiné avec des méthodes 
complémentaires de confirmation d’interactions protéine/protéine (Y2H basé sur un split-
Trp1, co-immunoprecipitation, SPR) a conduit à la découverte de deux partenaires 
d’interaction de l’AMPK : l’E3 ubiquitine-ligase NRDP1 et les protéines associées à la 
membrane des vésicules VAMP2 et VAMP3. Finalement, la gluthation S-transferase (GST) a 
été identifiée comme interacteur de l’AMPK au cours de recherches interactomiques dans 
lesquelles nous avons fait des pull-down entre l’AMPK et des protéines recombinantes 
contenant un tag GST. Nous avons alors montré que le tag GST interagissait directement avec 
l’AMPK. Au cours de cette thèse, ces partenaires d’interaction et substrats de l’AMPK  ont été 
caractérisés en détail, en particulier pour leurs fonctions dans les voies de signalisation de 
l’AMPK. 
 
Analyse de l’interactome d’AMPK 
De nouvelles protéines partenaire d’interaction de l’AMPK ont été identifiées par deux 
stratégies de criblage interactomique : (1) une nouvelle procédure combinant SPR et essais de 
phosphorylation a permis la détection de nouveaux substrats interagissant avec l’AMPK tel 
que FH ; (2) un criblage Y2H cytosolique à la recherche de nouveaux partenaires de AMPKβ1 
et AMPKβ2 a conduit à l’identification de 5 interacteurs putatifs de l’AMPK. Cette deuxième 
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approche fut particulièrement intéressante, car ne se limitant pas à la recherche de substrats 
d’AMPK. Une grosse partie du travail de cette thèse est basée sur deux candidats établis par 
ce criblage : NRDP1 et VAMP3.  
Les deux criblages ont conduit à peu de candidats par rapport à ce que nous attendions. La 
sélectivité avec laquelle nous avons validé les candidats explique pour partie leur faible 
nombre, même si les protocoles appliqués pour le criblage pourraient également être 
améliorés. Toutes les protéines sélectionnées ont été confirmées comme réels interacteurs 
de l’AMPK. De plus, nos données montrent aussi que l’analyse ne peut pas se limiter à des 
approches d’interactomique à haut débit mais doivent être suivies par des études ciblées afin 
de vérifier la relation comme par exemple celle entre deux partenaires d’interaction au sein 
d’un réseau complexe de signalisation. Ces études ciblées peuvent révéler des rôles très 
différents pour une interaction, allant d’une fonction de recrutement à différents types de 
modifications venant de l’une ou même des deux protéines interagissant.  
   
Glutathion S-transferase (GST) 
Nous avons montré par un premier essai de Y2H que la protéine GST de Schistosoma 
japonicum (GST-Sj), communément utilisée comme tag GST, et les isoformes GST de rat 
GSTM1 et GSTP1 interagissent avec l’hétérotrimère AMPK via le domaine N-terminal de la 
sous-unité β de l’AMPK. Ici nous avons confirmé l’interaction entre l’AMPK et GST par 
plusieurs procédures indépendantes telles que par pull-down et co-immunoprecipitation, 
mais également par SPR et Y2H. Nous avons ensuite recherché les fonctions possibles de 
l’interaction, notamment la possible phosphorylation et activation de GST par l’AMPK ainsi 
que la possible glutathionylation et activation de l’AMPK par GST. Nous avons pu montrer que 
la formation du complexe GST/AMPK augmente légèrement l’activité GST, en retour GST 
glutathionyle AMPK, augmentant ainsi son activité. Une telle S-glutathionylation de l’AMPK 
conduit à son activation de façon non-canonique, dans certaines conditions rajoute un niveau 
de complexité liant la régulation AMPK à la signalisation redox, et possiblement positionne 
AMPK comme senseur du stress oxydant. Une étude in vivo a précédemment montré que dans 
des conditions fortement oxydatives l’AMPK est glutathionylée et activée (Zmijewski et al., 
2010). Ici nous démontrons qu’in vitro dans des conditions d’oxydation moyenne, GSTM1 et 
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GSTP1 favorisent une glutathionylation d’AMPK. De plus, la glutathionylation (qui est une 
modification réversible) peut jouer un rôle protecteur contre d’irréversibles oxydations des 
thiols de la protéine, qui sont en général associées avec une perte permanente de la fonction 
et qui conduisent à sa dégradation (Giustarini et al., 2004). Ainsi la glutathionylation de l’AMPK 
dans des conditions moyennes d’oxydation peut être essentielle pour protéger l’AMPK. Un 
travail plus poussé est nécessaire pour démontrer l’importance du mécanisme de 
glutathionylation d’AMPK in vivo et pour confirmer l’implication de GST dans ce mécanisme. 
Pour ce faire des inhibiteurs de GST (l’acide ethacrynique et l’analogue peptidomimétique du 
glutathion TLK199 [γ-glutamyle-S-(benzyl)cysteinyle-R-phenyle glycine diethyle ester]) (Tew, 
2007) pourraient être utilisés sur des cellules in vivo dans différentes conditions oxydatives, 
suivi par le pull-down de protéines glutathionylées et Western blot pour la détection de 
l’AMPK.  
 
Fumarate hydratase (FH) 
Parmi les cinq substrats putatifs de l’AMPK trouvés en combinant SPR et par criblage de 
phosphorylation in vitro, fumarate hydratase (FH) a été confirmée par co-
immunoprecipitation et phosphorylation in vitro comme interacteur et substrat direct de 
l’AMPK. La phosphorylation de FH par l’AMPK affecte son activité in vitro et dans les cellules 
HeLa. Cependant, la recherche minutieuse de phosphosites par spectrométrie de masse (MS) 
et mutagenèse dirigée a révélé que FH est principalement phosphorylée au niveau de la 
serine 19, localisée au niveau du peptide signal mitochondrial clivé dans la protéine mature. 
FH est codée par un unique gène nucléaire et peut être localisée aussi bien au niveau de la 
mitochondrie que du cytosol (Yogev et al., 2011). Chez les mammifères, seule la forme 
mitochondriale contient le peptide signal. La phosphorylation de FH au niveau du peptide 
signal pourrait affecter la translocation mitochondriale, en réduisant par exemple la quantité 
de FH mitochondriale. D’un autre côté, l’activation de FH due à la phosphorylation doit être 
reconsidérée en tenant compte de l’absence du résidu phosphorylable dans la protéine 
mature. La production d’un anticorps contre la serine 19 phosphorylée serait un outil pour 
son étude in vivo, mais considérant que la durée de vie de la protéine native contenant le 
peptide signal est probablement très courte, la phosphorylation est surement difficile à 
observer. De plus La surexpression de FH sauvage et d’un mutant FH en S19A pourrait donner 
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de premières informations sur l’implication de S19 dans l’import mitochondrial par 
l’observation de la localisation (ex. : accumulation de FH-S19A dans le cytosol). 
 
E3 ubiquitine-ligase NRDP1 (NRDP1) 
Nous donnons ici pour la première fois un protocole pour la production de la protéine NRDP1  
complète qui avait jusque-là toujours été décrite comme conduisant à la production de 
protéine insoluble (Wu et al., 2004). Nous avons également remarqué la formation en grande 
proportion de corps d’inclusions lors de la production de NRDP1, mais nous avons pu réduire 
leur formation et augmenter le rendement de protéine soluble en baissant la température 
durant l’expression, et par l’utilisation d’un bioréacteur. La production en bioréacteur permet 
d’obtenir 3,1 mg de protéine NRDP1 soluble par litre de culture.    
L’analyse en Y2H a conduit à la détection et la confirmation de l’interaction entre NRDP1 et 
AMPK, et permet de déterminer les domaines d’interaction telle que le domaine C-terminal 
pour NRDP1 et le domaine N-terminal de la sous-unité β de l’AMPK. Dans le but de découvrir 
les conséquences fonctionnelles de cette interaction, nous avons premièrement analysé la 
phosphorylation et l’ubiquitination. Les essais d’ubiquitination dans les cellules HEK293 ont 
montré que bien qu’ AMPK puisse être ubiquitinylée in vivo (Zungu et al., 2011) cette fonction 
n’est pas régulée de façon spécifique par NRDP1. D’un autre côté, NRDP1 est phosphorylée in 
vitro mais a un faible niveau comparé à l’acetyl-CoA carboxylase (ACC) – substrat de référence 
de l’AMPK – ce qui rend sa pertinence physiologique incertaine. 
En considérant le haut taux de renouvellement de NRDP1 du à son importante 
autoubiquitination (qui conduit à sa dégradation par le protéasome) nous avons finalement 
étudié l’effet de l’AMPK sur le niveau cellulaire de NRDP1. In vivo, la surexpression d’AMPK 
dans les cellules HeLa réduit le niveau de NRDP1 en augmentant sa dégradation par le 
protéasome, probablement en augmentant l’autoubiquitination de NRDP1. Ce phénomène 
est indépendant de la phosphorylation par l’AMPK. Ces résultats suggèrent un rôle de l’AMPK 
dans le renouvellement de NRDP1, qui peut être causé par (i) des changements 
conformationnels de NRDP1 causant son activation ; (ii) un recrutement de NRDP1 par l’AMPK, 
positionnant les protéines NRDP1 proches les unes des autres ; (iii) la perturbation via l’AMPK 
de l’interaction entre NRDP1 et l’ubiquitine carboxyl-terminal hydrolase 8 (USP8, une protéine 
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majeure pour la stabilisation de NRDP1) (Avvakumov et al., 2006). Notre travail suggère un 
lien entre AMPK et NRDP1, même si plus de travail est nécessaire pour comprendre son rôle 
in vivo et la fonction de cette diminution du niveau NRDP1. L’immunohistochimie combinée 
avec de la microscopie confocale pourrait être utilisée pour l’analyse de la localisation de 
NRDP1 dans différentes conditions de surexpression AMPK. De plus, un travail d’analyse de 
l’impact de la diminution du niveau NRDP1 sur ses cibles serait très intéressant.    
 
Protéine associée à la membrane des vésicules (VAMP) 
Nous avons pour la première fois montré l’interaction entre VAMP2, VAMP3  et l’AMPK par 
un essai Y2H, confirmés ensuite par pull-down, co-immunoprecipitation et SPR. VAMPs ne 
sont pas des substrats de l’AMPK. Un travail plus poussé sur les conséquences fonctionnelles 
de l’interaction VAMP/AMPK est complexifié du fait que VAMP n’ait pas d’activité 
enzymatique mais plutôt des fonctions de tri. Afin de pouvoir étudier l’interaction 
VAMP/AMPK, nous avons cartographié le domaine d’interaction avec l’idée de pouvoir gêner 
l’interaction in vivo et d’analyser l’effet au niveau cellulaire.  
En se basant sur la cartographie des domaines d’interaction, nous avons décidé de générer 
une construction à partir de la sous-unité β2 de l’AMPK comprenant le domaine N-terminal 
interagissant avec VAMP (acides aminés 1-71) et le « glycogen binding domain » (acides 
aminés 72-168), construction que nous avons appelée « domaine AMPK-βN ». La SPR confirme 
l’interaction entre VAMP et AMPK et démontre également que notre domaine AMPK-βN est 
capable d’inhiber de façon compétitive cette interaction. In vitro, un essai de fusion de 
membrane impliquant VAMP2 et son partenaire in vivo t-SNARE (SNAP25) montre que 
l’interaction AMPK/VAMP n’interfère pas avec l’étape finale de fusion prise en charge par 
VAMP, indiquant que le rôle de VAMPs dans son interaction avec AMPK se trouve surement 
en amont.  
AMPK et VAMP2/3 sont impliquées dans la translocation à la membrane plasmique du 
transporteur de glucose GLUT4 et du transporter CD36 (long chain fatty acid, LCFA; Kurth-
Kraczek et al., 1999; Martin et al., 1998; McGee et al., 2003; Schwenk et al., 2010; Webster et 
al., 2010). Le mécanisme par lequel AMPK régule la translocation de ces transporteurs de 
nutriments n’est pour le moment pas entièrement élucidé, et l’interaction entre VAMP et 
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AMPK pourrait jouer un rôle majeur. A ce niveau, l’hypothèse à tester est que VAMP serait 
une protéine de recrutement (« scaffold ») de l’AMPK vers les vésicules en exocytose, facilitant 
ainsi la phosphorylation de substrat de l’AMPK tel que AS160 (sur la  serine 570 et 588 
(Geraghty et al., 2007)) au niveau de ces vésicules pour induire leur transfert à la périphérie 
cellulaire. En se basant sur ce modèle, la surexpression du domaine AMPK-βN dans des cellules 
eucaryotes (inhibant l’interaction AMPK/VAMP) devrait réduire la phosphorylation d’AS160 
et ainsi réduire la translocation de CD36 et GLUT4, observable en combinant 
immunocytochimie et microscopie confocale.   
Finalement, en plus de son implication dans la translocation GLUT4 et CD36, l’interaction 
AMPK/VAMP peut être importante pour d’autre procédés exocytotiques impliquant VAMP2 
et VAMP3 (par exemple la libération de neurotransmetteurs) et ceci pourrait aussi inclure 
d’autres VAMPs que nous n’avons pour le moment pas testées pour leur interaction avec 
AMPK. Un tel mécanisme de recrutement de l’AMPK est important pour comprendre le rôle 
de sa localisation, qui était en premier lieu considérée diffuse dans le cytosol. Des 
modifications secondaires de l’AMPK ont déjà été montrées comme localisant AMPK dans 
certains compartiments cellulaires (McGee et al., 2003; Oakhill et al., 2010; Suzuki et al., 
2007). Nous présentons ici un mécanisme par lequel AMPK serait localisée à des sites 
spécifiques via son interaction avec une autre protéine. 
 
De nouveaux interacteurs de l’AMPK dans le contexte de ses voies de signalisation 
L’analyse des quatre interacteurs putatifs de l’AMPK, GSTM1/GSTP1, FH, NRDP1 and VAMP2/3 
les a confirmés comme interacteurs avérés de l’AMPK, avec pour les quatre interactions un 
rôle extrêmement différent. Le seul interacteur clairement en aval d’AMPK est FH. La 
phosphorylation de FH au niveau du peptide signal suggère fortement un rôle d’AMPK dans la 
translocation FH mitochondrial. En changeant la charge du peptide signal, AMPK peut 
influencer sa propension à passer à travers la membrane mitochondriale (partie 4, p.79). 
L’interacteur GSTM1/P1 est clairement en amont d’AMPK, étant donné qu’il glutathionyle et 
active la kinase. La glutathionylation d’AMPK, facilitée par GST, ajoute un nouveau niveau de 
complexité dans l’activation de l’AMPK dépendant de l’état redox de la cellule (partie 3, p.49). 
Les deux autres candidats tirés du criblage Y2H, NRDP1 et VAMP2/3, se sont révélés ne pas 
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être des substrats classiques de l’AMPK. NRDP1 présente un exemple de protéine « cross-
talk », ce dernier affecterait le niveau cellulaire de NRDP1 (partie 5, p.123). Finalement, 
VAMP2/3 (partie 6, p.159) aurait une fonction de protéine « scaffold » recrutant l’AMPK, ainsi 
probablement ajoutant un niveau de complexité à la signalisation AMPK en introduisant un 
aspect de localisation cellulaire. Cette dernière interaction supporte un nouveau mécanisme 
pour la régulation de l’assimilation des nutriments via l’AMPK.  
Globalement, ces études donnent un nouvel aperçu dans la régulation et le rôle de l’AMPK et 
ouvrent plusieurs nouvelles perspectives pour la recherche sur la signalisation AMPK.   
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